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Abstract 
      
     Transient receptor potential vanilloid type 4 (TRPV4) is a calcium permeable non-
selective cation channel, originally identified in 2,000 by research teams led by Schultz (376) 
and Liedtke (229), respectively.  TRPV4 is now recognised as being a polymodal ionotropic 
receptor which is activated by a disparate array of stimuli, ranging from hypotonicity to heat 
and acidic pH.  Importantly, this receptor is constitutively expressed and capable of 
spontaneous activity in the absence of agonist stimulation which suggests that it serves 
important physiological functions – as does its widespread dissemination throughout the body 
and its capacity to interact with other proteins.  Not surprisingly, therefore, it has emerged 
more recently that TRPV4 fulfills a great number of important physiological roles and that 
various disease states are attributable to the absence, or abnormal functioning, of this ion 
channel.   Here, we review the known characteristics of this ion channel’s structure, 
localisation and function, including its activators, and examine its functional importance in 
health and disease.  
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1. Introduction 
 
2. Trpv4  Gene 
 
3. TRPV4 Protein Structure and Function 
 (i) Relevance of structural data relating to TRPV1 
 (ii) Structure of TRPV4 protein 
 (iii) Activation sites 
 (iv)    Interactions with other proteins 
 (v) Molecular structure-function correlates 
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 (x)   Involvement of Protein Kinase G in TRPV4-mediated effects 
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1. Introduction 
 
      Transient receptor potential vanilloid type 4 (TRPV4) ion channels are Ca2+ permeable 
non-selective cation channels which exhibit a remarkable range of expression throughout the 
human body.   TRPV4 belongs to the transient receptor potential vanilloid (TRPV) sub-
family of transient receptor potential (TRP) cation channels.  Thus far, twenty-eight TRP 
channels have been identified in mammals and these have been classified on the basis of 
sequence homology into six sub-families.  In addition to the TRPV sub-familly, these sub-
families comprise:  the TRPC (“Canonical”); the TRPM (“Melastatin”); the TRPP 
(“Polycystin”); the TRPML (“Mucolipin”); and the TRPA (“Ankyrin”)  (157, 194, 421).    
The TRPV4 cation channel was first described in 2000 (229, 380) and was surprising in that 
osmo-sensing, volume-regulatory, ion channels had been previously thought to be limited to 
the volume-regulated anion channel (VRAC)  (292).    TRPV4 was initially given different 
names derived from the key features observed by the denominating investigators.  Thus, the 
channel was respectively denominated as the osmosensitive transient receptor potential 
channel 4 (OTRPC4)  (229, 380), the vanilloid receptor-related osmotically activated channel 
(VR-OAC)  (229), the vanilloid receptor like channel 2 (VRL-2)  (88),  and the transient 
receptor potential channel 12 (TRP12)  (292, 442).  However, by 2002, it had been 
appreciated that the channels thus described were, in fact, the same TRPV4 channel which is 
activated by a diverse range of stimuli so that it has been well-described as exhibiting 
“promiscuous gating behaviour” (289, 296, 297, 320, 421, 432).   
 
      It is now known that TRPV4 plays a fundamental, and quite general, role in normal 
physiology and that its malfunction results in various diseases (109).  However, as the early 
nomenclature implies (ORTPC4 and VR-OAC), TRPV4 was initially identified as being of 
more limited importance as a mediator of responses to changing osmotic conditions in 
mammals (228).  Liedtke and colleagues (2003) showed that mice which do not have the 
TRPV4 receptor exhibit reduced responses to both hyper-osmolar and hypo-osmolar stimuli. 
These animals consume less water and become more hyperosmolar than normal animals.   
Antidiuretic hormone levels in the blood of TRPV4-null mice are also reduced when 
compared to normal animals which have been subjected to a hyperosmotic challenge.  
Moreover, TRPV4-null animals experience systemic hypotonicity on continuous 
subcutaneous infusion of the antidiuretic hormone analogue, deamino-8-D-arginine 
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vasopressin (dDAVP), although their renal water reabsorption capacity remains normal (230).  
At the single cell level, TRPV4, in certain at least of those cells where it is expressed, 
contributes  to regulatory volume decrease (RVD)  (32, 33, 309).   However, the nature and 
extent of the involvement of TRPV4 in osmoregulation remains very much in the course of 
elaboration as do the respective roles of the various other components of that complex system 
(365). 
    
       It is now recognised that TRPV4 function extends considerably beyond its role in 
osmoregulation and that this ion channel is involved in mediating a diverse array of 
physiological and pathological conditions.    TRPV4 ion channels perform an essential role in 
regulating the functioning of the cell by virtue of their being Ca2+ influx channels in the cells 
in which they are expressed (382, 420).   It is this capacity of TRPV4 to regulate intracellular 
calcium concentration ([Ca2+]i) in the manner, and to the extent, to which it does, and in 
diverse contexts, which enables TRPV4 to regulate a diverse orchestra of intracellular 
functional proteins which are essential for supporting the physiological processes required for 
maintaining homeostasis.   A revealing indicator of the physiological importance of TRPV4 
is found in its role in the vascular endothelium, where it contributes to intracellular  Ca2+ 
homeostasis and regulation of cell volume while responding to mechanical stresses on the 
vasculature (167).   Ca2+ influx mediated by activation of endothelial TRPV4  maintains 
shear stress-induced arterial vasodilation (158) and is essential for the regulation of arteriolar 
tone, as well as membrane permeability and the production of  antithrombotic factors (22, 
374, 375, 386).  Strikingly, excessive activation of this ion channel occasions circulatory 
collapse resulting from endothelial cell activation and damage as well as from leakage of the 
pulmonary microvascular permeability barrier (441).   Not surprisingly therefore, failure of 
normal TRPV4 expression and function is responsible for various disease states but, 
remarkably, this ion channel is also implicated in the aetiology of several hereditary 
channelopathy-induced diseases (295).  Thus, mutations in the TRPV4 gene  have been 
shown to result in the genetic disorders of brachyolmia (a syndrome principally characterised 
by short-trunk dwarfism), as well as various autosomal-dominant skeletal dysplasias and 
neuromuscular diseases, including Charcot-Marie-Tooth disease type 2C (CMT 2C), spinal 
muscular atrophy (SMA) and hereditary motor and sensory neuropathy type 2 (HMSN 2C) 
(81, 295, 414).   Of further interest, TRPV4 has been shown to play an important role in 
mediating certain pain sensations, with TRPV4 being an essential contributor to 
inflammation-induced  “mechanical hyperalgesia” (8, 12, 70, 72, 89, 476, 477), and also 
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being involved in mediating pain in several types of neuropathy (9, 10, 73, 94, 428).    Again, 
autophagy is an essential degradation system within the cell that causes  cytoplasmic 
components to be delivered to the lysosome, entailing sequential steps  comprising 
sequestration, subsequent transfer to lysosomes, then degradation, and re-use of the products 
of such degradation (271).   TRPV4 has been found to be involved in the regulation of 
apoptosis and autophagy in hepatic stellate (HSC-T6) cells.  When transfected with small 
interfering RNA (si-TRPV4) to prevent the expression of TRPV4 (si-TRPV4), these cells 
exhibit an increase in apoptosis and inhibition of autophagy.   On the other hand, when these 
cells are treated with the TRPV4 agonist, 4α-phorbol 12,13-didecanoate (4α-PDD), the result 
is reduction of apoptosis and an increase in autophagy (466).   It is already abundantly clear 
that the multiplicity of pathophysiological conditions in which TRPV4 has been implicated 
suggests that this ion channel may prove to be an immensely important target for therapeutic 
pharmacological intervention (293).   However, such targeting of TRPV4 is complicated by 
the risk of compromising the important physiological functions which this ion channel 
subserves.   
 
      Once regarded as a Cinderella amongst ion channels, functioning only in the maintenance 
of systemic osmotic equilibrium, TRPV4 is now credited as being a major player in human 
physiology, crucially functioning not only in the maintenance of vascular tone and 
endothelial cell function, but also in the cardiac, respiratory, urinary, skeletal and  digestive 
systems, as well as in the central and peripheral nervous systems, while also being 
responsible for various channelopathy-induced hereditary diseases and pain of several 
different contexts of origin.  These diverse aspects of the applied physiology of TRPV4 are 
afforded consideration in their turn in the later part of this Review; but, first, we address 
fundamental issues relating to this ion channel:  the Trpv4 gene, the protein’s structure;  the 
pattern of its expression; what is known about how it functions in relation to its structure and 
in relation to other associated proteins;  how it is activated; its antagonists;  and its role as an 
interactive molecular integrator of diverse stimuli. 
 
 
2.   Trpv4 gene 
 
     Directions for the manufacture of the human TRPV4 ion channel are provided by the 
Trpv4  gene which belongs to both the ANKRD (ankyrin repeat domain containing) and  the 
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TRP (transient receptor potential cation channel) families of genes.  The TRPV4 gene is 
found on the long (q) arm of chromosome 12 at position 24.1, being located from base pair 
109,783,086 to base pair 109,833,406 on chromosome 12  ((88); 
http://ghr.nlm.nih.gov/gene/TRPV4; Figure 1).   There is evidence that microRNA-203 
(miRNA-203) exercises control over this gene in rat (172).  Progesterone reduces expression 
of TRPV4 in human airways, mammary gland epithelial cells, and in vascular smooth muscle 
cells (190).   When rats suffering from visceral hypersensitivity, resulting from neonatal 
maternal separation, are given a combination of 8 probiotic bacteria strains (comprised in the 
medical food VSL#3),  their visceral pain is reduced while a variety of genes involved in pain 
and inflammation are found to be down-regulated, including TRPV4  (95).   Other factors 
identified as increasing TRPV4 expression are interleukins 1B and 17 (in DRG neurons), 
NGF (in urothelium) and hypoxia/ischaemia (in astrocytes and pulmonary arterial smooth 
muscle cells) (48, 132, 138, 343, 447). 
  
3.  TRPV4 Protein Structure and Function 
 
(i) Relevance of structural data derived from TRPV1 
 
      The characterisation of the molecular structure of TRPV4 is very much a work in 
progress.  TRPV1 is by far the best-characterised member of the vanilloid sub-family 
TRPV1-TRPV6 and its features have thus far been elaborated in much greater detail than 
those of TRPV4 (Figure 1(E)).  A major advance in the elucidation of TRPV1 structure was 
recently made by Liao and colleagues (2013).  These researchers managed to overcome the 
obstacles inherent in investigating the structure of a small membrane-bound molecule which 
is likely to be the subject of a high level of ongoing conformational change as suggested by 
the number and diversity of its potential activators (54, 163, 191, 226, 227).   The findings 
which have been made in relation to TRPV1 protein structure are relevant in the context of 
TRPV4 because there is high confidence that many of the features of TRPV1 are shared by 
TRPV4.  Indeed, it is generally accepted that many of the lacunae in our knowledge of the 
molecular structure of TRPV4 can be reliably filled by structural data from studies of TRPV1 
when considered in conjunction with studies of the evolutionary profiles of TRPV1-TRPV4 
(96, 291).  It has been suggested that the several features of the TRPV1-TRPV4 ion channels, 
namely, the ankyrin repeat domains (ARDs), membrane proximal domains (MPD), trans-
membrane domains (TMD) and transient receptor potential (TRP) domains (including TRP 
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box) all exhibit the same basic functional scaffold arrangement from the ARD to the TRP 
domain across TRPV1-TRPV4.  On the other hand, it has also been suggested that the distal 
N-terminus and the distal C-terminus, as well as certain extracellular loops are highly 
divergent and specific for individual TRPV1-TRPV4 channel types  (96).   
 
(ii)  Structure of the TRPV4 protein 
 
     The TRPV1 protein in rat is made of 838 amino acids, while that in the human comprises 
839 amino acids. The relative molecular mass of the TRPV1 molecule is predicted to be 
95,000 Da (57).  The TRPV1 protein itself is a multi-molecular structure in which its 
component molecules are arranged to constitute an ion channel. TRPV1 is an oligomer which 
comprises four monomers.  The protein structure is therefore tetrameric, demonstrating a 
four-fold symmetry around a central aqueous pore (273).  Individual molecules in the TRPV1 
tetrameric protein are usually referred to as TRPV1 “channel sub-units.” When expressed, 
these individual molecules have a specific protein component which enables them to combine 
to constitute a functional ion channel.  Each monomer has six transmembrane alpha-helices 
(S1-S6) which extend across the lipid bilayer, together with a re-entering loop which contains 
the pore helix  found between S5-S6. N- and C-termini are localised in the cytoplasm.  A 
helical S4-S5 linker runs parallel to the membrane and connects the S1-S4 and S5-P-S6 
segments within each TRPV1 subunit  (226).  These features of the TRPV1 protein are 
afforded further consideration in the succeeding paragraphs.  
 
     The TRPV4 protein is known to be composed of 871 amino acid residues ((380); Figure 
2) and possesses the same tetrameric structure (358).  TRPV4 is normally assembled as a 
homotetramer (378), although heterotetramers have also been reported, e.g., with TRPC1 
(244), TRPP2 (378), and even heteromeric TRPV4-TRPC1-TRPP2 complexes (98).  Each 
TRPV4 monomer has six transmembrane alpha-helices (S1-S6) stretching across the lipid 
bilayer, together with a re-entering loop which contains the pore helix found between S5-S6. 
The transmembrane region is similar to that of TRPV1.  N- and C-termini are localised in the 
cytoplasm (358).  
 
(a) The N-terminus 
      The N-terminus of TRPV1 possesses six ankyrin repeat domains (ARDs) (aa 101–364). 
These are 33-residue sequence motifs, which are frequently involved in protein-protein 
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interactions and are necessary for the channel to function ((164, 189, 226, 232, 250, 279); 
Figure 2(E)).    Liao and colleagues describe how residues in ARDs 3 and 4 from one 
subunit interact with a three-stranded anti-parallel B-sheet from an ARD-S1 linker region 
(K368-D383) and the C-terminus of an adjacent subunit to press the cytoplasmic component 
of TRPV1 together. In addition, this B-sheet structure anchors the cytoplasmic N- and C-
terminal domains together within the same subunit.  Residues G375 and P376 are found in all 
TRPV subtypes and produce a sharp turn which connects the N-terminal B-strands (226).  
The N-terminus of the TRPV1 molecule is also involved in interaction with some auxiliary 
proteins including snapin and synaptotagmin IX (277). Molecular modelling of human 
TRPV1 suggests that when the channel has been desensitised, the N-terminal becomes more 
proximate to the C-terminus (117).  The ARDs of the TRPV1 molecule also comprise a 
binding-site for ATP and a calcium-binding protein, calmodulin.  ATP and calmodulin have 
opposing roles in the desensitisation process in TRPV1 (232). 
 
     This ARDs’ binding site for ATP and calmodulin (CaM) is conserved in TRPV3 and 
TRPV4, but not in the TRPV2 molecule (319). Binding of phosphoinositides to a TRPV4 
ARD results in a reduction of channel function.  Phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2) binds more potently  to the TRPV4 ARD than do other phosphoinositides. The 
TRPV4 ARD has been characterised as a lipid-binding domain which interacts with 
PI(4,5)P2 to regulate the activity of TRPV4 (395).  Deletions from the N-terminus region are 
involved in a number of splice variants.  Arniges and colleagues (2006) describe five splice 
variants of the TRPV4 channel: TRPV4-A andTRPV4-B (delta384-444) variants, TRPV4-C 
(delta237-284), TRPV4-D (delta27-61), and TRPV4-E (delta237-284 and delta384-444) 
variants. These alternative splice variants all entail deletions in the cytoplasmic N-terminus 
region, affecting (except for TRPV4-D) the ankyrin domains.  They assign these variants to 
two groups:  Group I which comprises TRPV4-A and TRPV4-D;  and Group II which 
comprises TRPV4-B, TRPV4-C, and TRPV4-E.   The variants in Group I  (unlike those in 
Group II) are correctly processed, homo- and heteromultimerized in the endoplasmic 
reticulum, and targeted to the plasma membrane where they respond to typical TRPV4 
stimuli.  Group II variants, on the other hand, do not have parts of the ankyrin domains 
normally posessed by TRPV4, cannot oligomerize, and remain within the cell in the 
endoplasmic reticulum ((19); Figure 3).  The cytoskeleton protein PACSIN 3 interacts with a 
proline-rich region just upstream of the first ARD (79). ARDs are important in channel 
synthesis.  Studies on TRPV4 suggest that ion channel synthesis involves core glycosylation 
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and oligomerization in the endoplasmic reticulum with subsequent transfer to the Golgi 
apparatus for maturation. ARDs are necessary for such oligomerization (19).  In addition to 
ARDs, other parts of the N-terminus (residues 64–77) in TRPV channels may also be 
involved in channel assembly (63). Correct channel assembly of TRPV4 requires an 
interaction between the pre-S1, TRP, and the ARD-S1 linker domains.  When the pre-
S1 K462 of TRPV4 is neutralised, the result is that TRPV4 protein is retained in the 
ER, and there is impaired glycosylation and trafficking, while TRPV4 activators fail to 
elicit an appropriate response from the channel (131).  
 
     The N-terminus of TRPV4 has a proline-rich region which is important in mediating the 
effects of PACSIN 3 (Figure 2(G) & 5) which binds to TRPV4 to regulate the subcellular 
localisation of TRPV4 as well as to potently inhibit the basal level of activity of the ion 
channel and its activation by cell swelling or heat, but not its activation by 4α-PDD. 
Interaction of PACSIN 3 with TRPV4 requires both this proline-rich domain located before 
the ankyrin repeats of the TRPV4 N-terminus as well as the PACSIN 3 C-terminus Src 
homology 3 domain.  When mutations are made at certain proline residues found in the N-
terminus of TRPV4, the ion channel is saved from such inhibition of its activity by PACSIN 
3  (79, 93). 
  
 (b) The C-terminus 
      The C-terminus of TRPV1 is required for normal channel function and damage to this 
region can occasion major functional deficits (41, 419).  A segment in the C-terminus (aa 
684-721) contains the TRP domain, which is adjacent to the channel gate and is essential for 
the tetramerisation of the channel subunits into functional channels (134).  This TRP domain 
is involved in interactions between the constituent subunits of oligomeric TRPV1 and 
contributes to the linking  of stimulus sensing to channel gating (135).  Liao and colleagues 
describe the TRP domain as comprising a 23-25 amino acid segment found immediately after 
S6 which  has an alpha-helical structure that extends parallel with the membrane’s inner 
leaflet as a result of an acute bend after S6.  The alpha-helix embraces the initial two-thirds of 
the TRP domain before it is replaced by a random coil.  The TRP domain also contains 
charged side chains on the cytoplasmic side of the helix which interact with a pre-S1 helix by 
means of hydrogen bonding and salt bridging (226).  The TRP box describes a highly 
conserved, 6-mer segment in the C terminus, close to the channel gate, which is found in TRP 
channels within the TRP domain.  In TRPV1, mutation of this segment interferes with normal 
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gating of the channel and it can alter the response of TRPV1 to voltage, capsaicin, and heat 
(410).   It has been proposed that interactions either between, and/or within, subunits at the 
TRP box are essential for the proper linking of stimulus sensing to gate opening  (148).  A 
segment comprising R701 and T704, located beside the TRP box, is considered to function in 
decelerated gating associated with desensitisation of TRPV1  (302).  A CaM-binding motif is 
also attributed to five residues in the C terminus which putatively constitute an alpha helix to 
connect into the central cavity of calmodulin (149).   
 
       The C terminus region of TRPV4 is predicted to be structurally similar to that of TRPV1 
and to be located to the surface, rather than to the inside, of the cytoplasmic region of TRPV4  
(358) . Channel protein folding, maturation and trafficking are dependent on the C-terminus 
component of TRPV4;  and the segment which includes residues 838-857 is critical in 
enabling these processes to occur.   These residues 838-857 adopt a precise conformation, as 
demonstrated by structural modelling, with Gly849 and Pro851 becoming localised at 
essential positions  (222).  The  TRPV4 C-terminus interacts with the microtubule-associated 
protein 7 (MAP7)  (387).  A PDZ binding-like sequence is found in the final four amino acid 
residues of the TRPV4 C terminus (130). A single mutation at E797 in the C-terminus of 
TRPV4 results in the channel becoming constitutively open (433). 
 
(c) The pore region 
     The pore domain of TRPV1 is comprised of two transmembrane domains – S5 and S6 – 
and the loop between them. Salazar and colleagues (2009) showed that S6 opens the pore of 
TRPV1 as a result of binding by capsaicin or temperature increase. The S6 segments 
constituting the pore are helical in structure, while two constrictions are found in the pore. 
One of these restricts entry by large molecules, while the other impedes the ingress of smaller 
ions and constitutes an activation gate of TRPV1  (336). The S6 segment of TRPV1 
comprises a watery hollow within  an amphipathic alpha helix, with the majority of the 
hydrophobic residues oriented into the cavity (179).   The study of the TRPV1 channel in its 
closed state by Liao and colleagues (2013) identifies the outer pore of TRPV1 as having a 
broad funnel-like structure while a short selectivity filter (643GMGD646), with backbone 
carbonyls or side chains facing into the central entry-way, is found deeper into the central 
canal.  Diagonally opposed carbonyl oxygens at G643 form a restriction point which is 
consistent with the selectivity filter being in a non-conducting state.  The most constricted 
point in the lower gate is constituted by a constriction site deeper into the canal where a 
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hydrophobic seal of 5.3A is formed by the combination of I679 in the S6 helices from each 
subunit. Y671 and L681 are unlikely to amount to important contributors to the lower gate as 
side chains of Y671 are found ~10A above the most constricted point made by I679, while 
the side chain of L681 is oriented away from the conducting channel of the pore.  TRPV 
subtypes are highly similar in sequence within the S6 helix.  Moreover, each TRPV subtype 
has an isoleucine located at a position which is the equivalent of I679 in TRPV1, which 
strongly suggests that the lower gate in each TRPV subtype exhibits a similar constitution 
(226).  Gating of TRPV1 involves substantial re-arrangement of the structure of the outer 
pore as well as the pore helix and the selectivity filter, in addition to a significant reduction in 
the extent of the hydrophobic constriction found at the lower gate.  However, the S1-S4 
domain of TRPV1 does not appear to be active during gating of the channel (54).   
Simulations using molecular dynamics indicate that the TRPV1 pore has three main binding 
sites for cations.  One of these binding sites is associated with the pore’s intracellular cavity, 
while the remaining two are found at the interacellular and extracellular entries to the 
selectivity filter. The intracellular cavity is described as representing a broad attractive area 
which permits cations to diffuse freely.  Cations are subjected to electrostatic attraction at the 
outer entrance to the selectivity filter by reason of the presence of an arrangement of acidic 
residues in two rings constituted by E648 and D646.  TRPV1 appears to have a very flexible 
selectivity filter whereby its structure differs with the peameation of Na+ and K+, 
respectively.  Additional conformational changes of the selectivity filter are believed to be 
necessary to permit the permeation of Ca2+(83).   
     A consensus N-linked glycosylation motif lies within the loop which forms the pore 
between the fifth and sixth transmembrane segments of TRPV4  (449).    Asp672,  Asp682 
and Met680 are components of the channel pore of TRPV4; and neutralizing either of these 
aspartate residues to alanine results in a moderate reduction in the  permeability of TRPV4 to 
divalent cations and a similar reduction in the extent of outward rectification – a double effect 
which is increased by neutralisation of both of these residues concurrently.  Met680 is a 
putative component of the pore’s selectivity filter and its mutation strongly reduces whole 
cell current amplitude as well as the permeability of the channel to Ca2+ (420).  Mutation of 
E797 in the C-terminus of TRPV4 causes the pore to become constitutively open  (433). 
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(iii)  Activation sites 
       4α-phorbol esters have their binding site in a loop in the 3rd and 4th transmembrane 
domains of TRPV4.  Activation is dependent on the ester decoration of ring C and the A,B 
ring junction.   The lipophilic ester groups on ring C function principally to effect the 
positioning of the diterpenoid core into the ligand binding area (201).  Sensitivity of TRPV4 
to 4α-PDD and heat is diminished by the substitution of leucine for F617, Y621 or F624 in 
TM5 but, remarkably, the resulting F617L and Y621L mutants exhibit enhanced activation 
due to cell swelling.  A Y702L mutation  in TM6 diminishes sensitivity to 4α-PDD, heat and 
cell swelling.   Thus, there are distinct pathways which mediate the response of TRPV4 to 
4α-PDD and changes in osmolarity, respectively (200).  Two hydrophobic residues in the 
middle area of the fourth transmembrane segment (TM4; Leu584 and Trp586) govern the 
sensitivity of the channel to 4α−PDD, bisandrographolide A, and heat, but have no effect on 
the responses to cell swelling, arachidonic acid and epoxyeicosatrienoic acid (5,6 EET).  
However, two residues in the C-terminal area of TM4 (Tyr591 and Arg594) are implicated in 
the activation of TRPV4 by all of these stimuli (425).   Nitric oxide (NO) causes the S-
nitrosylation of TRPV4 on the Cys853 residue to reduce the activation of TRPV4 (Lee et al., 
2011).  Tyrosines 110 and 805 have been identified as phosphorylation sites of Src kinase in 
TRPV4 with the Tyr110 residue proposed to be important in the stimulus-specific modulation 
of TRPV4 channel function (Wegierski et al., 2009) (437).  The Ser824 residue of TRPV4 is 
phosphorylated by glucocorticoid-induced protein kinase 1 (SGK1) and phosphorylation of 
this residue is required for the interaction of TRPV4 with F-actin (361).  A voltage-dependent 
gating mechanism has been proposed to exist in series with the principal intracellular gate 
(238).   The N-tail has a binding site for PI(4,5)P2, while channel activation by physiological 
stimuli is enabled by the  PI(4,5)P2-dependent rearrangement of the cytosolic tails of TRPV4  
(133).  The C-terminus of TRPV4 has an intracellular CaM binding domain and this 
constitutes the structural component  for the effect of Ca2+ in the activation of the channel 
(381).   All three members of the PACSIN protein family can bind the amino terminus of 
TRPV4 in mouse (79). 
 
(iv) Interactions of TRPV4 with other proteins 
 
      Thus far, 38 interacting proteins have been identified for TRPV4 
(http://trpchannel.org/summaries/TRPV4; Figure 5). The function of many of these 
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interacting proteins has yet to be elucidated, but it is possible to categorise those whose 
functions are (in part at least) known into several broad categories (which are not mutually 
exclusive) for the purpose of facilitating this discussion.  On this practical basis, we consider 
these interacting proteins under four heads, namely:  (a) proteins which interact with TRPV4 
to modify the localisation of TRPV4;  (b) cytoskeletal proteins which interact with TRPV4;  
(c)  proteins which interact with TRPV4 to modulate  signalling;  and (d) ion channel proteins 
which interact with TRPV4, including those which interact to form heteromeric TRPV4 
channels.   
 
 
(a)  Proteins interacting with TRPV4 to modify TRPV4 localisation  
        Several proteins modify the localisation of TRPV4, including PACSIN 3, OS-9 and  
ubiquitin ligase AIP4.   PACSIN 3 is an auxiliary protein of TRPV4 and regulates the 
subcellular localisation of TRPV4 by affecting its endocytosis, as well as regulating its 
activity in a stimulus-specific manner.  The localisation of TRPV4 as between the plasma 
membrane and cytosol is influenced by the co-expression of PACSIN 3, although not by 
either of the other PACSINs.  When PACSIN 3 is also expressed with TRPV4, the extent to 
which TRPV4 is expressed in the plasma membrane increases at the expense of its expression 
in the cytosol.   The localisation of TRPV4 at the subcellular level reflects the influence of 
PACSIN 3 on the endocytosis of TRPV4.   The interaction of TRPV4 and PACSIN 3 requires 
a carboxyl-terminal Src homology 3 (SH3) domain of PACSIN 3 and a specific proline-rich 
domain upstream of the ankyrin repeats of  TRPV4 ((79); Figure 4).    PACSIN 3 strongly 
inhibits the basal activity of TRPV4, as well as its activation by cell swelling and heat;   but 
PACSIN 3 has no effect on the gating of the channel induced by 4α-PDD.   This inhibitory 
effect on TRPV4 is abolished by a single proline mutation in the SH3 domain of PACSIN 3 
which implies that PACSIN 3 binds to TRPV4 to regulate its activity (93).   The N-terminus 
tail of TRPV4 located in the cytosol interacts with a protein associated with the endoplasmic 
reticulum (ER) known as OS-9.   OS-9 functions to reduce the release of TRPV4 from the ER 
membrane by binding preferentially TRPV4 monomers and other non-developed variants of 
this ion channel which are localised there.   This enables OS-9 to reduce the level of TRPV4 
found at the plasma membrane (431).   Ubiquitination is an important factor in the regulation 
of TRPV4 expression at the plasma membrane. Increased ubiquitination of TRPV4 is 
mediated by the HECT (homologous to E6-AP carboxyl terminus)-family ubiquitin ligase 
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AIP4 but without inducing the degradation of TRPV4.  This ubiquitin ligase AIP4 instead 
facilitates the endocytosis of TRPV4, thereby reducing the extent of its expression at the 
plasma membrane. In the result, while TRPV4 levels are increased, there is nevertheless a 
reduction in the basal activity of the ion channel (436).  B-arrestin 1 interacts with AIP4 to 
produce the ubiquitination of TRPV4 (390). 
      The stromal interaction molecule 1 (STIM1) is a type 1 transmembrane protein that 
enables  Ca2+ influx to occur after intracellular Ca2+ stores have become depleted.  It 
functions by gating store-operated Ca2+ influx channels.  STIM1 functions as an auxillary 
protein of TRPV4 channels expressed in epithelium where it complexes with the C-terminus 
tail of TRPV4. Phosphorylation of serine 824 of TRPV4 controls the formation of the 
TRPV4/STIM1 complex and its localisation in the cell membrane.  It has been proposed that 
the TRPV4/STIM1 complex is essential for guiding TRPV4 from the endoplasmic reticulum 
to the cell membrane and for its proper functioning (360).  
 
(b)  Cytoskeletal proteins interacting with TRPV4 
      TRPV4 and actin are strongly co-expressed in some membrane structures.  These are 
highly dynamic structures and include microvilli, filopodia and lamellipodia edges as found 
in HaCaT keratinocytes and CHO cells.  Moreover, TRPV4 and F-actin interact and function 
in sensing hypotonicity and the development of RVD (32). Goswami and colleagues (2010) 
made remarkable observations concerning the physical interaction of TRPV4 with tubulin, 
actin and neurofilament proteins, as well as with PKCε and CamKII in DRG neurons and in 
DRG-neuron-derived F-11 cells.  The C-terminus of TRPV4 interacts directly with tubulin 
and actin which compete for binding.  When TRPV4 are activated, alteration in the 
morphology of neuronal and non-neuronal cell types is induced.  At the same time, 
microtubule activity exercises control over the functioning of TRPV4 (142).  TRPV4 is 
localised with caveolin 1 and filipin in a lipid raft.  Both Loop 4 and the TM5-Loop 4-TM5 
area of TRPV4 are capable of  physically interacting with cholesterol, as well as mevalonate, 
its precursor, and derivatives including stigmasterol and aldosterone (207). 
      B5-tubulin  is one of at least seven B-tubulin  isotypes produced in vertebrates that 
assemble together to form cellular microtubules.  Over-expression of B5-tubulin  can severely 
damage the microtubule network. Annexin A2 is a protein which acts as an autocrine factor 
to increase osteoclast formation and bone resorption.  TRPV4 is found co-localised with B5-
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tubulin  and annexin A2 in transfected HEK293 cells, but only TRPV4 and B5-tubulin  
interact to form a complex (174).  An association of annexin A2 with TRPV4 has also been 
found in DRG neurons together with evidence that annexin A2  is involved there in the 
regulation of  TRPV4-mediated Ca2+  influx and  substance P release in those neurons (298). 
 
(c)  Proteins interacting with TRPV4 to modulate signalling 
      The arrestins comprise a small group of proteins which function in the regulation of 
signal transduction.  Shukla and colleagues (2010) have demonstrated that ubiquitination and 
functional down-regulation of TRPV4 are mediated by β -arrestin 1.  When B-arrestin 1 is 
stimulated by angiotensin, it becomes attached to a constitutive complex in the cell 
membrane formed by the angiotensin receptor (AT1aR) and TRPV4.     B-arrestin 1 interacts 
with an E3 ubiquitin ligase (AIP4)  to result in the ubiquitination of TRPV4 and its 
internalisation and functional down-regulation (362).   The progesterone receptor also 
functions in the regulation of TRPV4 expression, with TRPV4 expression in human airways, 
mammary gland epithelial cells, and vascular smooth muscle cells, being reduced on 
exposure to progesterone (190).  TRPV4 channels and connexins colocalise with caveolin-1 
(the structural protein of caveolae) in the caveolar compartment of the plasma membrane of 
mouse endothelial cells and TRPV4 activity is reduced in the absence of caveolin 1  (337).  
The satellite glial cells (SGCs), which closely ensheath sensory neurons, influence their 
excitability in conditions involving inflammation and pain.  These SGCs express 
functional TRPV4 as evidenced by the presence of these ion channels in a subpopulation 
of neurons in mouse DRG.  The TRPV4 so expressed appear to be functionally 
regulated by the P2Y1 receptor which has been proposed to couple to, and activate, 
TRPV4 (329). 
 
 
      TRPV4 may perform functions in one sex that it does not in the other.  Thus, studies of 
endothelial function in isolated porcine coronary arteries show that, while no difference in the 
level of expression of TRPV4 is found using Western blot as between male and female, the 
TRPV4 antagonist, RN-1734, diminishes the strength of the NO component of the 
vasorelaxation induced by bradykinin in females but not in males, while inhibiting  in both 
sexes the maximum relaxation induced by the endothelium-dependent hyperpolarisation-type 
component  (443).  
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       It has already been observed that several enzymes affect the activity of TRPV4. Thus, 
enhancement of the activation of TRPV4 by phosphorylation of specific sites is dependent 
upon AKAP79 assembling PKC or PKA to constitute a signalling complex with TRPV4  
(112).  TRPV4 can be sensitised by PKC in central sensory and non-sensory nerve terminals, 
as well as in DRG neuronal cell bodies (53).   Annexin A2 is associated with TRPV4 in DRG 
and there is evidence that it is involved there in regulating TRPV4-mediated Ca2+ influx and 
substance P release (174, 298).  TRPV4 and TRPV1 are found together in a population of 
DRG neurons (53).  Both TRPV1 and TRPV4 are also expressed in rat intrapulmonary 
arteries and their agonist-induced activation results in pulmonary arterial smooth muscle cell 
migratory responses which are associated with re=organisation of the F-actin cytoskeleton 
and the tubulin and intermediate filament networks.  Proliferation and migration of 
pulmonary arterial smooth muscle cells leads to increased pulmonary vascular resistance 
characteristic of pulmonary hypertension (257).   TRPV4 interacts with F-actin in sensing 
hypotonicity and in effecting RVD (32).  The association and surface expression of aquaporin 
5 (AQP5) and TRPV4 is increased by hypotonicity, although actin depolymerisation reduces 
these effects and RVD.  AQP5 – and not cell swelling per se – is essential for the gating of 
TRPV4 by hypotonicity; and TRPV4 and AQP5 act in concert to control RVD (234).  
Aquaporin 2 (AQP2) is also involved in the activation of TRPV4 by hypotonicity in renal 
cells and regulation of the cellular response to osmotic stress, suggesting that both proteins 
are assembled in a signalling complex that responds to anisosmotic conditions (125).   
 
(d)  Ion channel proteins which interact with TRPV4  
 
     The closest interaction of other ion channels with TRPV4 is found where those ion 
channels comprise monomers which are assembled with TRPV4 monomers to form 
heteromeric TRPV4 channels.  The transient receptor potential canonical type 1 (TRPC1) 
channel and the transient receptor potential canonical type 6 (TRPC6) channel are stretch-
activated channels which are frequently found with TRPV4 in DRG neurons where they 
combine with TRPV4 channels to occasion the sensitisation of primary afferent nociceptors 
and the occurrence of mechanical hyperalgesia (7).   In human HEK293 cells transfected with 
both TRPV4 and TRPC1 and in native vascular endothelial cells, the loss of stored Ca2+ 
provokes the insertion of TRPV4-C1 heteromeric channels into the plasma membrane.  These  
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TRPV4-C1 heteromeric channels are preferentially localised to the cell membrane when 
compared to the extent of the translocation of TRPC1 or TRPV4 homomeric channels 
achieved (243).  The polycystin-2 (TRPP2) ion channel uses TRPV4 to form a mechano-
sensitive and thermosensitive molecular sensor in the cilium  (205)..   TRPP2 and TRPV4 
assemble identically to TRPP2-TRPC1, forming a heterotetramer with a 2:2 stoichiometry 
and an alternating subunit arrangement  (378).    TRPV4-TRPC1-TRPP2 channel complexes 
have been found in endothelial cells of cultured rat mesenteric arteries and in HEK293 cells 
when co-transfected with TRPV4, TRPC1 and TRPP2.  Functionally, the channel complexes 
thus constituted by these assemblies, when found in cells of the vascular endothelium, are 
activated by flow to mediate Ca2+ influx (98).  
 
     TRPV4 may also interact indirectly with other Ca2+-sensitive proteins located close to 
TRPV4 channels within signalling microdomains. Ca2+-sensitive large conductance K+-
channels (BK channels) function in conjunction with TRPV4 in both vascular smooth muscle 
and bronchial epithelium (103, 118). In the former case, amplification of the Ca2+-signal 
through ryanodine-receptor mediated Ca2+-store release seems to be important in the 
signalling process (80, 103). TRPV4 is found co-localised with BK channels in the 
endothelium of mesenteric resistance arteries and with CGRP in sensory neurons (128).  
TRPV4 physically interacts with KCa2.3 in the endothelial cells of rat mesenteric arteries 
where acetylcholine and 4α-PDD principally act through a TRPV4-KCa2.3 pathway to 
induce smooth muscle hyperpolarization and vascular relaxation (245).  TRPV4 channels 
functionally couple to low conductance KCa channels to mediate osmosensing in 
parvocellular neurones of the paraventricular nucleus of the hypothalamus which is involved 
in the regulation of cardiovascular as well as renal function  (115).   Gating of individual 
TRPV4 channels within a four-channel cluster in the vascular endothelium of resistance 
arteries is co-operative, with activation of as few as three channels per cell causing maximal 
dilation through activation of endothelial cell intermediate conductance, and small 
conductance, Ca2+-sensitive K+ channels  (374).    Mutations of the MLC1 gene are 
associated with megalencephalic leucoencephalopathy with subcortical cysts.  MLC1 is over-
expressed in astrocytoma cells where it is mainly localised in the plasma membrane and 
forms part of the Na+, K+-ATPase-associated molecular complex that includes the K+ channel 
KIr4.1, syntrophin and aquaporin 4 and functionally interacts with TRPV4 (212).   TRPV4 is 
richly expressed in the apical membrane of epithelial cells of the choroid plexus where it 
interacts physically and functionally with anoctamin 1 (ANO1) which is a Ca2+-activated Cl- 
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channel (396).   TRPV4, TRPC1 and KCa1.1 interact physically to constitute a triplex in 
human  internal mammary arteries with TRPC1 constituting the linker by means of which 
TRPV4 and KCa1.1(α) are enabled to interact.  11,12-epoxyeicosatrienoic acid (11,12-EET) 
acts on this TRPV4-TRPC1-KCa1.1 triplex to cause hyperpolarisation of  smooth muscle cells 
and vascular relaxation in these arteries  (248).  
  
(v) Molecular structure-function correlates 
 
       TRPV4 is a Ca2+ permeable non-selective cation channel which exhibits both inward and 
outward rectification, voltage-dependent block by ruthenium red, a moderate selectivity for 
divalent over monovalent cations, and an Eisenman IV permeability sequence (420). TRPV4 
is more permeable to Ca2+ than to Ba2+ and Sr2+.  Both spontaneous and agonist-induced 
(caused by hypotonic solutions or phorbol esters) TRPV4 currents are substantially 
diminished at all potentials without the presence of extracellular Ca2+.  During agonist-
induced activation of the channel, the rate and extent of channel activation is increased by 
Ca2+ entry.  Release of Ca2+ from intracellular stores can reinstate TRPV4 activity when 
extracellular Ca2+ is absent.   Site-directed mutagenesis suggests that the C-terminus 
CaM-binding domain is a prerequisite  for Ca2+-induced potentiation of  TRPV4 in 
certain expression systems (381).   However, the N-terminus ARDs of TRPV4 are also 
known to possess a CaM-binding site and this too may function in Ca2+-induced 
modulation of TRPV4 channel activity in other systems.  A molecular model proposed by 
Strotmann and colleagues (2010) proposes that, in the resting state, an autoinhibitory 
complex is formed between an N-terminus intracellular domain of the TRPV4 channel and a 
C-terminus domain comprising a binding site with a high-affinity for CaM.  Binding of CaM 
consequent on increases in [Ca2+]i displaces the N-terminus domain which may then interact 
homologously with the same domain of a second subunit (382).    
 
      Voets and colleagues (2002) found that the Ca2+ selectivity of the TRPV4 pore is 
influenced by two aspartate residues, Asp672 and Asp682. When either aspartate is 
neutralised to alanine, there is a modest decrease both in the relative permeability for divalent 
cations and in the extent of outward rectification. When both aspartates are neutralised at the 
same time, the extent of the decrease in Ca2+ permeability is much greater as is the reduction 
in channel rectification.  In addition, the permeability order for monovalent cations is 
changed toward Eisenman sequence II or I.  Neutralizing Asp682, but not Asp672, results in 
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a substantial diminution in the affinity of the channel for ruthenium red.  A substantial 
diminution in the amplitude of whole cell currents and loss of permeability to Ca2+ occurs in 
the case of mutations to Met680, which is found in the middle a supposed selectivity filter; 
but there is no evidence of an alteration in the properties of the pore (believed to be localised 
at Lys675) being effected by neutralisation of the only residue which is positively charged in 
that region (420).   One mutation at its C terminus (E797 to E797A or E797K) suffices to 
render the TRPV4 channel constitutively open (433).    
 
       PI(4,5)P2 is found in cell membranes and various signaling proteins are derived from it.   
PI(4,5)P2 is important for the proper functioning of TRPV4 and the role of this phospholipid 
in TRPV4 channel regulation has been explored by Garcia-Elias and colleagues (2013) who 
identified a PI(4,5)P2 binding site within the N-terminus.   PI(4,5)P2 binds and rearranges the 
cytosolic tails of TRPV4 to enable hypotonic and heat stimuli to activate the channel;  but 4α-
PDD, which binds directly to transmembrane domains, activates TRPV4 independently of 
PI(4,5)P2  (133).   The osmotransducing cytosolic messenger EET activates TRPV4 (434), 
and this is facililtated by PI(4,5)P2 which also enables activation of TRPV4 by heat in inside-
out patches (133). The ankyrin repeat domain found in TRPV1, TRPV3 and TRPV4 
possesses a ligand binding site for ATP and calmodulin, as well as for other ligands.  ATP 
and calmodulin function through this multi-ligand binding site to mould the varying 
sensitivity and adaptation profiles of these several ion channels.  ATP and CaM function 
interactively to determine receptor sensitivity to changes in Ca2+ concentration  (319).  ATP 
seems to promote stability in TRPV-ARDs which are capable of binding ATP (177).   
Binding of phosphoinositide to the ARD of TRPV4 reduces the activity of the channel.  
PI(4,5)P2 exhibits the strongest level of binding to the ARD of TRPV4 and it is effective in 
regulating TRPV4 activity.  Indeed, the activity of the channel is augmented by titration or 
hydrolysis of membrane PI(4,5)P2.  Interestingly, mutations in TRPV4, which result in “gain- 
of-function”-type channelopathies, eliminate PI(4,5)P2-binding and sensitiy to PI(4,5)P2 on 
the part of the mutant TRPV4 (395).  TRPV4-121AAWAA are mutant TRPV4 proteins which 
do not possess the phosphoinositide-binding site 121KRWRK125 or the normal reaction to 
physiological stimuli.  These mutants change the migration pattern of HEK293 cells in which 
they are expressed.  Cells expressing these mutants also exhibit a diminution in the activity of 
calpain which appears to function in focal adhesion disassembly.  Knock-down of TRPC1 
(which is known to participate in cell migration) results in a similar cell migration pattern to 
that exhibited by HEK293 cells overexpressing TRPV4-121AAWAA (280).     
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       Both high viscous load and hypotonicity activate TRPV4 via a phospholipase A2 (PLA2) 
dependent pathway, with the resulting production of EET being the principal mechanism for 
gating TRPV4.  When only limited activation of PLA2 is possible, these activators also use 
extracellular ATP-mediated production of  PLC-IP3 to regulate TRPV4 channel activity.   IP3 
alone does not activate TRPV4, but, in epithelial ciliated cells and in cells heterologously 
expressing TRPV4, it has been found to be capable of sensitising TRPV4 to EET.  The IP3 
receptor antagonist, xestospongin C, inhibits this effect.  The IP3 receptor engages in a 
physical interaction with TRPV4 (116).  IP3 sensitises TRPV4 to stimulation by mechanical 
and osmotic stimuli as well as to direct EET stimulation.  Binding of the inositol 1,4,5-
trisphosphate receptor type 3 (IP3R3) to TRPV4 is essential for IP3-effected sensitisation of 
TRPV4.   This binding site for IP3R3 resides in a C-terminus region of TRPV4 which is 
coincident with a binding site for CaM (130).  
  
         A 20-amino acid distal segment comprising residues 838-857 in the C-terminus area 
governs channel folding, maturation, and trafficking.  Loss of this segment by mutant 
proteins results in their ending up stuck and unglycosylated in the endoplasmic reticulum 
with early degradation and ending of channel activity.  This segment, comprising residues 
838-857, is believed to adopt a specific conformation, with Gly849 and Pro851 being 
positioned at important locations. Causing the temperature to fall from 37°C to 30°C rescues 
TRPV4 channel function in folding-defective mutants.  Interaction occurs between the C- 
terminus and the N-terminus as well as C-C terminus interaction (222).  Oligomerization is 
dependent on precise domains in both the N-terminus and the C-terminus of TRPV4.  This 
process is preliminary to plasma membrane trafficking and occurs in the endoplasmic 
reticulum (34). 
 
     TRPV4 can become sensitised via both PKC and PKA pathways.  Upon treatment with 
phorbol 12-myristate 13-acetate (PMA), TRPV4 is phosphorylated on Ser824 which activates 
PKC.  When forskolin activates the PKA pathway, Ser824 is also phosphorylated. Influx of 
Ca2+ via TRPV4 is increased in both resting and stimulated cells when phosphorylation is 
mimicked at this site by the insertion of aspartic acid in lieu of Ser824 (317).  PKCa 
facilitates the activation of TRPV4 by acetylcholine in endothelial cells (1). 
 
25 
 
     Interactions with other channels or channel sub-units may alter the behaviour of 
TRPV4.  This may explain why the IV characteristics for TRPV4-dependent responses 
in mature differentiated cells may differ from those identified with  homomeric TRPV4 
channels in expression systems.  Thus, the TRPV4 agonist GSK-1016709A activates a 
current in Muller glial cells that is blocked by the TRPV4 antagonist HC-067047 (332).  
This, however, does not show the classic outward rectification exhibited by homomeric 
TRPV4 (239, 433), being more akin to the stretch-sensitive voltage-independent cation 
current found in cultured Müller glial cells (325).  This difference may reflect changes 
in the biophysical properties of homomeric TRPV4 channels physiologically expressed 
in Müller cells; but it appears more likely that it is due either to the formation of 
heteromeric TRPV4/TRPC1 channels or TRPV4/TRPP channels and/or to linearization 
of the current due to the co-expression AQPs (332).  
 
 
4.  Expression pattern of TRPV4 
 
(i)  Nervous system 
 
        Consistent with its involvement in a wide range of physiological functions, TRPV4 is 
disseminated throughout the body in a number of different cell types (Table 1).  In the central 
nervous system (CNS), functional TRPV4 channels, which are constitutively active at 
physiological temperatures, are found in hippocampal neurons  (294, 355). They are also 
expressed in rat cortical astroglia, being especially plentiful in astrocytic membranes found 
between the brain and extracerebral liquid spaces (35), and in astrocytic “endfeet” that encase 
the blood vessels (102).  Astrocytes possess a TRPV4/Aquaporin-4  complex that is an 
essential component in the brain’s volume homeostasis  (36).  TRPV4 is found in the 
endothelium of cerebral arteries (256), in magnocellular neurosecretory cells (383), and in 
circumventricular organs in the CNS, which is a major location for osmotic sensing (230).    
It is richly expressed in the apical membrane of epithelial cells of the choroid plexus where it 
funtions with anoctamin 1 in cell volume regulation (396).   TRPV4 aggregate in the cell 
body of immature neurons in the hippocampus rather than in post-synaptic locales.  When the 
neurons are maturing, TRPV4 is found in dendrites and also accumulates in post-synaptic 
areas (356).   TRPV4 is expressed in cells of the immortalised neuroendocinre rat 
hypothalamic 4B cell line (340). 
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      TRPV4 is found in peripheral sensory neurons where TRPV4 protein is transported 
distally along the axons in the direction of the peripheral nerve endings (12, 233).   Co-
expression of TRPV4 and TRPV1 is found in a family of DRG neurons in rat and in their 
terminals located in the spinal dorsal horn  (53).    TRPV4-expressing trigeminal ganglion 
sensory neurons (72) innervate the dura (439), while DRG neurons expressing TRPV4 
innervate the colon, skin and internal elastic membrane of the tongue   (44, 367, 388, 389). 
Osmosensitive sensory neurons expressing TRPV4 innervate the blood vessels of the liver 
and have their perikarya in thoracic DRG  (214).  TRPV4 is also expressed in the cauda 
equina  (388), as well as in a range of other sensory and motor elements. These include both 
the inner and outer hair cells and spiral ganglion neurons in the cochlea as well as in 
sympathetic and parasympathetic nerve fibres, including those innervating the arrector pili 
smooth muscle in skin, sweat glands, intestine, and blood vessels  (88, 351, 392, 398). 
TRPV4 is found in the perikarya, axons and dendrites of retinal ganglion cells and at the 
optic nerve head in mouse, as well as in Muller glial cells  (333).  The satellite glial cells  in 
a subpopulation of mouse DRG express functional  TRPV4 (329).  
 
 
(ii)   Other organ systems 
 
       TRPV4 is found in multiple organ systems outside the nervous system.  TRPV4 channels 
are expressed in T cells where their activation results in Ca2+ ingress into those cells (252).  
TRPV4 is found in human corneal epithelial cells, retinal epithelial pigment cells, and 
endothelial cells of the eye  (266, 309, 478), in kidney, liver and heart (2, 88, 159, 168, 180, 
380, 388, 442), as well as in human odontoblast-like cells (105),  and  in the epithelial linings 
of both trachea and lung airways, serous cells of submucosal glands, and mononuclear cells 
(88, 184).   It is also found in the human oesophagus (409), in stellate cells of the human 
pancreas (470), and in Merkel cells from hamster buccal mucosa  (376).   In mouse skin, 
TRPV4 is found in free nerve endings and at cutaneous mechanosensory terminals co-
localised with neurofilament 200, including Meissner, Merkel, penicillate and intraepidermal 
terminals but not including hair follicle palisades (389).   TRPV4 has been suggested to act as 
a sensor/transducer of the mechanical stresses which are induced by flow in the collecting 
ducts of the kidney, where it is found throughout all of the collecting duct system, with 
functional ion channels demonstrated in principal cells and intercalated cells of split-opened 
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cortical collecting ducts and connecting tubules (37, 388).  Functioning TRPV4  is also 
demonstrated in the cell membrane of urothelial cells found in guinea-pig and mouse  (109, 
451, 452), in the urothelium lining the renal pelvis, ureters, urinary bladder, and urethra of the 
rat  (39), while both human and mouse bladders express TRPV4 in bladder urotehlial cell 
membranes near adherence junctions, with these ion channels being molecularly connected to 
those junctions  (183).   TRPV4 is found in primary nasal epithelial cells in humans where it 
regulates Ca2+ levels in epithelial cells and ciliary beat frequency, suggesting a role in 
mucociliary clearance and airway protection (6).   Laryngeal epithelium also expresses 
TRPV4 (153), as does mouse olfactory epithelium (3), and rat oral mucous membrane (283).   
Vascular endothelial cells, including human brain capillary endothelial cells, also express 
TRPV4, as do vascular smooth muscle cells (80, 103, 104, 160, 257, 435), human 
synoviocytes (180), articular chondrocytes   (304),  the guinea-pig and human endolymphatic 
sac  (393), and the acinar cells of the mouse submandibular gland  (472).   TRPV4 is found in 
the endometrium and also in the myometrium of the uterus of the pregnant and the non-
pregnant mouse.  Agonist-induced activation of TRPV4 increases myometrial contractions 
whether the animals are pregnant or not.  The contractions thereby induced can be blocked by 
a TRPV4 antagonist leading to the suggestion that the myometrial contractitlity induced by 
the activation of TRPV4 by endogenous ligands can be reduced by blocking TRPV4 where 
required in pre-term labour  (366).  Human endometrial stromal cells in culture expresss 
functional TRPV4 in both the cytoplasm and plasma membrane (85).  TRPV4 is also 
expressed in human hepatoblastoma (HepG2) cells (422) 
      TRPV4 may also be present in skeletal muscle since exposure to hypo-osmotic solutions 
increases the opening of mechanosensitive channels in skeletal muscle while recordings from 
skeletal muscle taken from TRPV4 knockout mice fail to show mechanosensitive activation 
of that channel  (169).  Functional TRPV4 are particularly plentiful in human pre-adipocytes 
(i.e., adipocyte precursor cells) where they are involved in adipogenesis via phosphorylation 
of Akt kinase  (66).  Functional TRPV4 receptors are found in human sebocytes where 
they mediate the lipostatic and antiproliferative effects of cannabidiol (305).   TRPV4 is 
also found in monocytes and in monocyte-derived dendritic cells (Szollosi et al., 2013), 
as well as in Langerhans' cells (385) , and in human pluripotent stem cell-derived 
cardiomyocytes in culture (326).     
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5.  Activators of TRPV4  
 
(i) Mechanical deformation and osmotic stimuli 
 
       The sensitivity of a mouse’s tail to pressure is markedly reduced when the TRPV4 gene 
has been disrupted.  Both the threshold to noxious stimulation by pressure and the conduction      
speed of myelinated nerves in response to pressure are also reduced  (388).    This suggests 
that TRPV4 is involved in the transduction  of mechanical pressure applied to tissues when 
that pressure goes beyond light touch.  However, TRPV4 is also a more subtle transducer of 
pressure at the cellular level in that it responds to extracellular osmotic pressure.   Indeed, 
TRPV4 was originally known as vanilloid receptor-related osmotically activated channel 
(VR-OAC) because it was first characterised as a receptor which responds to changes in 
extracellular osmolarity (Figure 6).  Thus, Strotmann and colleagues (2003) found that, in 
isotonic media, TRPV4 exhibits spontaneous activation.  However, decreases in extracellular 
osmolarity result in rapid TRPV4 activation, while increases in extracellular osmolarity 
inhibit activation of TRPV4  (380).  The role of extracellular hypotonicity as an activator of 
TRPV4 is well-established, but the effect of extracellular hypertonicity is less definite 
although this can, in some circumstances, result in TRPV4 activation.   Levine’s group have 
shown that exposure to hypotonic solution activates 54% of C-fibers in rat and that this effect 
is enhanced by PGE2   (12). They have also shown that TRPV4 mediates pain induced by 
mild hypertonicity in rat where intradermal injection of 2 per cent saline solution in the 
animal’s hind-paw induces a concentration-dependent pain-related behaviour, flinching  (11). 
Observations on pressurised arterioles also support the concept that TRPV4 channels are 
sensitive to mechanical loading, since reductions in intravascular pressure activate 
endothelial TRPV4 channels (22).  
 
      There is no evidence yet that TRPV4, across its multiple applications, acts as a sensory 
transducer in respect of mechanical force applied to the cell membrane. It has yet to be 
established that activation of TRPV4 as a result of force applied to the cell membrane can 
produce the graded response typical of sensory transducers.  Hence, the use of the descriptive 
terms “osmosensor” and “mechanosensor” in relation to TRPV4 has the potential to mislead.  
On the other hand, it is eminently clear that TRPV4 does respond, in several organ tissue 
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types at least, to the application of force to the cell membrane – whether that mechanical 
force is generated by hypotonicity, hypertonicity or trauma – to induce physiological effects. 
So it is certainly correct to describe TRPV4 as being “mechanosensitive.”  However, it is not 
established how the mechanical pressure brings about the gating of TRPV4 in those contexts 
where the ion channel is activated by mechanical force to induce physiological effects.  That 
mechanical pressure when applied to the cell memberane will typically result in (some) 
deformation of the cell membrane seems obvious.  The concept of deformation of the cell 
membrane embraces that of “cell stretch,” although such deformation may also be envisaged 
without cell stretch.  Certainly, it is now clear that “cell stretch” can activate TRPV4 in 
multiple organ tissue types. Thus, in urothelial cells from TRPV4 null mice, the increase in  
[Ca2+]i  evoked by stretch applied in a cell-stretch system is significantly reduced compared 
to that evoked in wild-type cells  (272), while TRPV4 in capillary endothelial cells adherent 
to flexible extracellular matrix substrates are activated when cyclically stretched  (400).  
Again, rat TRPV4 responds to pipette suctions that stretch the excised membrane patches  
(239), while “shear stress” evoked by flow, which inevitably involves stretch, activates 
TRPV4 in vascular endothelium  (263).   Finally, Merkel cells from hamster buccal mucosa 
express TRPV4 which are activated by membrane stretch (376). 
    The further (controversial) question remains, however, as to what constitutes the 
mechanism of action of such cell stretch, or other deformation of the membrane, which 
induces the activation of TRPV4?  There are several possible mechanisms of activation of 
TRPV4 in this context. First, TRPV4 may respond directly to the effect of mechanical 
deformation of the membrane. Variations in tonicity of the extracellular fluid may result in 
activation of TRPV4 to the extent that they alter the tension in the cell membrane.   On this 
view, mechanical deformation of the membrane  – whether secondary to hypotonicity or to a 
direct mechanical pressure impinging on the cell membrane – is the ultimate activator of 
TRPV4 by mechanical pressure.   Liedtke (2005), however, has correctly observed that a 
change in cell volume does not necessarily lead to a significant alteration in membrane 
tension where the membrane is loose as a result of its engagement in some other function, 
such as process formation  (228).  Loukin and colleagues (2010) expressed rat TRPV4 in 
Xenopus oocytes and repeatedly examined more than 200 excised patches bathed in a simple 
buffer.  They found that TRPV4 can be activated by tens of mm Hg pipette suctions with 
open probability rising with suction even in the presence of relevant enzyme inhibitors 
designed to eliminate any effect of enzymes brought into existence by the suction pressure   
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(239). Janssen and co-workers (2011) found TRPV4 to be present in human bladder 
urothelial cell membranes near adherence junctions and also identified the existence of a 
molecular connection of the ion channel to alpha-catenin (a component of the adherence 
junction that ties E-cadherin to the actin-microfilament network).  They suggested that the 
binding of TRPV4 to a rigid intracellular and intercellular structural network is consistent 
with the hypothesis that TRPV4 is activated by bladder stretch  (183).  TRPV4 has been 
shown to function in the cyclic stretch-induced realignment of human pluripotent stem 
cell-derived cardiomyocytes  in culture. Longitudinal stretch induces an increase in 
[Ca2+]i  which is inhibited by antagonists of TRPV4. Moreover, 2 hours of uniaxial 
cyclic stretch results in a realignment of these cells in the direction transverse to the 
direction of stretch – a result which is also inhibited by antagonists of TRPV4 (326).   
The evidence of TRPV4 interaction with the cytoskeleton  (142) supports the concept of 
mechanical deformation of the cell membrane per se being capable of activating TRPV4.   
Interestingly, the stretch-activated channels (SACs) TRPC1 and TRPC6 are also activated by 
mechanical and hypotonic stimuli and these ion channels are often found expressed with 
TRPV4 in DRG neurons.  Spinal intrathecal administration of oligodeoxynucleotides 
antisense to TRPC1 and TRPC6, or to TRPV4, reverses the hyperalgesia to mechanical and 
hypotonic stimuli induced by inflammatory mediators without affecting baseline mechanical 
nociceptive threshold, and it has been proposed that TRPC1 and TRPC6 channels cooperate 
with TRPV4 channels to mediate mechanical hyperalgesia and primary afferent nociceptor 
sensitisation  (7, 290).  Although the view that cell stretch does not gate TRPV4 by 
deformation of the membrane simpliciter appears to be in the ascendency at the moment, 
there are two very plausible mechanisms whereby mechanical force could gate the TRPV4 
channel  (315).  Thus, the application of mechanical force to the cell membrane can effect an 
alteration in the forces active within the lipid membrane which effect conformational changes 
within the ion channel and result in channel gating because of energy differences created 
between membrane tension in the open and closed conformations, respectively.  In this 
context, the lipid-bilayer directly effects the opening of TRPV4 when appropriate mechanical 
force is applied to the membrane. An alternative theory postulates that the opening of TRPV4 
is mediated by the response to mechanical force applied to cell membrane structures attached, 
or tethered, to the ion channel.  These structures include accessory proteins, the cytoskeleton 
or even the extracellular matrix.  The mechanical force is transmitted via these structures to 
effect an alteration in the conformation of the channel which results in gating  (46, 208, 315).  
In the case of the TRAAK and TREK1 ion channels – which are mechanosensitive K+ 
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channels with a two-pore domain – gating has recently been shown to be effected directly via 
the lipid bilayer  as “membrane-tension-gated” channels (46).  The manner in which the 
tension of the lipid bilayer is employed to regulate the gating and mechanosensitivity of the 
TRAAK ion channel has also been elucidated.  In the non-conductive state, the passage of 
ions is physically prevented by a lipid acyl chain entering the channel pore via a 5 Å-wide 
lateral opening in the inner leaflet of the cell membrane.  In the conductive state, ion entry is 
allowed by the action of a transmembrane helix (TM4) which rotates about a central hinge to 
seal the intramembrane opening and preclude the lipid block of the pore.  An increase in 
cross-sectional area of up to 2.7 nm2 in the conductive state is believed to result in a 
membrane-tension-dependent difference in energy levels between conformations that induces 
force activation  of the chanel  (45).  These findings support the plausibility of TRPV4 being 
gated directly by the application of force to the cell membrane – although, given its range of 
activators, it could not be unexpected that TRPV4 should have more than a a single 
mechanism of activation  (426). 
 
    A further putative mechanism of action which is consistent with the mechanosensitivity of 
TRPV4 is that membrane deformation may cause the release and activation of membrane 
products which, in turn, effect gating of TRPV4.  Thus, cell swelling has been described as 
activating TRPV4 by means of PLA2-dependent formation of arachidonic acid and its 
subsequent metabolization to 5’,6’-EET by means of a cytochrome p450 epoxygenase-
dependent pathway (434).   The implication of these latter findings is that it is not necessarily 
the abnormal mechanical pressure, as such, that proximately gates TRPV4 but rather the 
chemical signals generated in response to changes in cell stretch or other deformation of the 
cell membrane.  Both high viscous loading and hypotonicity have been said to employ the 
activation of phospholipase A2 (PLA2) and the resulting production of EET as the principal 
mechanism for gating TRPV4 in native ciliated epithelial cells.  When  only limited 
activation of PLA2 is possible, these stimuli employ  extracellular ATP-mediated activation 
of  IP3 to gate TRPV4.   IP3 is not itself an agonist of TRPV4.  However, it has been found to 
sensitise TRPV4 to EET in epithelial ciliated cells and in cells which heterologously express 
TRPV4.  The IP3 receptor antagonist, xestospongin C,  inhibits this result. A physical 
interaction appears to occur between TRPV4 and IP3 receptor 3 (116).   IP3-mediated 
sensitisation of TRPV4 requires IP3 receptor binding to a C-terminus domain of TRPV4 
which coincides with the location of a CaM binding site (130). 
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       A third possibility is that alterations in extracellular tonicity per se (induced by 
mechanical pressure or otherwise) activate intracellular proteins independently of affecting 
membrane tension, and that this in turn leads to gating of TRPV4. Osmotic stimulation can 
result in the activation of a succession of intracellular phosphorylation/dephosphorylation 
signalling processes (42, 43, 228).   
 
    Whatever the underlying mechanism of activation, TRPV4 is undoubtedly important in the 
homeostatic control of cell volume in the face of an osmotic challenge. When the 
extracellular fluid is hypotonic (i.e., at lower osmotic pressure than that found within the 
cell), the cell swells due to osmosis.  Swelling is followed by RVD, which allows the cell to 
regain its former volume notwithstanding that the extracellular fluid remains hypotonic.  
Studies  in a human keratinocyte cell line indicate that TRPV4 directly participates in RVD 
(33). Hypotonicity increases the association and surface expression of the water permeable 
channel AQP5 and TRPV4 in salivary gland cells. Both channel association and trafficking, 
as well as RVD, are reduced by actin depolymerization.  Activation of TRPV4 by 
hypotonicity does not depend on cell swelling itself, but rather on AQP5.  TRPV4 and AQP5 
are together believed to control RVD (234).  Hypotonic stress results in phosphorylation of 
residue Tyr253 of TRPV4 by a Src family tyrosine kinase.  This residue is essential for 
channel function in this context as a point mutation of Tyr253 precludes the activation of 
TRPV4 by hypotonicity (450).  Extracellular hypotonic solution induces stretch of the plasma 
membrane of mouse odontoblast lineage cells which results in TRPV1-, TRPV2-, and 
TRPV4-, mediated Ca2+ influx and inward currents.  The increase in intracellular-free Ca2+ 
concentration is extruded by Na+-Ca2+ exchangers (339).   Although TRPV4 directs 
behavioural responses to osmotic and mechanical stimuli (230), base-line sense of touch and 
non-noxious/non-nociceptive light touch are not mediated by TRPV4, i.e., TRPV4 only 
detects “a nociceptive level of mechanical stimuli” (389).    
 
      TRPV4 may not always promote RVD, as TRPV4 inhibition actually decreases 
swelling in response to hypotonic challenge in both Müller glial cells and ganglion cells 
(332).  This detailed study also identified key differences between the TRPV4-mediated 
response to extracellular hypotonicity in these two cell types, with distinct kinetics and 
activation pathways. Hypotonic activation of TRPV4 in retinal glial cells, but not in 
retinal neurones (ganglion cells), was dependent on a phospholipase A2/cytochrome 
p450 pathway. TRPV4 mediated increases in [Ca2+]i were seen in Muller glial cells when 
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extracellular tonicity was reduced to less than 70% of normal, with a maximal response 
at or below 50% (332). 
 
(ii) Heat 
    
      TRPV4 can be activated by heat.  When the temperature is increased above 25oC.  
currents are activated and [Ca2+]i  is increased in both HEK293 cells transfected with TRPV4 
and in endothelial cells of mouse aorta.  However, after removal of the three N-terminus 
ankyrin binding domains of TRPV4, heat fails to activate transfected TRPV4 in HEK293 
cells (435).   It has subsequently been found that this failure in activation is due to a defect in 
TRPV4 expression at the cell membrane in HEK293 cells and, moreover, that TRPV4 loses 
its sensitivity to stimulation by heat when expressed in excised cell membrane patches  (76, 
435).  TRPV4 generates large inward currents in Xenopus oocytes, as well as inward currents 
and Ca2+ influx in HEK293 cells, at temperatures which are less than those needed to activate 
TRPV1. The TRPV4 response to heat is increased in hypo-osmotic solutions and reduced in 
hyperosmotic solutions.  The threshold for activation of TRPV4 by heat varies with the 
context in which these ion channels are expressed.  Thus, activation of TRPV4 is found at 
temperatures >27˚ C in oocytes, while in HEK293 cells the threshold for activation is ~34˚ C.  
Continued stimulation of TRPV4 with heat above these thresholds causes the channel to 
desensitise.  However, once TRPV4-expressing HEK293 cells have been acclimated at 37˚ C, 
TRPV4 has the capacity to respond to additional increases in temperature (151).  This implies 
that this ion channel is constitutively active at normal body temperature.  Moreover, heat, at 
37°C, increases the efficacy of other stimuli in activating TRPV4  (129).   Heat (and phorbol 
esters) activate TRPV4 by means of a pathway in which an aromatic residue at the N-
terminus of the third transmembrane domain plays an essential role and which is independent 
of PLA2 and cytochrome P450 epoxygenase (426).   The heat-evoked currents observed in the 
majority of mouse keratinocytes appear to involve TRPV4 and exhibit an activation threshold 
of ~32 °C.  (76, 77). 
     Behaviourally, there is no agreement on the role of TRPV4 as a contributor to thermal 
responsiveness in vivo, although it does not appear to be a critical regulator of behaviour in 
response to heat.  Thus, TRPV4 null mice have been found by Lee and colleagues to select 
warmer floor temperatures than wild-type mice and to respond with extended withdrawal 
latencies during acute application of heat to the tail, although no distinction is found between 
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normal and knockout mice as regards circadian body temperature fluctuations and 
thermoregulation in a warm environment (217).  Todaka and colleagues found that wild type 
and TRPV4 null mice show the same latency of escape from 35-50oC hot-plates;  but mice 
lacking TRPV4 which suffer hyperalgesia as a result of carrageenan injection take a 
significantly longer time to leave hot-plates at 35-45oC than do wild-type animals  (404).  On 
the other hand,  Huang and co-workers found that TRPV4 knockout mice show thermal 
preference behaviour similar to wild-type animals on a thermal gradient, and little or no 
change in acute heat nociception or inflammatory heat hyperalgesia, even when TRPV1 is 
inhibited.  These authors conclude that the probability is that the involvement of TRPV4 in 
sensing harmless and noxious heat sensations is limited and strain-dependent and that one 
must look elsewhere to find the mechanism(s) which act as thermosensor  (175, 423).   It has 
been suggested that  thermosensation in mammals depends almost totally on two populations 
of sensory neurons which are “differentially tuned” to detect a range of temperature 
sensations (cold, cool, warm and hot).  Thus, neurons that express TRPV1 respond to high 
temperature and mediate the behavioural responses in mouse in the temperature range of 40o 
C to 50o C.  Neurons that express TRPM8  are responsible for cold aversion.  More extreme 
cold and heat cause the activation of further populations of sensory neurons, including those 
which express Mrgprd   (321). 
     Nicotinic acid, which inhibits the activity of TRPV4, also increases the ion channel’s 
threshold for activation by heat (242). 
    Activation of peripheral TRPV4 channels by topical treatment of the skin of rat with a 
TRPV4 agonist, RN-1747, results in hypothermia caused by activation of  peripheral TRPV4 
channels.  Blocking TRPV4 by intravenous admnistration of HC-067047, a TRPV4 
antagonist, increases core body temperature when the temperature of the surrounding 
environment is at 26° C or 30° C, but does not do so at 22° C or 32° C.   The hyperthermia 
induced at 26° C develops with a concomitant  increase in the animal’s  consumption of 
oxygen, while pharmacological activation of  TRPV4 results in an increase in tail heat loss, 
suggesting the involvement of TRPV4 in mediating these autonomic functions in rat  (418). 
 
(iii) pH 
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     TRPV4 expressed in vitro in Chinese hamster ovary cells has been reported to be opened 
by low pH or citrate, and mice which lack the TRPV4 receptor exhibit a substantially 
diminished response to acids (388).  On the other hand, acid (pH 5.0) has been found to 
inhibit Ca2+ influx via TRPV4 in mouse oesophageal epithelial cells, leading to the 
suggestion that the exposure to gastric acid of cells which express TRPV4 – as occurs in 
cases of gastro-oesophageal reflux disease – may adversely affect cell function and aggravate 
the sufferer’s condition  (359). 
 
 
(iv) PLA2-mediated metabolites of arachidonic acid 
 
     The endogenous cannabinoid neurotransmitter, anandamide, also known as N-
arachidonoylethanolamine, and its metabolite, arachidonic acid, gate TRPV4 channels 
indirectly via the formation of epoxyeicosatrienoic acids (EETs)  in a cytochrome P450 
epoxygenase-dependent pathway.  Arachidonic acid induces Ca2+ entry into coronary 
endothelial cells via TRPV4.  The initiation of this Ca2+ response involves, inter alia, 
membrane hyperpolarisation, phosphorylation of TRPV4 via PKA, and the action of 
arachidonic acid on gating of TRPV4 (Zheng et al., 2013)  (480).   TRPV4 is activated in a 
membrane-delimited fashion by the application of 5’,6’EET at below micromolar 
concentrations.  The like application 5’,6’EET occasions Ca2+ influx through TRPV4 
channels in vascular endothelial cells ((424, 434); Figure 6).    Cannabidiol activates TRPV4 
in cultured human sebocytes and human skin organ culture (305). 
 
        The N-acyl amides are a family of endogenous lipids which are structurally similar to 
anandamide and may provide activators of TRPV4   (327).    Indeed, N-arachidonoyl taurine 
has been shown to activate TRPV4 as well as TRPV1, although it fails to activate the CB 
receptors (334).   
 
(v) Inflammation 
      Inflammation increases interstitial fluid volume and tonicity, with local accumulations of 
cellular debris and other products of the inflammatory response. This creates abnormal 
mechanical pressures on the plasma membranes of local cells and inflammagens are 
inevitably introduced into the immediate environment of these cells (440).  In addition, 
TRPV4 is capable of being gated in response to one, or more, products of the local 
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inflammatory response to injury.   For example, increased tissue temperature and, and in 
certain instances, reduced pH have been found to activate TRPV4 (supra); and these are also 
components of the local inflammatory response.  Exposure to hypotonic solution or 
administration of 4α-PDD results in the release of neuropeptides in the urinary bladder and 
airways of mice.  Oedema formation, as well as recruitment of granulocytes, results from 
intraplantar injection of the same TRPV4 activators.  Moreover, knockdown of the TRPV4 
gene, or its deletion, reduces the oedema formation as well as granulocyte infiltration which 
results from intraplantar formalin injection in the mouse  (413).  The combination of an 
inflammatory mediator with a mild hypertonic stimulus activates TRPV4 to induce  
behaviour attributable to pain in animals  (11).   Ablation of TRPV4 in rat eliminates the 
increase in the pain-induced paw-withdrawal reflex which is found on exposure to 
mechanical or hypotonic stimulation after intradermal injection of carrageenan or a “soup” of 
inflammagens.  Consistent with the foregoing, intradermal injection of inflammatory soup 
fails to elicit significant osmotic or mechanical hyperalgesia in TRPV4 knockout mice (8).  
When prostaglandin E2 and serotonin is injected into the mechanical receptive fields of C-
fibres in wild-type and TRPV4 knock-out mice, the wild-type animals show both an increase 
in the number of C-fibres which respond to hypotonic stimuli and an increase in the extent of 
that response when compared with mice which lack TRPV4.   Moreover, evidence of receptor 
sensitisation, in the form of more spontaneous activity and reduced mechanical threshold, is 
only found in C-fibres from the wild-type animals  (70).  When activated, the TRPV4 found 
in epithelial cells of the intestine results in chemokine release and colitis.  The development 
of colitis is associated with an increase in colonic permeability  (82).   Increased expression 
of TRPV4 mRNA is found in the gastrointestinal tract of  patients suffering from 
inflammatory bowel diseases.  Moreover, in an animal model of colitis, specific inhibition  of 
TRPV4 reduces colitis and intestinal inflammation-induced pain  (119).  TRPV4 is sensitised 
to agonist challenge by prior exposure to serotonin or histamine.  Such exposure also results 
in increased expression of TRPV4 in the plasma membrane of sensory neurons in the colon    
(59). Protease-activated receptor 2 (PAR2), when activated, sensitises TRPV4 to result in 
mechanical hyperalgesia, while removal of TRPV4 prevents mechanical hyperalgesia 
induced by agonist activation of PAR2 and sensitisation  (147).    Activation of  PAR2  
induces only a transient increase in [Ca2+]i  in cells which do not express TRPV4.  However, 
in the presence of TRPV4, activation of PAR2 leads to a sustained increase in [Ca2+]i.  This 
activation of TRPV4 by PAR2  is dependent on a key tyrosine residue (Tyr-110)  without 
which PAR2 is unable to activate TRPV4  (322).   Cathepsin S is another product of the 
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inflammatory response which can activate PAR2 which then activates TRPV4.  Its injection 
in mouse results in inflammation and hyperalgesia which is reduced by deleting either PAR2 
or TRPV4 or by inhibiting adenylyl cyclase  (476).    TRPV4 functions in the development of 
inflammation in adipose tissue in mice occasioned by inflammatory insult, although this may 
be ameliorated by a prior regime of exercise.   Exercise-trained mice show a reduction of 
∼50% in the genes for IL-6, SOCS3 and tumour necrosis factor alpha (TNF-α) in epididymal 
adipose tissue induced by acute inflammatory challenge, as well as a reduction in the 
increases in plasma IL-6 found in non-trained animals.  These results are associated with 
reduction in the expression of TRPV4   (56).   Expression  of  TRPV4 is increased in burn 
scars which exhibit post-burn pruritus  (456). 
 
(vi) Dimethylallyl pyrophosphate (DMAPP)  
 
      Dimethylallyl pyrophosphate (DMAPP) is an endogenous activator of TRPV4.   TRPV4 
is activated by micromolar concentrations of DMAPP  in transfected HEK cells, in cultured 
sensory neurons and in keratinocytes. DMAPP induces acute inflammation and noxious 
mechanical hypersensitivity in a TRPV4-dependent manner   It also acutely elicits flinching 
on intraplantar injection in vivo in mice which is prevented by pre-treatment with TRPV4-
blockers (27). 
 
 
(vii)  Phorbol derivatives: 4α-PDD and PMA 
 
      Phorbol is an organic compound obtained from croton oil which comes from the seeds of 
croton plants.  Phorbol derivatives are agonists at the TRPV4 ion channel and are capable of 
directly gating TRPV4   (432).    The phorbol ester, 4α-PDD, is the most specific known 
agonist of TRPV4 and one of its most effective activators (Figures 2(B) & 8(B)).  It is 
widely employed experimentally, although its exclusivity for TRPV4 as its target receptor 
has been put in issue by the claim that it can activate cultured mouse DRG neurons 
independently of  TRPV4  (13).   Phorbol 12-myristate 13-acetate (PMA) is a powerful 
activator of PKC but is some 50 times less effective than 4α-PDD in effecting an increase in  
[Ca2+]i  in transfected TRPV4-expressing cells, notwithstanding its structural similarity to 4α-
PDD  (432).  Exposure to 4α-PDD induces a monophasic or biphasic increase in [Ca2+]i.  The 
PMA-induced  increase in [Ca2+]i  is eliminated where a PKC-specific inhibitor has been 
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introduced before exposure to PMA.  However, the same inhibitor has no effect on the 
increase in  [Ca2+]i  caused by 4α-PDD, which proves the involvement of mechanisms which 
are, respectively, dependent and independent of PKC in the activation of TRPV4 by phorbol 
esters  (448).   Gating by 4α-PDD of TRPV4 channels depends on the presence of both 
extracellular and intracellular Ca2+.  Mutations of single amino acid residues in the sixth 
transmembrane domain and in the C-terminus of TRPV4 affect this gating (433).  Mutations 
of two hydrophobic residues in the central part of transmembrane segment 4 (Leu584 and 
Trp586) result in a substantial loss of sensitivity of TRPV4 to 4α-PDD, bisandrographolide 
A, and heat.  However, these mutations do not affect the response of TRPV4 to arachidonic 
acid, 5,6-EET, or cell swelling. In contrast, gating of TRPV4 by multiple activating stimuli is 
affected by mutations of two residues in the C-terminus part of transmembrane segment 4 
(Tyr591 and Arg594).  This implies that these mutations impact on channel gating rather than 
with the channel’s activators (425).  Ligand-binding affinity for TRPV4 has been proposed to 
be determined by the length of the fatty acid moiety (425).   Phorbol esters and heat rely on 
an activation pathway for TRPV4 which is independent of both PLA2 and cytochrome p450 
epoxygenase.  This pathway depends on an aromatic residue at the N-terminus of the third 
transmembrane domain  (426).   4α-phorbol esters bind in a loop found in the TM3-TM4 
domain of TRPV4.  This binding site is similar to that of capsaicin to TRPV1.   Both the ester 
decoration of ring C as well as the A,B ring junction have been found to be essential for 
activity.   Ring C has lipophilic ester groups which are important in directing the diterpenoid 
core into the pocket of the ligand-binding site.  The A,B ring junction is responsible for the 
activation of TRPV4 being dependent on Ca2+.   4α-PDH exhibits a potency in activating 
TRPV4 which is almost five times greater than that of 4α-PDD  (201). 
  
(viii) Other plant extracts 
 
      Bisandrographolide A (BAA) is to TRPV4 what capsaicin is to TRPV1, i.e., a potent 
plant-derived agonist exclusive to its target receptor.  BAA is a compound isolated from an 
extract of the plant Andrographis Paniculata which can activate TRPV4 with an EC(50) of 
790-950 nM.  However, it does not activate, or block activation of, TRPV1, TRPV2, or 
TRPV3 channels.   BAA activates a large TRPV4-like current in immortalised mouse 
keratinocytes (308 cells) which are known to possess TRPV4. It also generates TRPV4 
currents in outside-out patches from HEK293T cells which overexpress TRPV4 cDNA   
(369, 425). 
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        Apigenin is a plant-derived flavone which is also an agonist at the TRPV4 receptor.  
Apigenin gates TRPV4 dose-dependently in HEK cells which over-express this receptor and 
in native endothelial cells.  It acts on TRPV4 in endothelial cells of small mesenteric arteries 
in rat to induce endothelium-derived hyperpolarizing factor (EDHF)-mediated dilation   
(246). 
 
        Eugenol is a liquid which can be obtained from the oil of cloves and from that of several 
other plants.  It is used as an analgesic in dentistry.  It is a vanilloid molecule which activates 
TRPV4 ion channels expressed in the endothelial cells of rat mesenteric arteries to dilate 
those blood vessels and reduce the systemic blood pressure (316). 
 
     Plant cannabinoids, like cannabidivarin and tetrahydrocannabivarin, exert agonist effects 
at TRPV4 to increase [Ca2+]i with an efficacy and potency in the moderate to high range.  
Plant cannabinoids also act as potent desensitizing agents of TRPV4  (92). Cannabidiol  
activates TRPV4 in cultured human sebocytes and human skin organ culture (305). 
 
(ix)  Sensitisation of TRPV4 by phosphorylation  
     Src family tyrosine kinases (SFKs) mediate tyrosine phosphorylation of TRPV4 (437, 
450).  Tyr110 and Tyr805 are SFK-induced phosphorylation sites found in the N-terminus 
and C-terminus cytosolic tails in TRPV4, respectively.  Phosphorylation of the N- terminus 
tyrosine by SFKs is effected before the activation of TRPV4 which suggests that  tyrosine 
phosphorylation sensitises TRPV4 rather than activates it.  The fact that reactive oxygen 
species, which are involved in mediating inflammatory pain, potently up-regulate the 
phosphorylation of TRPV4 when SFKs are present is consistent with a role for TRPV4 in 
mediating inflammatory pain (4437).  The phosphorylation of specific sites of the TRPV4 ion 
channel by PKC and PKA increases the activation of the ion channel.  Such phosphorylation 
requires the assembly by AKAP79 of  PKC and PKA into a signaling complex with TRPV4   
(112).  PMA induces the phosphorylation of TRPV4 on Ser824 which is found in the C-
terminus cytosolic tail of the ion channel.  PKC, and perhaps also PKA, phosphorylate this 
ion channel at Ser824 resulting in its sensitisation (317).  In addition, phosphorylation at 
Ser824 is necessary for the interaction of TRPV4 with F-actin, as well as the appropriate 
subcellular localisation of TRPV4. Phosphorylation at this site not only promotes the activity 
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of the channel but also results in protein stability as well as expansion of the cell membrane  
(361). PKC and AKAP150 (the anchoring protein for PKC) are necessary for TRPV4 
activation mediated by muscarinic receptors (375).  
 
(x)  Involvement of Protein Kinase G in TRPV4-mediated effects 
      Protein Kinase G (PKG) – also known as cGMP-dependent protein kinase – is a 
serine/threonine specific protein kinase which phosphorylates a variety of targets relevant to 
TRPV4.  Vascular smooth muscle hyperpolarization and relaxation in coronary arteries 
induced by 11,12-EET is inhibited by NO. This depends on a PKG-pathway 
which phosphorylates TRPC1 in the TRPV4-TRPC1-KCa1.1 complex at Ser172 and 
Thr313 (471). Flow-mediated Ca2+ influx into M1-cortical collecting duct 
cells via heteromeric TRPV4-P2 channels is inhibited by the actions of cGMP and PKG on 
these ion channels, through phosphorylation of TRPP2T719A and TRPP2S827A   (99). The flow-
induced ingress of Ca2+ into vascular endothelial cells via the TRPV4-C1 complex is also 
negatively controlled by PKG  (247). It appears that increases in [Ca2+]i resulting from 
activation of TRPV4 occasioned by hypo-osmotic stress of outer hair cells in the cochlea of 
the guinea pig result in the production of NO which, in turn, inhibits [Ca2+]i increase by a 
NO-cGMP-PKG pathway feedback mechanism (397). Similarly, increased intravascular 
pressure in pulmonary microvessels  induces TRPV4-mediated endothelial Ca2+-entry in 
endothelial cells, which both increases vascular permeability and activates a NO-dependent 
negative-feedback mechanism limiting the rises in both [Ca2+]i  and filtration coefficient   
(458). Inhibition of PKG reduces thermal hyperalgesia (evidenced by a decrease in pain-
related behaviour on exposure to heat) in rats suffering from chronic compression of the 
DRG, suggesting that a TRPV4-NO-cGMP-PKG pathway may contribute to thermal 
hyperalgesia resulting from this type of injury  (94). 
 
(xi)  Effect of serotonin or histamine on TRPV4 activation 
     There is some evidence that serotonin can activate TRPV4 in pulmonary arterial smooth 
muscle cells in rat (101).   TRPV4 is sensitised to agonist challenge by prior exposure to 
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serotonin or histamine.  Such exposure also results in increased expression of TRPV4 in the 
plasma membrane of sensory neurons in the colon   (59). 
 
(xii)  UVB radiation 
      UVB radiation activates epidermal TRPV4 in rat which, in turn, results in an increase in 
the expression of endothelin-1 which mediates pain.  TRPV4 is therefore implicated in the 
pain and tissue damage caused by sunburn  (276).  
 
 
6. TRPV4 as a molecular integrator of diverse stimuli 
 
      TRPV4 is a polymodal ion channel, activated by a range of diverse stimuli. 
Simultaneously applied stimuli of quite different natures may interact so that their effect, as 
mediated by TRPV4, is not necessarily determined by the sum of the responses to the same 
stimuli when applied individually. Thus, exposure of cells transfected with TRPV4 to 
hypotonic solution at room temperature, or to 4α-PDD, induces minor channel activation, 
while PMA and shear stress have little, or no, effect on activation of TRPV4.  However, at 
physiological body temperature (37˚C), TRPV4 is readily activated by all agonist stimuli     
(129).  This response is typical of many TRP channels and denominates  them as efficient 
integrators of numerous diverse stimuli arising from various independent inputs. The 
resulting channel behaviour  is characteristic  of signalling patterns seen in many 
physiological and pathophysiological conditions  (157). 
 
 
7.  Antagonists of TRPV4 
 
      Known agonists and antagonists of TRPV4 are shown in Table 2. A selective antagonist 
of TRPV4 has yet to be definitively identified, but HC-067047 is believed to be selective for 
TRPV4.  Ruthenium red is commonly used in experiments as a TRPV4 channel blocker that 
reversibly inhibits inward but not outward TRPV4 currents (432), but it is not selective for 
TRPV4.  Like gadolinium and lanthanum, ruthenium red inhibits TRP channels generally  
(220, 296).   Citral is sometimes mentioned as an antagonist of TRPV4, but it has multiple 
actions, activating TRPV1, TRPV3, TRPM8, and TRPA1 in primary afferents and producing 
a persistent blocking of TRPV1, TRPV2, TRPV3, and TRPM8 and temporary inhibition of  
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TRPV4 and TRPA1 (379).  The plant alkaloid, berberine, found in various Chinese 
herbal remedies, inhibits TRPV4 (429). Several small molecules have been suggested to 
function in the relief of various conditions (166), most strikingly in relation to the resolution 
of pulmonary oedema resulting from heart failure where GSK2193874 has been shown to 
function as an orally effective TRPV4 antagonist which blocks the influx of Ca2+ through 
recombinant TRPV4 ion channels as well as native TRPV4 currents in endothelium  (176, 
401).  However, none have been shown to be selective for TRPV4.  Butamben blocks TRPV4 
at micromolar concentrations, and it reduces acute animal pain behaviours in a TRPA1- or 
TRPV4-dependent manner (26).   Resolvin D1 (RvD1)  is an endogenous anti-inflammatory 
lipid molecule which reduces the activation of TRPV4 (and also TRPV3 and TRPA1) at 
nanomolar and micromolar concentrations.  It can also produce an analgesic effect in the 
context of inflammatory pain (28).  Given the problems of collateral injury presented even by 
a selective TRPV4 antagonist when administered for a therapeutic purpose, a non-specific 
channel inhibitor which coincidentally blocks other TRP channels in addition to its TRPV4 
target, presents extraordinary risks of complications arising out of its use in drug therapy.   
The antagonist RN-1734 completely inhibits both ligand-induced, and hypotonicity-induced, 
activation of TRPV4, without affecting the activity of other TRP channels, including TRPV1, 
TRPV3 and TRPM8, making it a useful tool for laboratory use  (417).   However, as with 
TRPV1, the difficulty in developing an antagonist of TRPV4 for therapeutic purposes resides 
in identifying a potent, selective and bioavailable small molecule which can target the 
TRPV4 channels of interest while preserving the function of TRPV4 channels necessary for 
non-pathological physiology.  HC-067047 is a  TRPV4 antagonist that has been found to 
improve working bladder capacity and to reduce frequency of micturition in rats and wild-
type mice with cystitis.  At the same time, it does not have an effect on bladder function in 
mice which lack TRPV4, suggesting that it may have a selective beneficial effect in this 
context  (110).    
 
 
8.  TRPV4 knockout mice 
 
    Two different “knockout” mouse models of TRPV4 have been developed (230, 270).  So 
where there is a conflict between the results of similar experiments derived from the 
responses of TRPV4 null mice, the initial question to be considered is whether that conflict 
may be capable of explanation by different TRPV4 knockout models having been used in the 
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respective experiments.  An additional complication concerns the reliability of TRPV4 null 
mice as an indicator of TRPV4 function.  In the case of animals which have been genetically 
engineered, there is always a question as to whether loss of the “knocked-out gene” has led to 
compensatory changes in the developmental physiology of the animal with the result that the 
knockout phenotype ceases to be a reliable indicator of the function of the knocked out gene.  
This concern is particularly acute in the case of TRPV4 knockout animals because of the 
importance of TRPV4 in homeostatic mechanisms.  Put simply, in the absence of the 
development of compensatory physiological changes, what we know of TRPV4 – not least in 
relation to its function in the cardiovascular system – would suggest that its efficient deletion 
throughout the entire animal would prove lethal to the animal.    
       It appears that neither muscular strength, exercise capacity, nor sensory inputs are 
affected in TRPV4 knockout mice.  Likewise, absence of TRPV4 does not affect normal 
learning behaviour in the Barnes maze.  Nor does it affect anxiety-like behaviour or 
locomotor activity in the light/dark transition test, the open field test, or the elevated 
plus maze test.  However, animals lacking TRPV4 exhibited increased activity in the 
Porsolt forced swim test, which is interpreted as indicating decreased “depression-like 
behavior”. Somewhat paradoxically, TRPV4 knockout animals also demonstrated 
decreased social behaviors in the tests used (354).   The significance of such conclusions 
from studies on mice in relation to human affective disorders is not clear.  
 
9.  TRPV4 Function in Various Organ Systems 
(i)  Cardiovascular system 
       Understanding of the role of TRPV4 in mediating vascular tone and arterial blood 
pressure is facilitated by a brief recapitulation of the relevant structural and functional aspects 
of these vessels.  The innermost layer of the artery comprises a single layer of endothelial 
cells.  This is surrounded by vascular smooth muscle which is, in turn, surrounded by a coat 
of connective tissue.  Successive branching of muscular arteries results in terminal arterioles 
which comprise endothelium surrounded by a single cell layer of smooth muscle. These 
supply capillaries which are endothelial tubes devoid of smooth muscle but with an abluminal 
layer of contractile pericytes.   Small muscular arteries and arterioles comprise the principal 
resistance vessels in the circulation. This resistance, and both blood pressure and tissue blood 
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flow, are regulated through contraction or relaxation of vascular smooth muscle in response 
to a diverse range of signals, including factors derived from the endothelium and perivascular 
adipose tissue, and the activation of ion channels (84, 86, 308, 363).  TRPV4 plays a role in 
controlling vascular resistance through a variety of actions on different tissues.  
 
(a)  Endothelial cell function 
      The endothelium dynamically regulates vascular smooth muscle tone by means of the 
vasoactive substances which it secretes (407). Moreover, endothelial cells express several 
enzymes and transport mechanisms which act on circulating hormones, including angiotensin 
converting enzyme (ACE), which catalyses the conversion of angiotensin 1 to angiotensin 2, 
an important vasoconstrictor (51). Impaired endothelial function (endothelial dysfunction) in 
resistance vessels is now known to be a feature of a range of major cardiovascascular 
diseases, including hypertension and the complications of diabetes  (143). The endothelium 
also regulates thrombus formation and breakdown and plays a crucial role in the generation 
of new blood vessels (angiogenesis), as well as controlling capillary permeability and tissue 
fluid exchange (87, 323, 444). In each case, increases in endothelial [Ca2+]i are key to the 
generation of the downstream signals  (288, 386), which include NO, prostacyclin (PGI2), 
endothelium-derived hyperpolarizing factor (EDHF) and endothelium-derived 
epoxyeicosatrienoic acids (EETs), substances which regulate vascular tone and 
thrombogenesis (67, 104, 123, 275, 471). There is now considerable evidence that endothelial 
TRPV4 channels play an important role in the control of endothelial [Ca2+]i and vascular 
function (289). Some of the key features of endothelial and TRPV4 dependent vasodilatation 
are illustrated in Figure 7. 
 TRPV4 is expressed in endothelium in situ and in endothelial cells freshly isolated 
from small mesenteric arteries  ((263); Figure 8). Flow, an important vasodilatory stimulus, 
increases [Ca2+]i in endothelial cells, with the [Ca2+]i  response varying with different flow 
conditions  (111, 165, 171). Shear stress, when applied to cultured human endothelial cells, 
causes TRPV4 channels localised near the nucleus to translocate to the cell membrane   
(235).  Shear-induced increases in endothelial [Ca2+]i are inhibited by ruthenium red, which 
blocks TRPV4, and by knockdown of TRPV4 using short interfering RNA.  TRPV4-
mediated  Ca2+ entry is also observed when HEK-293 cells transfected with TRPV4 are 
stimulated by flow.  Endothelial Ca2+ is increased by the application of  GSK1016790A,  a  
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selective TRPV4 agonist which also induces marked dilation of small mesenteric arteries 
from normal mice, but not those from mice lacking TRPV4.  Likewise, luminal flow in 
normal animals results in dilation which is endothelial-dependent, involving the release of 
both NO and EDHF, but these responses are markedly reduced in TRPV4 null mice  (263). 
Shear stress evokes oscillatory increases in [Ca2+]i in endothelial cells and activates Ca2+-
sensitive K+ channels, resulting in hyperpolarizing transient outward currents.  These 
responses are dependent on  Ca2+ influx which, in turn, induces Ca2+-release from ryanodine- 
sensitive intracellular stores  (171). Activation of TRPV4 with 4α-PDD dilates carotid 
arteries and arteria gracilis in an endothelium-dependent manner while TRPV4 antagonists 
inhibit shear-stress-dependent vasodilation of those vessels (203). Flow-induced vasodilation 
in mouse carotid arteries is reduced in TRPV4 knockout animals but only when NOS and 
cyclooxygenase are blocked.  Under control conditions, i.e., in the absence of any blocker, 
the response to flow does not differ significantly between normal and TRPV4 knockout mice  
(235).   
 Remarkably, the hyperpolarization and dilation of blood vessels induced by 
acetylcholine is reduced by ∼75% in mesenteric resistance arteries in TRPV4-/- mice. In 
normal mice, 11,12-EET activates a TRPV4-like current and hyperpolarises the membrane of 
vascular smooth muscle cells, resulting in the dilation of mesenteric arteries. When the 
endothelium is disrupted, 11,12-EET-induced hyperpolarization and vasodilatation is reduced 
by approximately half.  A similar effect is seen when either endothelial (small and 
intermediate conductance), or smooth muscle (large conductance) Ca2+-activated K+ channels 
are blocked. 11,12-EET is devoid of effect on membrane potential, diameter, or ionic currents 
in the same arteries taken from TRPV4 knockout mice (104). Other studies have 
demonstrated a role for PKCα in the acetylcholine-dependent activation of TRPV4 and 
consequent vasodilatation (1).  However, the hypotensive action of acetylcholine is not 
blocked by a TRPV4 antagonist in vivo   (310).  In vitro experiments using aortic rings 
suggest that mild hypothermia activates TRPV4 resulting in acetylcholine production 
by the endothelium, which, in turn, activates muscarinic receptors on nearby cells to 
contribute to endothelium-dependent relaxation in vitro. However, this TRPV4-
dependence was seen in rings from spontaneously hypertensive rats but not in 
normotensive controls (481).   There is also evidence that TRPV4 may co-assemble with 
other TRP subunits in endothelial cells to form heteromeric channels sensitive to flow and 
other dilatory stimuli, presumably increasing the complexity and diversity of signalling  (98). 
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Targeted signalling may also result from co-localization of relevant elements. The micro-
compartments constituted by the caveolae of human microvascular endothelial cells are 
enriched with TRPV4 and small-conductance K+Ca 2.3 channels.  Loss of Cav-1 (which 
can act as a scaffolding protein within caveolar membranes) is associated with a 
reduction in EDHF-mediated vasodilation after exposure to shear stress and 
acetylcholine, suggesting this is functionally significant (139).  
 When a fluorescent Ca2+-indicator protein is expressed in vascular endothelium and 
the region adjacent to the cell membrane imaged using total internal reflection fluorescence 
(TIRF) microscopy, the ingress of  Ca2+  through individual TRPV4 channels in the vascular 
endothelium of resistance arteries appears as local  Ca2+  signals (or “sparklets”).  Detailed 
analysis of these signals suggests that TRPV4 channels exist within four-channel clusters and 
exhibit co-operative gating.  The amplification effect of this co-operativity, when coupled 
with the large TRPV4 single channel Ca2+-conductance and the high Ca2+-sensitivity of the 
small and intermediate conductance endothelial K+-channels activated by the TRPV4 Ca2+-
signal, results in a high level of functional signalling sensitivity.  Activation of as few as three 
to eight TRPV4 channels per cell can maximally dilate resistance arteries (374).   
Mathematical modelling of vasodilatory signalling by TRPV4 involving these “sparklets” 
indicates that the opening of one individual TRPV4 channel causes a stochastic localised 
increase in Ca2+ in an area comprising some few μm2 near to the ion channel.   Further 
predictions include the occurrence of micromolar increases in Ca2+ extending over the 
channel’s open period which are capable of activating low-affinity KCa2+ channels in the 
endothelium. Simulations of burst and co-operative gating forces involving  a cluster of four 
TRPV4 channels predict quantal (“step”) increases in  Ca2+ comparable to the Ca2+ sparklets 
experimentally observed.  It is these localised Ca2+ events which result in endothelium-
derived hyperpolarization, the size of which is dependent on the frequency of these events 
(312). 
      Reductions in intraluminal pressure, in the absence of flow, can also increase endothelial 
TRPV4 activity, resulting in dilation through activation of intermediate conductance K+ 
channels in the endothelium. This may contribute to the autoregulation of blood flow in the 
face of changing perfusion pressures, promoting increased flow by decreasing vascular 
resistance at low pressures, and so augmenting the myogenic response  (22).    Endothelial 
TRPV4 channels appear to be involved in inhibiting α1-adrenergic vasoconstriction in feed 
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arteries of skeletal muscle in response to increases in temperature, and so may help explain 
heat-induced sympatholysis  (137). 
 Myoendothelial projections (MEPs) are areas in which the membrane of endothelial cells 
crosses the internal elastic lamina of arteries to make close contact with smooth muscle cells. 
Gap junctions formed by connexins provide low resistance intercellular pathways for both 
electrical and chemical signalling at these sites. There is growing evidence that MEPs 
function as specialised signalling microdomains allowing endothelium and smooth muscle to 
communicate in both forward and reverse directions   (107, 406). These regions express high 
levels of both PKC and the PKC-anchoring protein AKAP150   (375).  When muscarinic 
acetylcholine receptors on endothelial cells of mouse arteries are stimulated, they only 
activate TRPV4 channels that are localised at these MEPs. There is an increased Ca2+ influx 
at these projections as a result of co-operative opening of clustered TRPV4 channels. The 
same level of co-operative activation of TRPV4 channels is not found in other areas and is 
diminished when intracellular Ca2+ is chelated or when AKAP150 is knocked out. Muscarinic 
receptor stimulation fails to activate TRPV4 channels, co-operation between TRPV4 
channels at myoendothelial projections is diminished and vasodilation in response to 
muscarinic receptor stimulation is reduced when localisation of AKAP150 at MEPs is 
disrupted in a mouse model of angiotensin II-induced hypertension  (375). However, TRPV4 
channel signalling does not appear to be exclusive to MEPs. Channel expression in the 
endothelium of rat uterine radial arteries is not colocated with the holes in the internal elastic 
lamina.  Both TRPV4 expression and the contribution of EDHF to vasodilatory responses in 
uterine arteries are increased in pregnant rats, again supporting a functional role for the 
channel in endothelium-dependent dilation (346).  
 TRPV4 channels have been implicated in the regulation of endothelial structure and help 
maintain the normal orientation of endothelial cells, with their long axis parallel with the 
direction of flow.  Cyclically stretching capillary endothelial cells activates TRPV4. This 
stimulates downstream phosphatidylinositol 3-kinase and induces binding of additional B1 
integrin receptors to promote remodelling of the cytoskeleton and reorientation of the 
endothelial cells. Strain-induced capillary cell reorientation is suppressed by integrin 
inhibition and TRPV4 knockdown using siRNAs (400). The initiation of Ca2+ influx through 
TRPV4 channels when force is applied to B1 integrins is astonishingly fast, occurring within 
4 msec. Deformation of the lipid bilayer or sub-membranous cortical cytoskleton alone is not 
adequate to activate the TRPV4 channels.  It has been suggested that binding of CD98 to the 
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distal integrin tail in the cytoplasm, thereby increasing the strength of focal adhesions, is 
necessary to ensure the presence of sufficient mechanical connectivity within the focal 
adhesion to allow TRPV4 channels to respond to the stresses applied to the extracellular 
domain of adjacent cell surface integrins (262).  TRPV4 may also play a role in regulating the 
endothelial barrier between blood and the surrounding tissue. TRPV4 agonists have been 
shown to increase lung endothelial permeability, a response that is absent in TRPV4-/- mice. 
This suggests that TRPV4 activation may be one mechanism underlying acute lung injury, 
possibly by activating matrix metalloproteases  (15, 415, 446). Pulmonary oedema secondary 
to high pulmonary venous pressure, typically caused by left ventricular failure, is also 
associated with TRPV4 activation in pulmonary capillaries in rodent models  (185, 458). This 
suggests TRPV4 channels are a promising target in the treatment and prevention of lung 
damage and pulmonary oedema   (192, 401, 415). 
 There is emerging evidence that TRPV4 plays an important role in vascular repair and 
remodelling. The channel has been implicated in the formation of collateral circulation 
around sites of arterial blockade. Activation of endothelial TRPV4 by flow shear-stress 
results in an increase in channel expression and encourages active proliferation of vascular 
cells that ultimately result in collateral vessel growth  (341, 342, 408).   Circulating human 
endothelial progenitor cells – whose function is to repair damaged blood vessels and 
substitute for injured endothelial cells – express functional TRPV4 before their incorporation 
into vessels  (97). There is also evidence supporting a role for TRPV4 in tumor angiogenesis, 
with increased expression in tumor endothelial cells from human breast cancers. Knockdown 
of the TRPV4 channel prevents arachidonic acid-induced endothelial cell migration, one of 
the processes required for angiogenesis   (122).  
 A wide range of cardiovascular diseases, including hypertension, diabetic vasculopathies 
and atherosclerosis are associated with endothelial dysfunction, with diminished 
endothelially-mediated vasodilatation and reduced antithrombogenic activity  (40, 345, 405). 
A number of observations have implicated loss of TRPV4 activity in the pathogenesis of 
endothelial dysfunction. The dilatory responses to both TRPV4 agonists and acetylcholine are 
reduced in small resistance arteries from an angiotensin II mouse model of hypertension and 
this is associated with a failure of TRPV4 activation in the MEPs (375). Endothelial 
expression of TRPV4 and downstream Ca2+-sensitive K+-channels (K(Ca)2.3) are reduced in 
mesenteric arteries and  retinal arterioles of streptozotocin-induced diabetic rats, while 
culturing microvascular endothelium in a hyperglycaemic environment downregulates both 
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structural and functional TRPV4 expression  (245, 274). TRPV4- mediated vasodilatation in 
cerebral arteries is also diminished in a number of different animal models of cerebrovascular 
pathology related to Alzheimer’s disease  (469). It has been speculated that TRPV4 may play 
a role in renal ischaemia/reperfusion injury and that upregulation of endothelial TRPV4 
contributes to the protective effect of hypoxic pre-conditioning  (193, 330).  It seems 
reasonable to conclude that TRPV4 is emerging as a potentially important contributor to 
vascular pathology. 
 
(b)  Vascular smooth muscle cell function  
     TRPV4 is also expressed in systemic and pulmonary arterial smooth muscle where it may 
promote relaxation and vasodilation or contraction and vasoconstriction (455).  TRPV4 in 
cerebrovascular smooth muscle forms a Ca2+ signaling complex with ryanodine receptors and 
BKCa channels.  Endothelial-derived 11,12-EET dilates cerebral arteries, an effect that is 
abolished by suppression of TRPV4 in intact cerebral arteries. EET activates TRPV4 in 
smooth muscle, leading to Ca2+-induced Ca2+ release and activation of BKCa channels. The 
resulting hyperpolarisation of the smooth muscle causes vasodilatation by reducing L-type 
Ca2+-channel activation  (103). Other studies support the conclusion that TRPV4, TRPC1 and 
BKCa form an EET sensitive, vasodilatory molecular complex within systemic vascular 
smooth muscle   (248, 471).  
    Activation of TRPV4 in the smooth muscle of pulmonary arteries, on the other hand, 
appears to induce a pro-constrictor effect (Figure 9).  Hypoxia evokes constriction in distal 
pulmonary arteries (hypoxia-induced pulmonary vasoconstriction) and prolonged hypoxia 
can result in irreversible pulmonary hypertension. The TRPV4 agonist 4α-PDD elicits a 
contractile response in pulmonary arteries and this is potentiated under hypoxic conditions  
(80). Consistent with this functional response, TRPV4 expression in pulmonary artery 
smooth muscle is increased in response to hypoxia, with a parallel increase in the myogenic 
responses to transmural pressure in endothelium-denuded vessels, leading to the suggestion 
that this may contribute to pulmonary hypertension  (446). On the other hand, short-term 
culturing of rat pulmonary artery smooth muscle under hypoxic conditions has been found to 
increase TRPV4 Ca2+-signalling and cell migration without increasing ion channel 
expression. This is associated with hypoxia- induced nuclear translocation of the NFATc4, 
part of a transcription complex regulating gene expression, suggesting that TRPV4 plays an 
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upstream role in hypoxic signalling in these cells, and may be involved in the pathogenesis of 
pulmonary hypertension  (314). TRPV4 appears to be necessary for hypoxic pulmonary 
vasoconstriction (HPV), since inhibition or genetic knockdown of TRPV4 reduces the 
increase in pulmonary arterial pressure due to hypoxia.  Blockade of TRPV4 in pulmonary 
arterial smooth muscle cells prevents Ca2+ influx and phosphorylation of myosin light chain 
(MLC) (141).  MLC phosphorylation  is important in several cell functions, including 
vascular smooth muscle contraction  (195). Constrictor responses to serotonin are also 
reduced both following pharmacological blockade of TRPV4 and in TRPV4-/- mice, as is the 
enhancement in serotonin responses seen following chronic hypoxia   (447). Others have 
suggested that TRPV4 activation by serotonin  may promote smooth muscle cell proliferation 
in pulmonary arterial smooth muscle   (101).  
 There is also evidence that TRPV4 can promote constrictor as well as dilator responses 
to certain stimuli in systemic vascular smooth muscle. The A kinase anchor protein 
AKAP150 is a scaffolding protein which is involved in local control of L-type Ca2+ channels 
found in arterial smooth muscle.  In arterial myocytes, AKAP150-targeted protein kinase 
Calpha signalling controls “stuttering persistent” Ca2+ entry through these channels, as well as 
increased vascular tone and blood pressure under normal conditions.  It also mediates 
angiotensin II-dependent hypertension  (285), and increased persistent Ca2+ sparklet activity  
is found in arterial myocytes in hypertension (287).   TRPV4 channels are gathered into 
puncta of differing sizes along the sarcolemma of arterial myocytes. Although basal TRPV4 
sparklet activity is low, Ca2+ entry during elementary TRPV4 sparklets is 100-fold greater 
than that during L-type CaV1.2 channel sparklets. The activity of TRPV4 sparklets in 
specific regions of the cells can be increased by administering the TRPV4 channel agonist 
GSK-1016790A or angiotensin II (AngII).  However, PKC and AKAP150 are required for 
AngII-induced increases in TRPV4 sparklet activity.   The existence of  dynamic subcellular 
signalling domains –  comprising AKAP150, PKC, and TRPV4 – that control Ca2+ influx into 
arterial myocytes has also been proposed on the basis of evidence that initiation of AngII 
signalling increases the proximity of AKAP150 and TRPV4 puncta in arterial myocytes, 
while  local stimulation of diacylglycerol and PKC signalling results in TRPV4-mediated 
Ca2+  influx   (265).  TRPV4 mediates vasoconstriction in the aorta of mouse in conjunction 
with an agonist at the Tx receptor which is generated by cyclo-oxygenases and depends upon 
signalling by MAPK as well as Src kinase.  The vasoconstriction induced is increased by 
means of EGF receptor activation and the involvement of PKC leading to the activation of 
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the G-protein coupled receptors for angiotensin or proteinases (AT1 and PAR1/ PAR2, 
respectively)   (335). 
(c) Astrocyte function and neurovascular coupling 
     Neurovascular coupling refers to mechanisms linking neuronal activity to vasomotor tone 
in the brain and retina, and plays an important role in the local control of cerebral blood flow 
to meet changing metabolic needs  (120). Astrocytes, which contribute to the coupling 
process, have been shown to express functional TRPV4 channels   (35). As in endothelial 
cells, signalling to vascular smooth muscle is triggered by a rise in astrocyte [Ca2+]i, and 
TRPV4 channels in the astrocytic end feet contribute to this rise  (102).  TRPV4 also 
performs a regulatory function in relation to the permeability of the blood cerebrospinal fluid 
barrier and transepithelial protein transport.  In pigs, this ion channel is broadly expressed on 
the apical membrane of choroid plexus epithelial cells which are found in the ventricles of the 
brain and comprise the blood cerebrospinal fluid barrier.  Application of the TRPV4 agonist, 
GSK-1016790A,  causes a major ingress of Ca2+ accompanied by serine/threonine 
phosphorylation.  It also reduces filamentous actin and results in disintegration of cell 
junctions of the blood-cerebrospinal fluid barrier within 10-20 minutes.   When normal 
TRPV4 activity is inhibited using the antagonist, HC-067047, there is a reduction in the 
basolateral-to-apical transport of α-2-macroglobulin (A2M) (284). 
  
(d)  Heart 
      Human coronary arterioles express endothelial TRPV4 which are functionally related to 
both flow-mediated dilation and the production of reactive oxygen species (47). There is 
limited evidence to date for a direct role of these channels in cardiac myocyte function. 
Exposure to hypotonic solutions increases cardiac contractility and modulates Na+-currents. 
These effects are inhibited by ruthenium red, a non-selective inhibitor of TRPV channels   
(173, 223).   TRPV4 expression in cultured cardiac myocytes is mainly nuclear with 
translocation out of the nucleus in response to hypotonic stimulation (479). TRPV4 (and 
TRPC1) are expressed in sensory nerve endings in the atrial endocardium where they are 
coincident with the nerve ending vesicle marker synaptophysin   (352).   Perhaps the most 
significant observation to date is that TRPV4 is functionally active in cardiac fibroblasts and 
is involved in the differentiation of cardiac fibroblasts to form myofibroblasts in response to 
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tumour growth factor-β (TGF-β) signalling  (2, 159). This offers the prospect that myocardial 
repair and remodelling may be modified through selective TRPV4 activation. 
     TRPV4 is found in the endocardium while heart valve development is occurring and is 
essential for normal heart valve development.  Oscillatory flow activates TRPV4 which 
regulates the Ca2+ response of endocardial cells and expression of the klf2a promoter, an 
atheroprotective transcription factor which also responds to flow.  Similar findings have been 
made with respect to TRPP2 which is known to associate with TRPV4.  The absence of either 
TRPV4 or TRPP2 is associated with valve defects, suggesting they play an important role in 
valve formation (162). 
 
(e) In vivo effects and BP control 
       Consistent with its ability to dilate blood vessels and reduce peripheral resistance, 
TRPV4 exerts a hypotensive effect when activated.  Indeed, generalised systemic activation 
of TRPV4 can be catastrophic.  When the TRPV4 agonist GSK-1016790A is given 
intravenously in mouse, rat or dog  ¸it has no direct effect on cardiac contractility or rate but 
causes a dose-dependent fall in blood pressure, indicating a fall in resistance. This is followed 
by major circulatory collapse associated with failure of the permeability barrier constituted by 
the pulmonary microvasculature  (441).  On the other hand, the plant alkaloid, berberine, 
which is an inhibitor of  TRPV4, induces vascular relaxation and lowers blood pressure 
in both mice with steroid induced hypertension and aged apolipoprotein E knockout 
mice. These effects were reversed by overexpression of TRPV4 (429).  Knockout mice 
which lack the  K+Ca 3.1 channel -- an intermediate conductance Ca2+/CaM-regulated 
K+ channel – avoid the fatal pulmonary circulatory collapse otherwise induced by 
pharmacological activation of TRPV4 in normal animals.  Hence, inhibition of these 
Ca2+ -activated K+ channels may prove protective against dangerously high endothelial 
Ca2+   signalling induced by excessive activation of TRPV4 (427).     Although basal blood 
pressure is similar in wild type and TRPV4 knockout animals, the transient hypertension 
produced by inhibition of NOS is greater in mice which lack TRPV4, suggesting that TRPV4 
channel activity opposes hypertensive stimuli in vivo (104).   GSK-1016790A dilates blood 
vessels and reduces arterial pressure in both pulmonary and systemic vascular beds in rat. 
When NOS is inhibited, however, the same TRPV4 agonist doses cause a more marked fall in 
systemic pressure but evoke pulmonary vasoconstrictor responses that are reduced by 
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isradipine, an L-type Ca2+ channel antagonist.  This suggests that TRPV4 activation has 
different actions in pulmonary and systemic vascular beds (311). Intravenous injection of 
acetylcholine decreases blood pressure by more than twice as much in normal mice as it does 
in TRPV4 knockout mice whereas pharmacological blockade of TRPV4 does not inhibit the 
hypotensive action of acetylcholine in rats (310, 467). The physiological significance of 
TRPV4 to cholinergic control of pressure control, therefore, remains unclear.  
 The effects of TRPV4 in the intact animal will reflect the net effect not just on 
endothelium and vascular smooth muscle but also any TRPV4-mediated changes in nervous 
or hormonal control of the cardiovascular system. TRPV4 activation reduces blood pressure 
in Wistar rats but this effect is exaggerated in animals fed on a high salt diet. TRPV4 
expression in the sensory nerves of the DRG and mesenteric arteries is increased in these 
animals, as is release of the vasodilatory transmitters calcitonin gene-related peptide (CGRP) 
and substance P. This is consistent with a compensatory mechanism in which TRPV4 
activation opposes the hypertensive effects of salt intake  (126). The hypotensive response to 
intravenous administration of the TRPV4 agonist 4α-PDD is reduced in animals lacking 
capsaicin-sensitive sensory nerves and in animals to which a CGRP antagonist has been 
administered, as well as in animals which have been given a combined dose of blockers of 
small, intermediate, and large conductance Ca2+-activated K+ channels.  Agonist activation of 
TRPV4 increases plasma levels of the vasodilator transmitter CGRP in normal rats and this 
may contribute to the hypotensive effect.  Interestingly, TRPV4 is found co-localised with 
CGRP in vascular sensory neurons as well as with Ca2+-activated K+ channels in the 
endothelium of mesenteric resistance arteries (128).  
A potential antihypertensive role of TRPV4 has also been tested using Dahl salt-
sensitive and salt-resistant rats, which are differentiated by their relative sensitivity to the 
hypertensive effects of a high salt diet. Activation of TRPV4 reduces mean arterial pressure 
in male Dahl salt-resistant rats on a high sodium diet but has considerably less hypotensive 
effect in Dahl salt-sensitive rats on a high sodium diet. A high salt diet increases TRPV4 
expression in Dahl salt-resistant rats but decreases it in salt-sensitive animals, and blockade 
of TRPV4 increases blood pressure in Dahl salt-resistant rats on a high sodium diet only. This 
suggests that differential control of TRPV4 expression and function may explain, at least in 
part, the differences in salt-sensitivity which have been found  (127). In other circumstances, 
however, TRPV4 appears to have a hypertensive role, e.g., the increase in blood pressure 
after drinking water is effected by  activation of the sympathetic nervous system, with 
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TRPV4 being an essential component of that response   (251).   When given l-NAME in 
drinking water for seven days, TRPV4 null mice exhibited a slightly greater increase in mean 
arterial pressure when compared to wild type controls. However, in mice given subcutaneous 
infusion of Ang II for 14 days, similar increases were found in mean arterial blood pressure  
in both groups of animals.  Thus,  TRPV4 appears to have a minor role in regulating blood 
pressure in the hypertension  induced by l-NAME;  and does not appear to function in 
regulating hypertension  induced by Ang II  (300).  
 
 (ii)  Respiratory system 
       Expression of TRPV4 in the epithelium of the foetal lung increases during the course of 
gestation. TRPV4 has been implicated in the mechanism by which mechanical stress engages 
an inflammatory response and resulting injury in the foetal lung.  TRPV4 controls the release 
of the cytokine IL-6 through pathways which involve p39 or ERK.  TRPV4 is also involved 
in the regulation of stretch-occasioned differentiation of epithelial cells in the foetus (286). 
Functional TRPV4 is expressed in human airway smooth muscle cells (184, 249), and is also 
present in a human bronchial epithelial cell line (118).   Extracellular Ca2+ influx following 
agonist-induced activation of TRPV4 in epithelial cells results in the activation of Ca2+-
dependent K+ channels, which are important in the regulatory volume decrease (RVD) after 
hypotonic stress.  The Ca2+ signal in this context is capable of being generated away from the 
location of  Ca2+-dependent K+ channels at the plasma membrane of epithelial cells and is not 
the result of release of intracellular Ca2+ via ryanodine receptors   (118). In airway epithelial 
cells of cystic fibrosis sufferers, however, swelling of these cells fails to initiate Ca2+ ingress 
through  TRPV4 channels thereby contributing to failure of RVD (20).  The TRPV4 ion 
channel is of particular functional importance in ciliated epithelia (16).   The channels are 
mainly expressed on the ciliary membrane of ciliated tracheal epithelium. Ciliary beat 
frequency is heightened by increases in [Ca2+]i, governing the rate at which mucus is cleared 
in the airways.   Ca2+-signalling in response to 4α-PDD and moderate temperatures is reduced 
in ciliated epithelial cells of the trachea of TRPV4(-/-) mice, although this does not prevent 
autoregulation of ciliary beat frequency in the presence of highly viscous solutions.   The 
facilitation of Ca2+ entry by TRPV4 is also implicated in increases in ciliary beat frequency 
induced by ATP, suggesting a role in epithelial receptor operated Ca2+-entry  (236). 
Activation of TRPV4 in the smooth muscle of human airway evokes contractions which are 
inhibited by a TRPV4 antagonist but, also, by a 5-lipoxygenase blocker and by two cysteinyl 
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leukotriene 1 receptor antagonists which have been shown to be structurally distinct.  It has 
been suggested that activation of TRPV4 causes airway constriction that is reliant upon the 
production of cysteinyl leukotrienes (249).  
 TRPV4 is implicated in several pulmonary disease states in addition to cystic fibrosis 
(140).  The endothelial cells of rat main pulmonary artery express TRPV4 and its activation 
by a pharmacological agonist results in strong concentration-related relaxation of the 
endothelium-intact pulmonary artery.   This TRPV4-mediated endothelium-dependent 
vasodilation is contributed to by NO and EDHF (384).  Agonist-induced activation of TRPV4 
and ingress of Ca2+ is attenuated in rat pulmonary microvascular endothelial cells after pre-
treatment with an inhibitor of myosin light chain kinase, while surface TRPV4 expression is 
reduced by pre-treatment with the same inhibitor (313).  TRPV4-mediated Ca2+ entry in 
septal endothelium increases lung endothelial permeability (416, 446).  TRPV4 is expressed 
in the alveolar septal wall in human, rat, and mouse, and there is evidence that its agonist-
induced activation can result in its participation in acute lung injury.  In isolated rat lung, 
agonist-induced activation of TRPV4 increases endothelial permeability in the lung in a dose- 
and Ca2+-dependent manner in rat and mouse, resulting in disruption of the endothelial and 
epithelial layers of the alveolar septal wall with blebs or breaks (15).  In accord, fast ingress 
of Ca2+  via  TRPV4 is a major factor in determining the extent of the increase in vascular 
permeability in lungs after high peak inflation pressure ventilation  (155).  Filtration 
coefficients measured in isolated perfused lungs after high peak ventilation pressure show no 
significant increase in mice lacking the TRPV4 receptor, but exhibit a more than two-fold 
increase in lungs taken from normal animals.  This may depend on the expression by alveolar 
macrophages of TRPV4  (154).  Inhalation of nanoparticles releasing a TRPV4 inhibitor 
serves to prevent ventilator damage in mice for several days  (192). Increased microvascular 
pressure in lung, as is seen in left ventricular failure, heightens endothelial [Ca2+]i  by TRPV4 
activation which results in increased lung vascular permeability.    The endothelial [Ca2+]i  
activates myosin light-chain kinase and at the same time stimulates NO synthesis to 
transiently increase the filtration coefficient.  In mice lacking TRPV4, increases in 
endothelial [Ca2+]i  induced by pressure are largely blocked, as are the synthesis of NO and 
the lung wet/dry ratio.  Endothelial NO formation provides a negative feedback mechanism 
which limits the increase in permeability by a cGMP-dependent  inhibition of TRPV4 activity   
(458). Matrix metalloproteinases (MMPs) may also play a role in TRPV4 mediated lung 
pathophysiology, regardless of the underlying cause. These enzymes are involved in the 
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proteolytic processing of extracellular matrix structural proteins.  Activation of TRPV4 and 
the resulting Ca2+ influx thereby occasioned leads to the activation of  MMP2 and MMP9 
which damage cell-to-cell or cell-matrix adhesion.  This increases the permeability of the 
septal barrier and thereby contributes to lung injury (415). 
 TRPV4 also appears to participate in the pathology of pulmonary hypertension of 
varying causes.  TRPV4 is up-regulated in pulmonary arteries of rats within one day of 
hypoxia exposure;  and activation of TRPV4 results in an increase in the Ca2+ response in 
hypoxic pulmonary arterial smooth muscle cells. Hypoxia-induced pulmonary hypertension, 
right ventricular hypertrophy and vascular remodelling are reduced in TRPV4 null mice  
(454).   There is an increase in TRPV4 expression in the pulmonary vasculature in human 
heart failure patients.  Moreover, blockade of TRPV4 inhibits heightened vascular 
permeability and consequential pulmonary oedema associated with heightened pulmonary 
venous pressure (401).  TRPV4 is important in mediating the enhanced pulmonary 
vasoreactivity to serotonin which is seen in chronic hypoxic pulmonary hypertension (447). 
Both TRPV1 and TRPV4 are expressed in rat intrapulmonary arteries and their agonist-
induced activation results in increased [Ca2+]i  in pulmonary arterial smooth muscle cells.  
Stimulation of these ion channels induces pulmonary arterial smooth muscle cell migratory 
responses which are associated with cytoskeletal reorganisation which may result in the 
increased pulmonary vascular resistance characteristic of pulmonary hypertension (257).  The 
TRPV4 and RyR2 expression found in pulmonary arterial smooth muscle cells is increased in 
the same cells of chronically hypoxic rats.  Blockade of the ryanodine receptor significantly 
reduces the increase in  [Ca2+]i  and the arterial contraction which results from agonist 
activation of TRPV4  (80). NOS appears to regulate the responses to activation of TRPV4 
differently in pulmonary vascular beds and systemic vascular beds, respectively.  L-NAME 
increases the hypertensive effect of agonist activation of TRPV4 on the systemic circulation 
but converts agonist activation of TRPV4 in the pulmonary circulation from inducing an 
hypotensive effect to an hypertensive effect  (311).  The shear stress-mediated rise in [Ca2+]i 
and the protein expression level of TRPV4 (and TRPM7) channels are greater in the 
pulmonary arterial smooth muscle cells of  sufferers of idiopathic pulmonary arterial 
hypertension than in healthy individuals.  Blockade of TRPV4 by ruthenium red inhibits 
shear stress-induced rise in   [Ca2+]i  in pulmonary arterial smooth muscle cells in patients 
with both normal blood pressure and  in those with idiopathic pulmonary arterial 
hypertension.  4α- PDD-induced activation of TRPV4 results in a greater increase in [Ca2+]i 
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in pulmonary arterial smooth muscle cells of patients with such hypertension than in non-
hypertensive patients.   Knockdown of  TRPV4 (and TRPM7) by siRNA attenuates the shear 
stress-mediated [Ca2+]i increases in both myocyte types (372). 
     TRPV4  has been implicated in the development of idiopathic pulmonary fibrosis, which 
is a fibrotic lung disease resulting from the development of myofibroblasts.  Myofibroblast 
generation, in turn, is dependent on mechanical signalling and activation of TGF-β1.  Lung 
fibroblasts obtained from patients with idiopathic pulmonary fibrosis exhibit increased 
TRPV4 activity, while mice which lack TRPV4 do not suffer from lung fibrosis.   When 
TRPV4 is inhibited either by genetic ablation or pharmacologically, then differentiation of 
myofibroblasts fails to occur – a phenomenon which is reversed by the reintroduction of 
TRPV4   (328).  
      These channels also seem to play a role in lung injury following exposure to chemical 
irritants. Post-exposure treatment with a TRPV4 inhibitor suppresses pulmonary 
inflammation in response to acid or chlorine gas by diminishing neutrophils, macrophages 
and associated chemokines and cytokines, while improving tissue pathology (Figure 10).   
These findings are confirmed using knockout mice which lack the TRPV4 receptor.  TRPV4 
inhibitors likewise produce similar anti-inflammatory effects in chlorine-exposed mice where 
they also improve  blood oxygen saturation.  Increased concentrations of N-acylamides, a 
class of endogenous TRP channel agonists, are found in both models of lung injury (25).  
Studies using the TRPV4 inhibitors, GSK-2220691 or GSK-2337429A, in TRPV4 deficient 
mice, confirm this ion channel as an important contributor to inflammation of the lung 
resulting from direct chemical injury.   These inhibitors have also been shown to exert 
vasculoprotective effects when administered in the aftermath of exposure to chlorine gas, 
preventing leakage from blood vessels while increasing the oxygenation of the blood (278).  
In the context of acid-induced acute lung injury, the absence, or inhibition, of TRPV4 
reduces the platelet activating factor-induced  increases in neutrophil [Ca2+]i and 
neutrophil responses (including ROS formation, neutrophil adhesion and chemotaxis) 
resulting from pro-inflammatory stimuli  are inhibited (459). 
     TRPV4 has also been implicated in obstructive airways disease. Increased expression of 
TRPV1 and TRPV4 is found in tissue samples taken from the lungs of patients suffering from 
chronic obstructive pulmonary disease (COPD).  Blockade of the TRPV1, TRPV4 and 
pannexin-1 channels reduces the increase in ATP released from primary airway bronchial 
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epithelial cells as a result of cigarette-smoking (29).  In severe asthma, airway smooth muscle 
cells are caused to proliferate, contributing to the alteration and permanent obstruction of 
airways.  TRPV4 agonists increase the proliferation of primary airway smooth muscle cells.  
Ca2+ sparklets resulting from opening of single TRPV4 channels generate targetted Ca2+-
signalling microdomains in these cells.  TRPV4 channels are co-expressed with calcineurin in 
primary airway smooth muscle cells.  Activation of calcineurin results in the 
dephosphorylation of nuclear factor of activated T cells (NFAT) transcription factors 
cytosolic (c) to permit nuclear translocation and the activation of synthetic transcriptional 
pathways.   Activation of TRPV4, which results in airway smooth muscle cell proliferation is 
accompanied by calcineurin-dependent nuclear translocation of the NFATc3 isoform.   Ca2+ 
microdomains created by TRPV4 Ca2+ sparklets have been proposed to activate calcineurin to 
induce nuclear translocation of NFAT and airway smooth muscle cell proliferation (475).  
 
(iii)  Urinary system    
(a)  Kidney   
 
      The early study by Liedtke and Friedman (2003) reported that mice lacking the TRPV4 
channel exhibit impaired osmotic regulation. They drink less water, and become 
hyperosmolar when compared to wild-type animals under control conditions and when 
exposed to hyperosmolar challenges, with reduced levels of antidiuretic hormone despite 
increased osmolarity. TRPV4 null animals demonstrated smaller reductions in drinking and 
experienced systemic hypotonicity when subjected to continuous subcutaneous infusion of 
the antidiuretic hormone analogue, dDAVP at dosages that had no effect on control animals. 
(230).   However, these effects were relatively small in magnitude and were only revealed in 
animals housed individually without food to remove group and feeding influences. A more 
recent study found no evidence for a role of TRPV1 and TRPV4 in thirst responses to 
hypertonic stimuli in single knockout animals for either gene or double knockouts for both 
(199). The reason for this discrepancy remains unclear as very similar protocols were used in 
both cases.  
 
        TRPV4 has an extensive distribution in the renal vasculature (68). Moreover, TRPV4 is 
expressed at the cell membranes of cultured M-1 collecting duct cells and at the luminal 
membrane of mouse kidney collecting duct cells (445).   TRPV4 is found in cells of the 
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human collecting duct but such expression is reduced by approximately half at 48 hours after 
exposure to high glucose, and this can only be accounted for in part by the resulting increase 
in osmolarity occasioned by the glucose (168).   A PKA-dependent cascade promotes TRPV4 
trafficking and translocation to the apical membrane and increases channel activity in the 
distal nephron (253).  Activation of TRPV4 by luminal flow increases intracellular calcium 
and causes NO to be produced in the thick ascending limb in rat (49, 50).  TRPV4 and 
TRPP2 assemble to form a 23-pS divalent cation-permeable non-selective ion channel at the 
apical membrane of renal principal cells of the collecting duct.  The TRPV4/TRPP2 complex 
exhibits a different biophysical amd pharmacological profile to that of either of its constituent 
channels.  Epidermal growth factor (EGF) stimulates the TRPV4/TRPP2 channel through 
EGF receptor (EGFR) tyrosine kinase-dependent signalling.  In addition, EGF increases cell 
proliferation in cells which do not possess normal cilia and this is dependent upon a 
TRPV4/TRPP2 channel mediated increase in [Ca2+]i  (474).   
      A synergistic interaction has been proposed to occur in mouse cortical collecting duct M-
1 cells between TRPV4, the small conductance SK3 (K(Ca)2.3) channel and the large 
conductance BK channel (K(Ca)1.1).  When the cells are depolarised by selective inhibition 
of the BK channel (by iberiotoxin) or by selective inhibition of the SK3 channel (by apamin), 
TRPV4-mediated Ca2+ influx is found to depend on the activation of both K+ channels (188).  
Selective activation of TRPV4 in cortical collecting duct cells in mouse gates both SK3 
channels and the BK channels and this results in hyperpolarization of the cell membrane  
(38).  TRPV4 is important in causing the sustained  elevation of [Ca2+]i  during purinergic 
stimulation via P2Y2 receptors in aldosterone-sensitive distal nephron cells, as evidenced by 
the fact that an ATP-induced Ca2+ plateau is dramatically reduced in TRPV4 null mice (254).   
    TRPV4 activity is reduced in freshly isolated collecting duct cysts in rat models of 
polycystic kidney disease. This is associated with reduction in basal [Ca2+]i, and a failure of 
flow-mediated [Ca2+]i signalling, as well as an alteration in the location of TRPV4 within the 
cell.  The renal symptoms of autosomal recessive polycystic kidney disease (ARPKD) are 
reduced by agonist-induced augmentation of TRPV4 activity systemically over time.   
Selective activation of TRPV4 reinstates mechanosensitive Ca2+ signalling and restores 
TRPV4 functioning and localisation within the cell.  Thus, pharmacologically-induced 
increase in the activity of TRPV4 in the longer term slowly reinstates sensitivity to 
mechanical stimuli in cyst cells and substantially reduces renal ARPKD progression.  There 
appears to be a connection between impairment of TRPV4-dependent mechanosensitivity in 
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collecting duct cells and cystogenesis which suggests that there may be a therapeutic value to 
manipulating  TRPV4 activity pharmacologically in order to slow the progression of ARPKD  
(463). An associated finding is that biliary cholangiocytes from rats with polycystic kidney 
disease exhibit a substantial over-expression of TRPV4, as do the livers of (ARPKD) disease 
patients, although the significance of this remains unclear (146). 
 
 (b)  Bladder 
      TRPV4 is found in mouse and rat urothelium (which is the epithelium covering the 
surface of the urinary bladder) and  in the vascular endothelium of the bladder.  TRPV4 is 
important for normal bladder voiding, and  mice lacking this receptor are incontinent and 
show, on cystometry, a lower frequency of voiding contractions  as well as a higher 
frequency of non-voiding contractions (136).  Functional TRPV4 is found in the urothelium 
lining the renal pelvis, ureters, urinary bladder, and urethra (39).   TRPV4 in the urothelium 
of the mouse bladder is mainly found at the basal plasma membrane domains of the basal 
urothelial cells (452), and is prominently localised to the abluminal surfaces of the umbrella 
cells (462).   TRPV4 is also expressed in the suburothelium and suburothelial nerve plexus of 
the urinary bladder and in small- and medium-sized lumbosacral (L1, L2, L6-S1) DRG cells 
from mice;  and such expression is increased by over-exposure to NGF (138).   TRPV4 is 
also found in detrusor muscle in rat and may be involved in detrusor over-activity associated 
with bladder outlet obstruction in rat (74).  TRPV4 is not co-localised with TRPV1 in sensory 
neurons serving the bladder, but each of these channels is present in a different population of 
bladder afferents.  Bladder hyperactivity resulting from lipopolysaccharide-induced cystitis 
remains unaffected by separate low-dose treatment with an antagonist of TRPV4 or TRPV1 
(176.7 ng/kg RN-1734 and 143.9 ng/kg SB-366791, respectively).  However, co-
administration of both antagonists at the same low dose completely reverses bladder 
hyperactivity caused by lipopolysaccharide-induced cystitis and partially reverses cystitis-
induced bladder pain behaviour (64). TRPV4 is expressed in urinary bladder smooth muscle 
where it is important in bladder contraction.  Agonist-induced activation of TRPV4 with 
GSK-1016790A causes the contraction of mouse bladders in vitro as well as bladder 
hyperactivity (402). TRPV4 plays a role in bladder dysfunction resulting from stress.  When 
rats are subjected to repeated but varied stresses over a period of a week there is a resulting 
increase in the level of TRPV4 found in urothelium.  On the other hand, inhibition of TRPV4 
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receptors reduces the extent of bladder dysfunction resulting from such stress (267). The 
TRPV4 agonist, GSK-1016790A (0.1 μM), has been shown to increase the amplitude of 
spontaneous contractions in bladder strips of rat and may have a role in the treatment of 
underactive bladder disease  (461). TRPV4-KO mice exhibit a markedly higher voiding 
frequency  and a lesser volume of urine when voiding than wild-type animals.  However, the 
TRPV4-KO mice have a greater urine output than normal mice.   TRPV4-KO animals 
generate bladder contractions which do not occasion voiding in advance of each successful 
voiding, while normal mice do not generate similar bladder contractions (460).   
       Agonist-induced activation of TRPV4 in rat urinary bladder urothelial cells evokes Ca2+ 
ingress, promotes ATP release, and increases the ATP released by hypo-osmolarity.  In 
awake rats during continuous infusion cystometrograms, intravesically given 4α-PDD (10-
100 microM) substantially increases micturition pressure (39).  Application of stretch, via a 
cell-stretch system, to cultured mouse primary urothelial cells results in [Ca2+]i  increase and 
ATP release, effects which are reduced in cells lacking TRPV4 (272). Activation of TRPV4 
by intravesical application of GSK-1016790A participates in the micturition reflex in rat by 
activation of the C-fibers of primary bladder afferents which are mechanosensitive but non-
responsive to capsaicin (4).  Use of the TRPV4 antagonist, HC-067047, can increase 
functional bladder capacity and reduce micturition frequency in normal mice and rats with 
cystitis ((110); Figure 11).    
 
(iii)  Musculoskeletal system 
(a) Bone and cartilage  
         There is increasing evidence that TRPV4 plays an essential role in regulating various 
musculoskeletal tissues  (150).    TRPV4 is found in both osteoblasts (which synthesise bone) 
and in osteoclasts (which resorb bone tissue) (269).   Activation of TRPV4 in osteoclasts 
increases both their number and their resorption activity and this results in bone loss (258), 
while absence of TRPV4 reduces bone resorption thereby increasing bone mass (259).   
Where patients are confined to bed, they may develop so-called “unloading-induced 
osteoporosis” where the absence of load on bones, which are normally accustomed to bear it, 
results in a reduction in bone mass.  Removing the mechanical stress of normal load-bearing 
from the hind-limbs of  naïve mice results in osteopenia, while this phenomenon fails to 
occur in animals which lack TRPV4.    Absence of TRPV4 prevents the diminution in the 
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rates of mineral apposition and of bone formation induced by loss of normal load-bearing.  It 
also prevents the rise in the number of osteoclasts in primary trabecular bone and the 
shortening of its longitudinal length which is otherwise caused by such “unloading”  (269).   
TRPV4 controls the end-stage differentiation of osteoclasts and their activity (259) and 
higher levels of TRPV4 expression are found on differentiation of osteoblasts in culture  
(390). Activation of TRPV4 reciprocally controls Ca2+/CaM signalling, which involves  
TRPV4 associating with non-muscle myosin IIa (258).  TRPV4  appears to mediate the Ca2+ 
signalling in osteoblasts which is induced by flow (390).      
       TRPV4 may be a male-specific determinant of bone strength. In male mice lacking the 
TRPV4 receptor there is a 20 per cent increase in mass in cortical and trabecular bones, but 
intracortical porosity is heightened and there is a reduction in bone matrix mineralisation.  
The end result is that the presence or absence of TRPV4 is irrelevant to measures of 
maximum load, stiffness and work to failure of the femoral bone.  However, the bone 
material exhibits  a lower resistance to stress and less elasticity in TRPV4 null mice.  When 
compared with normal female mice, TRPV4 null female mice do not show any of these 
variations in skeletal measurements  (411). 
      Ca2+ signalling mediated by TRPV4 appears to be essential for healthy joints and the 
maintenance of a normal skeletal structure.   Male mice lacking TRPV4 experience major  
osteoarthritic abnormalities which are age-related and dependent on male sex.  Again, such 
mice exhibit heightened sub-chondral bone volume and heightened calcified meniscal volume 
(78).       
      Chondrocytes are cells found in cartilage where they produce and maintain the 
cartilaginous matrix.   Functional TRPV4 are found in articular chondrocytes and mediate the 
responses of these cells to hypo-osmotic stress (318).  Mice lacking TRPV4 fail to exhibit the 
Ca2+ responses to hypo-osmotic stress exhibited by chondrocytes of normal animals (78).    
TRPV4 in chondrocytes embedded in agarose gel are important in determining how those 
chondrocytes respond to dynamic compression (181, 304).   TRPV4 is involved in the 
regulation of Sox9, which is a transcription factor required for differentiation in chondrocytes 
and for chondrocyte-specific gene expression (281).  Activation of TRPV4 has been 
employed in tissue engineering to improve the tensile properties of self-assembled articular 
cartilage constructs  (106).   The collagen-binding receptor integrin α1β1 is important in 
mediating the response of chondrocytes to hypo-osmotic stress by alterations in [Ca2+]i . 
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TRPV4 is expressed on normal and integrin α1-null chondrocytes but is only capable of 
being activated on the normal chondrocytes   (181).   The phosphorylation of ERK1/2 is 
important in determining the level of TRPV4 expressed in chondrocytes subjected to hypo-
osmotic stress.  Inhibition of  ERK1/2 using the specific blocker  (PD-98059) inhibits an 
increase in the number of  TRPV4 channels in response to  hypo-osmotic stress.  It also 
reduces the level of TRPV4 below the expression level of controls in iso-osmotic conditions   
(161).    The expression of TRPV4 by chondrocytes of the temporomandibular joint in rat is 
inhibited by an over-expression of microRNA-203 (miR-203), while the expression of NO in 
the same cells is increased, apparently by this micro-RNA targeting the Trpv4 gene  (172).  
       Type VI collagen is not required for Ca2+ signalling via TRPV4 in mouse, but loss of 
type VI collagen changes the mechanical features of the pericellular matrix and this age-
dependently increases  cell swelling and the signalling by TRPV4 which is induced by hypo-
osmotic pressure (465).  There is evidence that the mechanical qualities of neocartilage 
constructs may be improved at cellular and tissue levels in tissue engineering by the use of  
hyperosmolarity and the TRPV4 agonist, 4α-PDD.  In combination, 4α-PDD interacts with 
hyperosmolarity to promote its impact on collagen content as well as tensile strength (221). 
 
(b) Muscle 
    TRPV4 is functionally expressed in mouse skeletal muscle (169, 324).  Skeletal muscle 
contraction is essentially regulated by release of Ca2+ and its removal into the sarcoplasmic 
reticulum;  and TRPV4 activation in skeletal muscle governs resting Ca2+ influx and muscle 
fatigue (324).   Absence of TRPV4 results in heightened metabolic capacity in mouse skeletal 
muscle and resistance to weight-gain due to  a high-fat diet.  Loss of activity of TRPV4 
appears to result in compensatory increases in TRPC3 and TRPC6 production in skeletal 
muscle, as well as heightened calcineurin activity, in TRPV4 null mice when compared to 
normal animals (209).  Lengthening contraction, which can cause soreness and pain on 
movement after the passage of time, causes mechanical hyperalgesia in wild type mice within 
6 to 24 hours, but fails to do so in mice which  lack either TRPV1 or TRPV4  (307). 
 
(v)  Skin 
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       TRPV4 is found at the site of formation of adherens junctions in skin keratinocytes 
where it functions  with beta-catenin which links these cell-to-cell junctions with the actin 
cytoskeleton to enhance their development and ensure the formation of a tight barrier 
between skin keratinocytes.  In the absence of TRPV4 in the area of cell-to-cell junction 
formation, abnormal cell-to-cell junction formation occurs and structures develop which 
result in increased intercellular permeability in vitro  (370).   TRPV4 mediates the entry of 
Ca2+ from the extracellular space at normal skin temperature to cause Rho activation which 
encourages the organisation of actin fibres and the formation of junctions to heighten the 
integrity of the barrier formed by these cell-to-cell junctions  (90, 371).  TRPV4 is essential 
for the development and maintenance of the barrier constituted by skin epidermal 
keratinocytes using tight cell-to-cell junctions, which avoids excess dehydration of human 
skin.  Activation of TRPV4 by normal skin temperature, or by an agonist, enables the ingress 
of Ca2+ from extracellular spaces which encourages the development of cell-to-cell junctions 
(197).  TRPV4 activation reinforces the epidermal tight junction barrier between human 
epidermal keratinocytes in culture (5).   UVB radiation increases the expression and 
activation of epidermal TRPV4 resulting in damage to the skin and an increase in endothelin-
1 which mediate the pain of sun-burn  (276).  Expression of TRPV4 is enhanced in two 
sub-types of the inflammatory facial skin disease known as rosacea, namely, 
papulopustular rosacea and phymatous rosacea (Sulk et al., 2012). 
      Functional TRPV4 receptors are found in human sebocytes  (305).  Moreover, 
cannabidiol has been found to induce lipostatic and anti-proliferative effects from its 
activation of TRPV4 expressed by these cells (305).  When cannibidiol activates TRPV4 
expressed by sebocytes, it disrupts the prolipogenic ERK1/2 MAPK pathway and down-
regulates nuclear receptor interacting protein 1 (NRIP1).  These effects alter glucose and lipid 
metabolism resulting in inhibition of sebocyte lipogenesis.  The anti-inflammatory actions of 
cannabidiol are related to A2a adenosine-dependent up-regulation  of tribbles homolog 3 
(TRIB3) and inhibition of NF-kB signalling.  These findings suggest that cannabidiol may 
prove an effective treatment for acne vulgaris (305). 
       
 
(vi)  Head and neck  
(a) Submandibular gland    
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      TRPV4 is expressed in the mouse submandibular gland  where it is found in the acinar 
cells.  Activation TRPV4 in the submandibular gland results in Ca2+   ingress and salivation  
(472). 
 
(b) Eye 
      Functional TRPV4 expression is found in human endothelial cells of the cornea  (266).   
It is also found localised at the surface of the cell membrane and in the cytosol of human 
epithelial cells of the cornea and the activation of these ion channels plays a role in relation to 
RVD in these cells  (309).   TRPV4 is expressed in neurons of trigeminal ganglion nerve 
endings in the inner walls of the anterior chamber of the eye in rat   (264).  TRPV4 is found 
in retinal ganglion cells and at the optic nerve head in mouse, as well as in Muller glial cells   
(333).  TRPV4 is expressed in the apical microvilli  of a small group of cells of cultured 
human foetal retinal pigment epithelium (478).   
     TRPV4 mediates the effects of the inositol polyphosphate 5-phosphatase, OCRL, in the 
cells of the trabecular meshwork in the eye which are involved in the control of intraocular 
pressure, and a pathological OCRL allele is believed to inhibit Ca2+ signalling through 
TRPV4  (241).  TRPV4 is expressed in the epithelium of the porcine lens and functions in the 
reaction of the lens to hypo-osmotic stress.   ATP is released from the intact lens when it is 
subjected to an hypo-osmotic solution, with a more than threefold increase in its 
concentration being found in the bathing solution. This release is blocked by HC-067047 and 
RN-1734, both of which are antagonists of TRPV4.  Consistent with the involvement of 
TRPV4 in ATP release, GSK-1016790A, an agonist of TRPV4, effects release of ATP when 
the lens is exposed to isosmotic solution.  A hypo-osmotic solution also activates Src family 
kinase which also increases Na+-K+-ATPase activity in the lens epithelium – effects which 
are also blocked by TRPV4 antagonists.  The ATP does not exit the cell via TRPV4 in 
response to hypo-osmotic shock.  The ATP molecule is too large for this to occur.  Instead, 
TRPV4 causes hemichannel-mediated release of ATP   (347, 348, 349).    "Hemichannels" 
describe the half of a gap junction channel (formed from connexin proteins) that is provided 
by one cell.  Hemichannels are regarded as being functional when they are open in non-
junctional membranes without pairing with a partner from an adjacent cell  (377).  
Surprisingly, Ca2+ ingress in response to hypo-osmotic activation of TRPV4 appears to occur 
via connexin hemichannels, presumably as a result of a TRPV4 activation-induced 
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conformational change occasioned in these hemichannels which facilitates Ca2+ influx 
through these channels.   Interestingly, the resulting increase in [Ca2+]i  is kept within 
physiological limits even though these hemichannels have a large capacity to facilitate entry 
into the cell of Ca2+ ions (255).  Astrocytes of the optic nerve head in rat, when subjected to 
mechanical strain, release ATP via pannexin 1 channels.  This is proposed to account for the 
high level of extracelluar ATP exhibited in the optic nerve head of glaucoma patients (30). 
TRPV4 appears to enable epithelial cells of the porcine lens to identify damage to the 
tightly-packed fibre mass which comprises most of the lens.  It then promptly activates 
Src family kinases and increases Na+, K+-ATPase activity which allows the lens to 
improve its regulation of ion concentrations in the fibre mass. It has been suggested that 
the mechanosensitive TRPV4 may be activated as a result of swelling of the  lens 
structure resulting from fibre damage (350).  TRPV4 channels are also functionally 
expressed in the endothelium of retinal microvessels. This expression is down-regulated in a 
rat model of type 1 diabetes and channel function is reduced in bovine endothelial cells 
exposed to high glucose in culture, suggesting that TRPV4 may be a useful molecular target 
in diabetic retinopathy (274).  This pathogenic link remains to be established. 
      Melatonin is found in the eye where it is involved in the regulation of intraocular 
pressure. TRPV4 may be involved in regulating extracellular melatonin in the eye since 
activation of TRPV4 by its agonist GSK-1016790A has been found to produce an increase in 
the level of extracellular melatonin in cells of a cell line derived from human non-pigmented 
ciliary epithelial cells  (14).  
 
(c) Ear   
     Hearing involves exceptionally sensitive mechanosensation which is dependent on 
specific ion channels which transduce vibrations induced by sound.  In mammals, TRPML3, 
TRPV4, and TRPC3/TRPC6 have been identified as being involved in the functioning of the 
inner ear  (464).   TRPV4 in the guinea pig and in mouse is expressed in the hair cells and 
supporting cells of the organ of Corti, in marginal cells of the stria vascularis, spiral ganglion 
cells, sensory cells, transitional cells, dark cells in the vestibular end organs, vestibular 
ganglion cells and epithelial cells of the endolymphatic sac (178, 398).   TRPV4 null mice 
have normal hearing at 8 weeks, but exhibit impairment of hearing by 24 weeks (392).   
Hearing loss is a known accompaniment of TRPV4 mutation-induced neuropathy in some 
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instances and it has been suggested that TRPV4 may be essential for maintaining cochlear 
function in stress conditions, such as exposure to noise capable of causing acoustic injury  
(306).  TRPV4 ion channels are involved in aminoglycoside uptake and retention in the inner 
ear (196, 220). Both TRPV1 and TRPV4 ion channels are involved in the trafficking of 
gentamicin in cochlear hair cells.  Gentamicin results in damage to cochlear hair cells in the 
rodent in a manner which reflects duration of exposure to the drug and drug-dose.   Increased 
vulnerability to gentamicin is found in hair cells located at the basal turn as compared to hair 
cells located at the apical turn (220).   
 
(d) Nose     
     TRPV4 is found expressed in the olfactory epithelium in mouse  (3, 282), but in the 
methimazole-treated mouse, the expression of  TRPV4 is  reduced and recovers only over 
time  (282).  Activation of TRPV4 in human nasal epithelial cells results in an increase in 
ciliary beat frequency.  However, challenge with a TRPV4 agonist, GSK-1016790A, can 
cause an increase in ciliary beat frequency followed by cell death (6). 
 
(e) Larynx    
      TRPV4 is expressed in laryngeal epithelial cells in both mouse and human  (152, 153).  
 
(f)  Mouth   
     Odontoblasts are found at the edge of the dental pulp.  These cells are responsible for the 
process of dentine formation throughout life (18).   TRPV4 are found in minor collections of 
these cells within a general odontoblast population taken from adult rat  (210).    When an 
odontoblast cell is exposed to mechanical stimulation, [Ca2+]i  increases  as a result of the 
activation of TRPV1, TRPV2, TRPV4 and TRPA1  (357). 
 
 
 
(vii)  Digestive system   
(a) Oesophagus    
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       Functional TRPV4 expression is found in keratinocytes of the mouse oesophagus, and 
agonist-induced activation of these ion channels increases the release of ATP from these 
keratinocytes  (268).  TRPV4 is also expressed in human oesophageal tissue as well as in 
HET-1A, an epithelial cell line  (409).  
 
(b) Gastrointestinal tract    
      DRG neurons innervating the colon express TRPV4 which, when activated by 4α-PDD, 
result in a visceral hypersensitivity which is dose-dependent  (58).   The human colon 
expresses TRPV4.  Mouse colon which has become inflamed expresses an increased level of 
TRPV4 compared with control non-inflamed tissue.  When 4α-PDD is introduced within the 
colon in mouse, colitis is found after 3 to 6 hours, and in live animals an increase in the 
permeability of the colon is found 3 hours later.  However, the induced inflammation clears 
within 24 hours  (82).   Pre-treatment of DRG neurons innervating the colon with either 
histamine or serotonin enhances the responses of neuronal TRPV4 to activation by 4α-PDD.   
The same treatments increase the expression of TRPV4 at the plasma membrane.  Abolition 
of TRPV4 reduces the hypersensitivity  resulting from administration of serotonin or 
histamine  (59).   Inflammatory bowel disease in humans is accompanied by an increased 
level of TRPV4 expression in the gastrointestinal tract.   Blocking TRPV4 in a mouse model 
of colitis reduces colitis and pain (119).  Cenac and colleagues have confirmed the 
importance of TRPV4 activation in mediating the visceral hypersensitivity found in irritable 
bowel disease (IBS).  Higher levels of 5,6-EET (an agonist of TRPV4) are found in tissue 
taken from the colons of patients suffering from IBS. Supernatants of IBS biopsies cause 
visceral hypersensitivity in mice which is inhibited where TRPV4 has been eliminated in 
mice primary sensory neurons by siRNA knockdown.  Polyunsaturated fatty acid metabolites 
whether derived from IBS biopsies or from the colons of mice suffering from visceral 
hypersensitivity activated primary sensory neurons of mice in vitro by activating TRPV4. 
These authors also found that TRPV4  is expressed in 35% of neurons in human DRG (60).  
        Activation of TRPV4 reduces resistance across intestinal epithelium.  The non-steroidal 
anti-inflammatory drug (NSAID), indomethacin, produces a similar effect resulting in 
increased permeability of the intestinal epithelium in part by occasioning the activation of 
TRPV4 by metabolites of arachidonic acid.  Hence, TRPV4 is implicated in damage to the 
intestine resulting from the use of NSAIDs  (453).  
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(c)  Pancreas 
     TRPV4 is found in cells of the murine pancreatic beta cell line MIN6 and in mouse 
pancreas.  Abolition of TRPV4 avoids the increase in [Ca2+]i  otherwise induced by human 
amyloid polypeptide (hIAPP), and reduces both the endoplasmic reticulum stress response 
and level of cell death induced by hIAPP  (55).  Agonist-induced activation of TRPV4 results 
in a swift increase in [Ca2+]i   and an increase in the insulin secretion induced by glucose in 
INS-1E pancreatic beta cells.  When TRPV4 is inhibited, the same activators fail to increase  
[Ca2+]i   and insulin secretion in these cells (368).   More than two-thirds of the pancreatic 
stellate cells isolated from rats with pancreatitis caused by a diet of high-fat and alcohol have 
increased levels of TRPV4 and increased Ca2+ responses when exposed to TRPV4 activators 
(470).   The TRPV4 antagonist, HC-067047, reduces the hypersensitivity experienced by 
rats suffering from chronic pancreatitis induced by an alcohol and high fat diet which 
results in the animals developing referred visceral pain-like behaviours.  TRPV4 may 
therefore constitute an appropriate target for therapeutic intervention designed to 
relieve the pain of pancreatitis (468). 
 
(d) Liver 
     The epithelial cells of the bile duct are known as “cholangiocytes.”   These cells have 
primary cilia at the apical membrane which extend into the lumen of the ducts.  
Cholangiocyte cilia express TRPV4 which respond to luminal tonicity to secrete bicarbonate, 
the principal factor governing the formation of ductal bile, by a process which involves apical 
ATP release.  Agonist stimulation of TRPV4 results in an increase in the flow of bile, in 
addition to the release of ATP and the secretion of bicarbonate (145).  TRPV4 expression is 
increased in the cholangiocytes of rats suffering from polycystic kidney disease.   When 
TRPV4 are activated in these cells, the result is an increase of 30 per cent in [Ca2+]i, as well 
as inhibition of cell proliferation by some  25%-50%  and a three-fold reduction in cyst 
growth in 3-dimensional culture.  However, activation of TRPV4 in vivo results in a 
reduction in renal cystic area but not in liver cysts  (146).  In donor liver of rat preserved for 
12 hours before transplantation, the expression of TRPV4 in the bile ducts disappears 
completely after 8 weeks, a phenomenon which is not found where the donor liver is 
preserved for 1 hour only before transplantation (240).   TRPV4 expression is substantially 
increased in fibrotic liver tissue and proliferation of HSC-T6 cells caused by TGF-B1 is 
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reduced by blockade of TRPV4   (373).   Application of TGF-B1 results in greatly enchanced 
expression of TRPV4 in HSC-T6 cells.  Transfection of these cells with small interfering 
RNA (si-TRPV4) to prevent the expression of TRPV4, results in the cells exhibiting an 
increase in apoptosis and inhibition of autophagy.   On the other hand, when these cells are 
treated with the TRPV4 agonist, 4α-PDD, the result is reduction of apoptosis and enhanced 
autophagy.  Autophagy is believed to be induced by TRPV4 by its regulation of Akt 
signalling  (466). 
 
(e) Metabolism 
       Human preadipocytes express high levels of TRPV4 which participate in adipogenesis 
through the phosphorylation of p-Akt kinase.  Silencing either of TRPV4, TRPV2 or TRPM7 
individually results in reduced adipogenic differentiation  of preadipocytes through reducing 
the availability of p-Akt kinase  (66).   Whether TRPV4-deficient mice are protected from 
diet-induced obesity is unclear.   Ye and colleagues (2012) found that mice lacking functional 
TRPV4 exhibit heightened thermogenesis in adipose tissues and do not suffer from obesity 
resulting from their diet.  Moreover, these authors concluded that these animals are also saved 
from resistance to insulin and, interestingly, from inflammation of adipose tissue (457).  
Kusuda and colleagues (2012)  found that TRPV4-deficient mice demonstrate a heightened 
oxidative capacity in skeletal muscle and are protected against obesity resulting from a high-
fat diet.  These authors suggested that loss of TRPV4 results in compensatory increases in the 
production of TRPC3 and TRPC6, as well as an increase in calcineurin activity, which alters 
energy metabolism by means of heightened expression of genes which function in the 
oxidation of fuel in skeletal muscle. This is suggested to result in heightened expenditure of 
energy, as well as affording protection from obesity occasioned by a high-fat diet (209).   
O’Conor and colleagues (2013) reported that, in mice which do not possess the TRPV4 ion 
channel, a high-fat diet results in an increase in the severity of knee osteoarthritis, as well as 
reducing their normal cage activity.  It also increases their weight gain and results in 
increased adiposity.  Bone marrow-derived stem cells and adipose-derived stem cells from 
TRPV4 deficient mice also exhibit a change in differentiation potential.  Bone marrow-
derived stem cells have reduced adipogenic and osteogenic differentiation potential when 
compared with similar cells from wild-type animals.   Adipose-derived stem cells from mice 
lacking TRPV4 possess an increased adipogenic potential as well as a reduced chondrogenic 
potential.  These authors point to significant differences between their study and that of 
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Kusuda and colleagues (209), including the age of the animals when the high-fat diet was 
commenced, the composition of the diet, and period during which it was fed to the animals 
(303).  Various factors associated with the development of obesity are involved in modulating 
the activity of TRPV4.  Thus, hypo-osmolarity evokes a TRPV4-mediated, mainly inward, 
current, an increase in [Ca2+]i and  membrane depolarisation in bovine articular chondrocytes 
which is reduced by insulin, TNF-α, IL-1β, and, to a lesser extent, resistin and leptin  (338).  
Moreover, an association has been found between a TRPV4 gene variant and obesity in a 
study of human subjects in Taiwan.  It has been suggested that this association should be 
considered in the context of the high expression of TRPV4 found in the hypothalamus which 
is known to be involved the regulation of body mass   (100). 
 
         Castellani and colleages (2014) have confirmed a role for TRPV4 in the development of 
inflammation in adipose tissue occasioned by inflammatory insult.  This may be countered, in 
part, by the subject mice having previously undergone an exercise regime.  Training mice on 
a treadmill over several weeks results in an increase in the indicators of mitochondrial content 
in skeletal muscle, as well as the development of PPAR-gamma coactivator 1 alpha in 
epididymal adipose tissue.  The genes for IL-6, SOCS3 and TNF-α induced in epididymal 
adipose tissue by acute inflammation are reduced by ~50% in mice which are exercise-
trained compared with animals which have not been so trained.  In addition, the increases in 
plasma IL-6 found in the latter animals are reduced in the trained animals which also exhibit 
a reduced expression of TRPV4 (56).  
 
(viii)  Nervous system 
(a)  Central nervous system   
     TRPV4 is widely distributed within the brain  (294, 412), being expressed in the 
endothelium of cerebral arteries where it regulates Ca2+ influx into endothelial cells under the 
influence of PLA2  (256).  Increased expression of TRPV4 is found in cerebral collateral 
arteries after fluid shear stress stimulation, and agonist-induced gating of TRPV4 increases 
cerebral arteriogenesis  (342).   Agonist-induced activation of TRPV4 governs [Ca2+]i  in the  
endothelial cells of human brain capillaries and contributes to the control of proliferation of 
those cells  (160).  TRPV4 channels on endothelial cells effect the dilation in cerebral arteries 
caused by acetylcholine  (469).  TRPV4 functions to regulate the activity of Na+ channels in 
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hippocampal neurons.  Intracerebroventricular injection of either of the TRPV4 agonists, 
GSK-1016790A or 4α-PDD, inhibits voltage-gated Na+ current in hippocampal CA1 
pyramidal neurons, shifting the voltage-dependent inactivation curve to hyperpolarization, 
with no effect on the voltage-dependent activation curve.  Blocking PKA reduces GSK-
1016790A-induced inhibition of this current while blocking PKC or p38 MAPK fails to alter 
the effect of GSK-1016790A.  Sustained activation of TRPV4 results in increased expression 
of the α-subunit of voltage-gated Na+ channels in the hippocampus.  Hippocamapal Nav1.1, 
Nav1.2, and Nav1.6 levels are increased in TRPV4 agonist-injected mice, but Nav1.3 and 
Navβ1 levels are almost unaltered  (170).  Intracerebroventricular injection of a hypotonic 
solution (270 mOsmol) of artificial cerebrospinal fluid (ACSF) reduces mean blood pressure 
compared to control mice or mice injected with 300 mOsmol of artificial cerebrospinal fluid. 
However, heart rate is not similarly affected.   The reduction in blood pressure is eliminated 
by RN-1734, an antagonist of TRPV4, which indicates that activation of TRPV4 produces 
this depressor effect.  This suggests that activation of TRPV4 can cause periventricular 
structures in the brain to effect a depressor response to such activation  (114).  
        TRPV4 functions in regulating the permeability of the blood-cerebrospinal fluid barrier 
(BCFSB) which comprises the choroid plexus epithelial cells of the brain ventricles.  These 
cells control the passage of plasma proteins and immune cells into the central nervous 
system. In choroid plexus epithelial cells in swine, TRPV4 is found concentrated on the 
apical membrane.  Treatment with the TRPV4-specific agonist, GSK-1016790A, occasions 
pronounced Ca2+ influx and instant serine/threonine protein phosphorylation.  Within 10-20 
minutes of this treatment, a pronounced diminution in the extent of filamentous actin is 
induced as well as disintegration of cell junctions.  On the other hand, when basal TRPV4 
activity is inhibited by a TRPV4-specific antagonist, there is a reduction in alpha-2-
macroglobulin (A2M) transport in the basolateral-to-apical direction  (284). 
       Functional TRPV1 and TRPV4 are required to sustain normal excitability in murine 
mangocellular neurosecretory cells;  and normal excitability becomes reduced in the absence 
of functional TRPV1 and TRPV4.    Loss of functional TRPV4 does not affect heat-induced 
variations in the excitability of these cells, although loss of functional TRPV1 does do so 
(383).   
        Functional TRPV4 is found in the cell membranes of cortical astrocytes in rat, 
particularly   in membranes found between the brain and the fluid-filled spaces surrounding it 
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(35).   TRPV4 ion channels are expressed in the endfeet of astrocytes where their  Ca2+ 
signals are increased and transmitted as a result of Ca2+-induced Ca2+ release from inositol 
1,4,5-trisphosphate receptors.  Ca2+ ingress effected via TRPV4 channels is a component of 
the Ca2+ response of astrocytic endfeet and increases vasodilation.  TRPV4 is involved in 
regulating local blood flow within the brain to meet the requirements of neuronal activity  
(102).   It  has been implicated in mediating the cell death of astrocytes caused by oxidative 
stress in cultured hippocampal slices (23).   TRPV4 channels expressed on astroycytes in the 
hippocampus can be gated by synthetic amyloid-beta 40 with resulting injury to neurons and 
astrocytes.  The level of TRPV4 expression is increased and so also is the level of free Ca2+ 
found within astroycytes (24).   Seven days after cerebral hypoxic/ischaemic injury, the level 
of TRPV4 is substantially increased in astrocytes of the CA1 region of the rat hippocampus 
and this is accompanied by astrogliosis.  The responses of astrocytes to 4α-PDD are also 
increased after hypoxic/ischaemic injury (48).  TRPV4 channels expressed in astrocytes 
appear to be important sensors of blood flow/pressure in parenchymal arterioles while 
purinergic signalling emanating from glia is proposed to contribute to alterations in the tone 
of parenchymal arterioles resulting from flow/pressure.  However, TRPV4 does not appear to 
be expressed in the endothelium of parenchymal arterioles (198).  TRPV4 is expressed in 
cells of the immortalised neuroendocrine rat hypothalamic 4B cell line where its expression 
in the cell membrane can be enhanced by the effect of Ang-II on the Ang-1 receptor (AT1R) 
via a Src kinase pathway   (340). 
      Alterations in TRPV4 expression in the central nervous system have been investigated 
using SOD1(G93A) mutant transgenic mice as an animal model of amyotrophic lateral 
sclerosis (ALS).  An increased expression of TRPV4 is found  in the cerebral cortex, 
hippocampal formation, thalamus, cerebellum and spinal cord of symptomatic SOD1(G93A) 
transgenic mice. Increased expression of TRPV4 can be identified in multiple brain regions 
of these animals and in the spinal cord, suggesting a role for TRPV4 in the pathology of this 
disease  (219).  
     Stroke generates various activators of TRPV4 and it has been suggested that inappropriate 
activation of this ion channel may have a damaging effect in the aftermath of a stroke.   In a 
murine model of focal cerebral ischaemia, agonist-induced gating of TRPV4 increases 
NMDA-activated current in CA1 pyramidal neurons of the mouse hippocampus.  The current 
thus evoked is affected by antagonists of TRPV4 and of NMDA receptors, respectively, 
suggesting that gating of  TRPV4 increases activation of NMDA receptors  (224).  TRPV4 
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effects the strengthening of synaptic transmission found in the hippocampus as a result 
hypotonic stimulation  (225). 
 
       Over-activation of microglia in the mouse brain by an injection of lipopolysaccharide 
into the mouse cerebral ventricle results in an increased release of TNF-α and increased 
expression of galectin-3.  These increases in TNF-α and galectin-3 are reduced by concurrent 
agonist-induced activation of TRPV4 (204).   Infrasound – which is a form of low frequency 
noise capable of injuring neurons in rat – heightens the level of TRPV4 expressed in glial 
cells.  Absence of functional TRPV4 in glial cells (astrocytes and microglia) in culture 
reduces the extent of  IL-1β  and TNF-α present and limits NF-kB nuclear translocation and 
apoptotic cell death in neurons.   Hence, the view that TRPV4 expressed in glial cells may be 
involved in mediating neuronal injury resulting from infrasound  (353).  
     Co-expression of TRPV4 and TRPV1 is found in the cell bodies of a population of DRG 
neurons and in the central terminals of laminae I and II of the spinal dorsal horn in rat  (53).  
Anoctamin 1 is a Ca2+-activated Cl- channel which interacts both physically and functionally 
with TRPV4 in the apical membranes of epithelial cells of the choroid plexus to affect cell 
volume  (396). 
      Interestingly, it appears that TRPV4 expression throughout the brain and in the spinal 
cord of rats is increased with old age  (218).  However, the significance of these age-related 
increases in the expression of TRPV4 in the central nervous system has yet to be elucidated. 
       TRPV4 is expressed in approximately one-third of the astrocytes which are found in the 
brain.   Agonist-activation of these TRPV4-expressing astrocytes results in that activation 
spreading to adjacent astrocytes via gap junctions as well as by the release of ATP from the 
TRPV4-expressing astrocytes. In the aftermath of such activation, glutamate is released from 
both astrocytes which express TRPV4 and astrocytes which do not.  This glutamate functions 
as an excitatory gliotransmitter which augments synaptic transmission via mGluR, type 1 
(356).  
 
(b) Peripheral nervous system   
      TRPV4 is found in peripheral sensory neurons.  TRPV4 protein is conveyed axonally to 
neuronal terminals at the periphery.  TRPV4 mediates nociceptive responses to hypotonic 
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stimuli  (12).  TRPV4 is found in DRG neurons  (388, 389)  and, in rat, it is also found co-
expressed with TRPV1 in the cell bodies of a population of DRG neurons  (53).    TRPV4 is 
generously expressed in trigeminal ganglion sensory neurons.  It makes a crucial contribution 
to pain in mice caused by inflammation of the temporomandibular joint  (72).   TRPV4 is also 
found in dural afferents in rat and gating of these ion channels by agonist or other activating 
stimulus causes allodynia of the animal’s face and hind-paw  (439).  Primary afferent neurons  
expressing TRPV4 innervate the colon; and PAR2 activation results in mechanical 
hyperalgesia and excitation of sensory nerves of the colon only in the presence of functional 
TRPV4   (44, 367).   TRPV4 is also expressed in the cauda equina (388), as well as in inner 
hair cells, outer hair cells, and spiral ganglion neurons of the mouse cochlea   (351, 398).  
TRPV4 is also found on sympathetic and parasympathetic nerve fibres, such as those 
innervating the arrector pili smooth muscle in skin, sweat glands, intestine, and blood vessels  
(88). It is found in the perikarya, axons and dendrites of retinal ganglion cells and at the optic 
nerve head in mouse, as well as in Muller glial cells  (333).   Sensory neurons innervating the 
blood vessels of the liver are capable of detecting hypo-osmotic variations in the osmolality 
of the blood.  These neurons have their perikarya in the thoracic DRG and can accurately 
translate progressive alterations in osmolality by a mechanism which is dependent on 
TRPV4.  In the absence of TRPV4, these neurons lose their capacity to generate inward 
osmosensitive currents and there is a complete loss of the capacity to activate peripheral 
osmoreceptors (214).    
 
         TRPV4 is found in sensory and spinal motor neurons not only in the adult, but also in 
early development.   Activation of TRPV4 promotes neurotrophic factor-derived 
neuritogenesis (i.e., formation of neurites) in developing peripheral neurons, while the loss of 
such activation has the contrary effect. NGF or cAMP treatment increases the level of 
expression of PLA2 and TRPV4, and a PLA2 –TRPV4 pathway has been proposed as a 
regulator of neurotrophic factor-derived neuritogenesis in developing peripheral neurons 
(182).  
 
 
(ix)  Immune system 
      TRPV4 channels are expressed in T cells where their activation results in Ca2+ ingress 
into those cells.   TRPV4 expression can be enhanced in T cells in the course of  
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concanavalin A-driven mitogenic and anti-CD3/CD28 stimulated TCR activation of T cells.  
It has been proposed that antagonism of TRPV4 may have a role to play in the regulation of 
mitogenic and T cell receptor mediated T cell activation as well as the resulting production of 
cytokines (252).  
 
(x)   TRPV4-evoked ATP release 
    Whereas ATP functions within the cell as an essential component of cell metabolism, 
extracellular ATP interacts in an autocrine or paracrine fashion with P2X receptors which are 
ATP-gated non-selective cation channels on the surface of cells which affect a range of 
physiological events  (65).  Heat, mechanical stimulation and hypo-osmotic stress can cause 
intracellular ATP to escape in a TRPV4-dependent manner from within to outside the cell in 
several tissue types.  Thus, the cilia of cholangiocytes express TRPV4 which, when activated 
by the TRPV4 agonist, 4α-PDD, causes the flow of bile to increase, ATP to be released and 
bicarbonate to be secreted  (145).  Activation of TRPV4 in the oesophageal keratinocytes of 
mice results in Ca2+ ingress and the egress of ATP to outside the cell by exocytosis  (268). 
Reduced osmolality activates TRPV4 to cause the release of ATP from the thick ascending 
limb of the renal medulla  (364).   Stretch-induced activation of TRPV4 in cultured primary 
urothelial cells  results in Ca2+ influx and the secretion of ATP  (272).    ATP secretion from 
urothelial cells into the bladder evoked by distension or LPS is contributed to by pannexin 
channels and this release affects voiding function (31).  TRPV4 activation also contributes to 
hypotonicity-induced release from airway epithelial cells of ATP via pannexin 1 channels    
(344).   The TRPV4 found in epithelium of the porcine lens is involved in mediating the 
response of the lens to hypo-osmotic conditions.  In a hypo-osmotic solution, the lens releases 
ATP in a manner which is dependent on activation of TRPV4 and results in a greater than 
three-fold increase in the concentration of ATP in the solution.  The ATP molecules exit the 
cell via hemichannels as a result of TRPV4 activation, being too large to exit via TRPV4. 
(347, 348, 349).  When astrocytes of the rat optic nerve head experience mechanical stress, 
ATP is released through pannexin-1 channels.  This may explain why glaucoma patients are 
found to have increased extracellular ATP in the optic nerve head (30).    However, TRPV4 
may not be invariably involved in the secretion of extracellular ATP.   Airway smooth muscle 
cells are involved in the secretion of ATP in the airways in which ATP functions as an 
extracellular mediator.    ATP is released when mechanical stretch is applied to cultured 
primary human airway smooth muscle cells.  However, although cyclic stretch-induced 
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release of ATP is significantly reduced by inhibitors of Ca2+- dependent vesicular exocytosis, 
this does not result from the application of a hemichannel blocker or from blockade of 
TRPV4  (394).    Activation of TRPV4 and TRPA1 in human odontoblast-like  cells can 
stimulate the release of ATP   (105). 
     Cigarette smoking causes primary airway epithelial cells of the bronchus to release 
increased levels of extracellular ATP in a dose-dependent manner. The extent of this release 
is reduced by blocking pannexin-1, TRPV1 and TRPV4 channels.  In addition, mRNA 
expression of TRPV1 and TRPV4 is found to be enhanced in samples of tissues taken from 
patients suffering from COPD (29). 
 
(xi)  TRPV4 and barrier function 
        TRPV4 functions in linking cell-to-cell junctions in skin keratinocytes with the actin 
cytoskeleton to ensure the development of a tight barrier between these keratinocytes  (5, 
197, 370, 371) (discussed at Skin, supra).   Activation of TRPV4 results in reduction in the 
level of filamentous actin and disintegration of cell junctions between the choroid plexus 
epithelial cells of the brain ventricles which constitute the blood-cerebrospinal fluid barrier  
(284). 
 
10.  Role of TRPV4 in Acquired Diseases  
 
(i)  Pain   
  
     TRPV4 plays an important role in mediating certain pain sensations due to inflammation 
or neuropathy.   
 
(i)  Inflammation-induced mechanical hyperalgesia 
      The inflammatory response typically results in local “mechanical hyperalgesia” in the 
area affected by the inflammation  (440).   “Mechanical hyperalgesia” refers to a noxious 
sensation experienced after contact or pressure is applied to the inflamed area.  TRPV4 is 
essential for the occurrence of such inflammation-induced mechanical hyperalgesia.   
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Injecting a mix of inflammatory mediators (inflammatory soup) fails to induce any significant 
mechanical or osmotic hyperalgesia in mice or rats which lack functional TRPV4 ion 
channels, but normal animals respond to such injections with an increase in pain-related 
behaviour  (8, 12, 70).   TRPV4 is also involved in mediating inflammation-evoked pain in 
temporomandibular joint (TMJ) disorder in mice.   When carrageenan is introduced by intra-
articular injection into the rat TMJ, the levels of both TRPV4 and PAR2 are increased.  
Administration of TRPV4 activators results in a dose-related increase in the extravasation of 
plasma and the extent of mechanical allodynia (89).  Injection into the TMJ of complete 
Freund’s adjuvant results in inflammation in which the TMJ innervating trigeminal sensory 
neurons in wild-type mice exhibit an increase in both TRPV4 and phosphorylated ERK.  
Both of these effects are absent in mice which lack TRPV4 (72).  TRPV4 also has a role in 
eliciting the nocifensive behaviour which results from injection of formalin into the mouse 
whisker-pad.  In experiments with isolated cells, formalin appears to activate TRPV4 directly 
to induce Ca2+ influx, and both TRPA1 and TRPV4 contribute to mediate trigeminal pain 
induced by formalin  (71).    Cathepsin S is another product of the inflammatory response 
which can activate PAR2 which then activates TRPV4.  Its injection in mouse results in 
inflammation and hyperalgesia which is reduced by deleting either PAR2 or TRPV4 or by 
inhibiting adenylyl cyclase  (476).  Tyrosine kinases have been implicated in the activation of 
TRPV4 by PAR2 (144).  Activation of PAR2 creates a signal, probably via lipid mediators 
derived from arachidonic acid, which induces the activation of TRPV4 (Figure 12).  This 
functional coupling between PAR2 and TRPV4 is necessary to maintain a sustained 
inflammatory response.  PAR2  activation of TRPV4 in this process is dependent on tyrosine 
phosphorylation which depends on an essential tyrosine residue,TRPV4-Tyr-110  (322).  
Neutorophil elastase is another substance released at sites of inflammation as part of the 
inflammatory reponse.  Neutrophil elastase activates PAR2 which in turn causes Gαs-
dependent activation of adenylyl cyclase and PKA which activates TRPV4 to occasion 
neurogenic inflammation and pain by sensitising nociceptors.  Thus, neutophil elastase 
activates PAR2   to sensitise TRPV4 currents generated in Xenopus laevis oocytes;  and when 
elastase is given to mice by intraplantar injection it occasions oedema and mechanical 
hyperalgesia via activation of PAR2 and TRPV4   (477). 
     TRPV4 is commonly found with TRPC1 and TRPC6 in DRG.   Deletion of TRPV4 or of 
TRPC1 and TRPC6 eliminates the effect of inflammation in inducing hyperalgesia to 
mechanical or hypotonic stimulation without altering the normal threshold for mechanical 
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nociception.  TRPC1 and TRPC6 are believed to function with TRPV4 to result in 
mechanical hyperalgesia and the sensitisation of primary sensory neurons  (7).    Interleukin-
17 (IL-17) increases the expression of TRPV4 in mouse DRG neurons and may thereby 
promote the development of mechanical  hyperalgesia (343).   
        TRPV4 in primary sensory neurons can readily translate increases or decreases in 
osmolarity into pain sensation.  Thus, injection beneath the skin of the hindpaw in rats of 2% 
(607 mOsm) or 10% (3,250 mOsm) saline solution results in dose-related pain-induced 
behaviour, namely, flinching.   In the presence of PGE(2), the flinching caused by 2% saline 
is increased  by a multiple of 7;  but the flinching caused by 10% saline remains unaffected 
by the presence of PGE(2).  Deletion of TRPV4 reduces the flinching caused by 2% saline by 
46% but has no effect on the extent of the flinching caused by 10% saline. Likewise, only the 
pain-related behaviour resulting from 2% saline is reduced in TRPV4 knockout mice.  Hence, 
the suggestion that TRPV4 mediates pain sensation resulting from variations in osmolarity 
(11).    The use siRNA targeting TRPV4 has been shown to inhibit TRPV4 expression and 
function in DRG neurons in culture leading to the suggestion that it may have a role in the 
treatment of  TRPV4-induced disease (233). 
     TRPV4 is found abundantly in the sensory neurons innervating the colon.  In mice, it is 
found co-localised  with CGRP in a subpopulation of these sensory neurons  (44)  and also 
with PAR2  (367).  TRPV4 contributes to the visceral pain response mediated by mechanical 
stimulation of colonic serosal and mesenteric sensory neurons  (44).   The presence of 
TRPV4 is necessary for the excitation of colonic primary sensory neurons and the 
development of the mechanical hyperalgesia which is mediated by activation of PAR2 in 
mouse  (367).   Activtion of TRPV4 by its agonist, 4α−PDD, generates a cationic current and 
Ca2+ ingress in colonic primary sensory neurons in mouse to produce a dose-related visceral 
hypersensitivity  (58).   Moroever, the visceral hypersensitivity induced by this agonist 
activation of TRPV4 in these primary afferents is aggravated by the sensitisation of TRPV4 
effected by the presence serotonin or histamine (59).   Functional TRPV4 are found in 
intestinal epithelial cells of mice.  Moreover, agonist-induced activation of these receptors 
occasions the development  of  colitis in mice within 3 to 6 hours  (82).   Patients suffering 
from inflammatory bowel disease show higher levels of TRPV4 mRNA expression.  In an 
animal model of this disease, blockade of this receptor relieves colitis and reduces the pain 
occasioned by inflammation of the intestine (119).   
 
80 
 
     TRPV4 and TRPA1 are found in DRG neurons serving the pancreas.  These ion channels 
contribute to the pain of pancreatitis in mice, while TRPA1 also mediates pancreatic 
inflammation (61).   
 
     The endogenous lipid molecule, Resolvin D1 (RvD1), reduces inflammation and the 
activation TRPV4 (as well as the activation of TRPV3 and TRPA1) at nanomolar 
concentrations.  It may also function as an analgesic to relieve inflammatory pain (28).   In a 
mouse model of inflammatory pain, electroacupuncture at the ST36 acupoint reverses both 
mechanical and thermal hyperalgesia.   Moreover, TRPV4 and TRPV1 protein levels in DRG 
neurons (which are increased at four days after injection of carrageenan or complete Freund’s 
adjuvant) are reduced by such treatment while the threshold, rise-time and fall-time of action 
potentials in DRG neurons  are indicative of a reduction in neuronal excitation and are 
consistent with an antinociceptive effect of treatment with electroacupuncture  (69).   
 
(ii) Peripheral neuropathy-induced mechanical hyperalgesia or allodynia 
       TRPV4 contributes to mechanical hyperalgesia in several types of painful peripheral 
neuropathies, including that associated with taxol, paclitaxel, or vincristine chemotherapy, 
alcoholism, diabetes and human immunodeficiency virus/acquired immune deficiency 
syndrome therapy (9, 10, 73).   Alpha2- β1 integrin and Src tyrosine kinase are involved with 
TRPV4 in mediating such mechanical hyperalgesia and, indeed, a direct interaction occurs in 
sensory neurons between these several contributors to mechanical hyperalgesia  (9).   
      The mechanical allodynia resulting from paclitaxel-induced neuropathy in mouse is 
dependent on the activation of both TRPA1 and TRPV4.  Mechanical allodynia caused by 
paclitaxel is diminished in part by the antagonist of TRPA1, HC-030031, and also by the  
TRPV4 antagonist, HC-067047.  Moreover, it is wholly abolished by the  combined 
administration of both of these antagonists  (260).   Paclitaxel administration causes neuronal 
degeneration  in DRG, as well as an increase in TRPV4 expression.  Hyperalgesia resulting 
from paclitaxel-induced neuropathy is attenuated by administration of  goshajinkigan which 
appears to achieve this effect by preventing neuronal degeneration and inhibiting increases in 
expression of TRPV4  (261). 
       TRPV4 contributes to the development and maintenance of mechanical allodynia in the 
rodent neuropathic pain model of chronic compression of the DRG (CCD).   TRPV4 
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expression is elevated at 7 to 28 days after CCD-type injury in rat, peaking at 7 days after 
such injury;  and deletion of TRPV4 partially alleviates the mechanical allodynia  resulting 
from such injury  (473).  CCD in rat also results in thermal hyperalgesia to which TRPV4 
may contribute and in which NF-κB also appears to be involved (428, 430).    Colchicine is a 
depolymerising agent of microtubules.  Cholchicine, given intrathecally in rat,  results in a 
dose-related and partial diminution in mechanical and thermal allodynia resulting from CCD,  
with the diminution in allodynia accompanied by a dose-related reduction in the level of 
TRPV4 expression.  Colchicine also reduces TRPV4 currents in DRG neurons and in 
TRPV4-transfected HEK293 cells (438).  When administered intrathecally, colchicine 
reduces the effect of agonist-induced activation of TRPV4 on mechanical and thermal 
hyperalgesia in rats resulting from chronic compression injury to DRG neurons  (299). 
     Approximately half of the primary sensory neurons innervating the dura of the brain 
express TRPV4, with currents being generated by exposure to a hypotonic solution or some 
other TRPV4 activating stimulus.  Activation of TRPV4 within the dura of rat results in face 
and hindpaw allodynia that is inhibited by the TRPV4 antagonist RN-1734  (439).    
 
 
(ii)   Cancer   
        TRPV4 is expressed at a higher level in tumour-derived endothelial cells when 
compared with normal endothelial cells.  TRPV4 is important in the migration of the former 
cell type but not in relation to the latter.   Arachidonic acid results in actin being remodelled 
in tumour cells derived from human breast carcinoma.  This, in turn, causes elevation of the 
level of  TRPV4 found in the plasma membrane.  This increased level of TRPV4 in the 
plasma membrane is believed to be important in promoting endothelial cell migration which 
results in angiogenesis and tumour growth  (122).   On the other hand, the level of TRPV4 
found in healthy or inflamed skin keratinocytes is reduced in premalignant lesions and in 
non-melanoma skin cancer, although whether this is a component of the mechanism of the 
disease remains unknown (124, 231). 
 
(iii)   Brain injury and disease 
 
    TRP channels expressed in the brain may function in acquired brain disease, 
neurodegenerative disease and psychotic disorder (294).  TRPV4 is increased in astrocytes of 
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the CA1 region of the hippocampus in mouse at 7 days after hypoxia-induced ischaemia 
resulting from bilateral occlusion of the common carotid arterties for 15 minutes in hypoxic 
conditions. This is accompanied by astrogliosis.  The 4α-PDD-induced response of astrocytes 
is also considerably increased in the aftermath of hypoxia-induced ischaemia  (48).  Many 
by-products of stroke have the ability to activate TRPV4 and there is increasing evidence that 
excessive activation of TRPV4 as a result of stroke may mediate important aspects of the 
damage which results from stroke.  There is evidence that stroke-induced neuronal injury is 
occasioned – at least in part – by upregulation of TRPV4 and its effect on NMDA receptor 
activation through its NR2B subunit and a related downregulation of the Akt signalling 
pathway  (186, 224).  In a mouse model of focal cerebral ischaemia, agonist-induced 
activation of TRPV4 increases NMDA current in hippocampal CA1 pyramidal neurons.  This 
increased activation of NMDA receptors results from phosphorylation by CaMKII of the 
NR2B subunit.  Intracerebroventricular injection of the TRPV4 antagonist, HC-067047, 
reduces brain infarction after 1 hour of occlusion of the middle cerebral artery  (224).    
Expression of TRPV4 is increased in the ipsilateral hippocampus from 4 to 48 hours after 
such occlusion in the mouse model and is at its maximum level at 18 hours after the event.  
Administration, at 24 hours after the event, of the TRPV4 antagonists, HC-067047 and 
ruthenium red, dose-dependently reduces brain infarction.  When the TRPV4 agonist, GSK-
1016790A , is administered by intracerebroventicular injection, hippocampal neuronal death 
is dose-dependently induced while there is an accompanying increase in the phosphorylation 
of the NR2B subunit of  NMDA receptors.  In addition, the p-Akt level declines while the p-
ERK level rises after GSK-1016790A injection – effects which are inhibited by 
administration of an antagonist of NR2B (186).  Blockade of TRPV4 has also been found to 
reduce brain oedema in a mouse model of middle cerebral artery occlusion – an effect which 
has been proposed to result from  inhibiting the activation of the matrix metalloproteinase 9 
(MMP-9) and preventing tight junction protein loss (187).    
     TRPV4 expressed in the endothelium of mouse cerebral arteries functions in mediating the 
dilation induced by acetylcholine in those arteries, but the functioning of these ion channels is 
impaired in mouse models of Alzheimer’s disease. Experimental removal of the endothelium 
in posterior cerebral artery segments of wild type mice almost completely abolishes the 
dilation normally induced by a TRPV4 agonist or by acetylcholine.  Dilation in response to a 
TRPV4 agonist or acetylcholine is impaired in arteries taken from mouse models of brain 
vascular pathology associated with Alzheimer’s disease, namely, the mouse model of 
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enhanced amyloid β, that of cerebrovascular fibrosis, and that exhibiting both cerebrobascular 
fibrosis and enhanced amyloid β. Pre-treatment of wild type arteries with a TRPV4 
antagonist prevents TRPV4 agonist-induced dilation and greatly reduces the dilation induced 
by acetylcholine, but has little effect on the dilation induced by acetylcholine on arterial 
segments obtained from the mouse models of  Alzheimer’s disease  (469).   In the mouse 
model of enhanced amyloid β production, the soluble Aβ impairs blood vessels principally by 
enhancing oxidative stress.  This causes a reduction in dilations mediated by NO, and 
impairment of signalling by TRPV4 in the endothelium and by KATP channels in smooth 
muscle. These functional impairments are found in the early stages of the disease and can be 
reversed by the use of antioxidants in animals expressing this model of Alzheimer’s disease 
(156).   
 
11. TRPV4 channelopathies  
      Diseases caused by mutations of TRPV4 are described as TRPV4 channelopathies  (295).  
Mutations of TRPV4 result in both a range of skeletal dyplasias and  peripheral neuropathies 
(Figure 13).  Mutant TRPV4 can result in skeletal dysplasia and degenerative neuropathy in 
the same patient.  TRPV4 mutations expected to result in “neuropathies” can also cause 
skeletal dysplasias while TRPV4 mutations of the “skeletopathic” type can also result in 
neuropathies  (75).    Evangelista and colleagues (2015) report a c.805C > T (p.Arg269Cys)  
TRPV4 mutation  where the patient exhibits signs of skeletal dysplasia as well as 
scapuloperoneal spinal muscular atrophy.   A  c.184G > A (p.Asp62Asn) mutation of TRPV4 
results in a clinical phenotype which is consistent with Charcot-Marie-Tooth disease (CMT) 
type 2C and in which  basophic inclusions are found in the patient's muscle  (108).  
 
(i) Skeletal dysplasias 
      Mutant TRPV4 ion channels result in a wide phenotypic spectrum of skeletal dysplasias    
(206, 301).   The extent to which the mutations to TRPV4 cause the channel’s basal activity 
to be elevated is a predictor of the severity of the resulting skeletal dysplasia.  Normal 
TRPV4 in Xenopus oocytes has a ~1% open probability (Po) without exposure to any 
channel activator.  However, Po of most of the lethal metatropic dysplasia (MD) channels is 
close to 100%.   Higher basal open probabilities are common to all mutant channels and this 
precludes additional channel gating in response to further exposure to channel activators. The 
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extent of TRPV4 channel over-activity correlates with the severity of the clinical disease   
(237).  An increased level of follistatin (FST) in chondrocytes caused by TRPV4 mutations 
has been identified as a probable contributing factor in skeletal dysplasias  (215).  There is 
evidence that TRPV4 mutants which result in channelopathies  with a “gain-of-function” 
phenotype  lack sensitivity to PIP2 and lack the capacity to bind  PIP2  to the TRPV4 ARD in 
the normal manner exhibited by TRPV4.   Normally, the binding of phosphoinositide to an 
ARD of TRPV4 results in dampening channel activity (395).  When expressed in Xenopus 
oocytes, each of two TRPV4 mutants (L596P and W733R, respectively) activates normally in 
response to depolarization and exhibits outward rectification. On the other hand, these 
mutants possess increased basal open probabilities and exhibit reduced responses to  GSK-
1016790A,  a TRPV4 agonist, which explains their “gain of function” phenotypes. In 
addition, current through the W733R mutant does not switch off during depolarization.  The 
L596P mutation in TRPV4 is responsible for preventing bone development in human 
Kozlowski-type spondylometaphyseal dysplasia.  The W733R mutation possesses a strong 
gain-of-function  characteristic that reduces growth when this mutant is expressed in yeast   
(399).  
       Five TRPV4-mediated skeletal dysplasias have been identified:  (i) autosomal dominant 
brachyolmia type 3; (ii) spondylo-epymetaphyseal dysplasia Maroteaux pseudo Morquio type 
2;  (iii) spondylometaphyseal dysplasia Kozlowski type;  (iv) parastremmatic dysplasa;  and 
(v) metatropic dysplasia  (295).    
      Autosomal dominant brachyolmia type 3.  Brachyolmia features a short trunk, scoliosis 
and mild short stature and has been attributed to point mutations in TRPV4 that encode 
R616Q and V620I substitutions, respectively (331).  It   has been suggested that AD 
brachyolmia may not constitute a distinct entity but may rather be the mildest phenotypic 
expression of SMDK (spondylometaphyseal dysplasia Kozlowski-type) (17).   
     Spondylo‐epimetaphyseal dysplasia Maroteaux pseudo‐Morquio type 2 (SEDM-PM2).   
This dysplasia is autosomal dominant and results in abnormalities of the vertebrae and long 
bones.  During childhood, affected individuals develop short trunk and height and typically 
suffer from kyphoscoliosis, short fingers and toes, as well as “knock-knees” and osteoporosis    
(295).  R594 in exon 11 is a hotspot for SMDK mutations  (81).      
     Spondylometaphyseal dysplasia Kozlowski type (SMDK).  This is an autosomal dysplasia 
which primarily results in abnormalities of the vertebrae and the metaphyses.  During 
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childhood, affected individuals fail to grow to normal height and, indeed, remain very short 
in stature while also suffering from severe scoliosis.  Frequently, the disease also afflicts the 
sufferer with early degenerative joint disease (295). 
     Parastremmatic dysplasia.  This is an autosomal dominal dysplasia which manifests itself 
in severe dwarfism, which is frequently accompanied by major twisting and distortion of the 
limbs. This dysplasia is manifest at birth and progresses rapidly during the early years.  A 
failure in bone mineralization is believed to be responsible for the bony distortions effected 
by the disease (295).  
      Metatropic dysplasia (MD).  This is an autosomal dysplasia which can be lethal in some 
of its forms.  When not lethal, MD is congenital, with affected individuals exhibiting short 
limbs relative to their trunk.  During the course of childhood, subjects experience 
kyphoscoliosis with the result that their upper and lower limbs lengthen relative to their torso. 
“Metatropic” describes the alteration in skeletal phenotype which occurs.  Lethal MD 
frequently manifests in foetal akinesia, severe contracutres of the joints and respiratory 
problems which result in perinatal death  (295).  P799 in exon 15 is a hot codon for MD 
mutations, as four different amino acid substitutions have been observed at this codon   (81).   
In two cases of lethal MD, histology has identified obviously disrupted endochondral 
ossification with reduced numbers of hypertrophic chondrocytes  and the presence of islands 
of cartilage within the zone of primary mineralization.   This suggests that altered 
chondrocyte differentiation  in the growth plate leads to the clinical features of this disease 
type  which involves short extremities, a short trunk with progressive kyphoscoliosis and 
craniofacial abnormalities  (52). 
        
(ii) Peripheral axonal neuropathies 
      TRPV4 mutants can also result in the development of degenerative diseases of the 
peripheral nerves.   Three missense substitutions (R269H, R315W and R316C) in the  
TRPV4 gene affect  the intracellular N-terminal ankyrin domain of TRPV4 and are 
responsible for: (i) congenital distal spinal muscular atrophies (SMA); (ii) scapuloperoneal 
SMA; and (iii) hereditary motor and sensory neuropathy 2C (HMSN 2C)  (295).   These 
substitutions affect channel development, resulting in diminished expression of functional 
TRPV4 channels.  TRPV4-induced Ca2+ ingress is diminished even when the receptor is 
subjected to recognised TRPV4 gating stimuli (21).    
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       Congenital spinal muscular atrophy (CDSMA). CDSMA is an autosomal dominant 
neuropathy involving a congenital loss of lower motor neurons which, fortunately, does not 
progress.  However, it causes muscle weakness and atrophy as well as failure of certain 
neurological reflexes, such as the knee jerk reaction, in the lower body.  Individual subjects 
will also frequently suffer from clubfoot and contractures on flexion of the knees and hips   
(295). 
     Scapuloperoneal spinal muscular atrophy (SPSMA). SPSMA is an autosomal dominant 
neuropathy which involves a congenital decrease in the peroneus and shoulder blade muscles, 
accompanied by the phenomenon of “scapular winging.”  Individual subjects frequently also 
suffer from paresis of the vocal cords (295).   A c.805C > T (p.Arg269Cys) TRPV4 mutation 
has been identified where the patient exhibits signs of skeletal dysplasia as well as 
scapuloperoneal spinal muscular atrophy  (108).  
      Hereditary motor and sensory neuropathy 2C (HMSN 2C).  HMSN 2C is also known as 
Charcot-Marie-Tooth disease type 2 (CMT 2C).   CMT 2C is an autosomal dominant 
peripheral neuropathy  which can affect the functioning of both motor and sensory neurons.  
Patients experience progressive weakness and atrophy of the muscles, especially of the distal 
muscles, together with loss of the sensation of touch.  These signs and symptoms are often 
accompanied by paresis of the vocal cords, sensorineural hearing loss on both sides, urgency 
in micturition and event incontinence (295).   A  c.184G > A (p.Asp62Asn)  mutation of 
TRPV4 results in a clinical phenotype which is consistent with CMT 2C and in which 
basophilic inclusions are found in the patient's muscle (108).  
          Landoure and colleagues (2010)  expressed the view that the mutant TRPV4 mediate 
their pathological effect  to occasion CMT 2C via “gain of function” instead of “loss of 
function” of the TRPV4 mutants.  These authors identified two heterozygous missense 
mutations in the TRPV4 gene, C805T and G806A, resulting in the amino acid substitutions 
R269C and R269H, found in a specific area of the ankyrin repeats in TRPV4.    In cells 
transfected with TRPV4, the CMT 2C mutations result in distinct cellular toxicity and 
elevated  constitutive and activated channel currents, consistent with TRPV4 mutant “gain of 
function” being the author of the pathological condition  (213).   Deng and colleagues (2010) 
identified mutant TRPV4 channels as the causes of scapuloperoneal SMA and CMT 2C and 
found increased channel activity to be a feature of these mutant TRPV4 channels (91).  Fecto 
and colleagues (2011) sought to resolve the apparent conflict between the findings and 
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conclusions of the Auer-Grumbach and the Deng/Landoure studies. The Fecto study (113) 
investigated the three mutant TRPV4 ion channels  responsible for three independent axonal 
neuropathies.   They found that these mutant channels had normal localisation but exhibited 
elevated Ca2+ channel activity which produces greater cytotoxicity.  Moreover, their 
transfected HeLa cells demonstrated  ~ 6-fold greater whole-cell currents than normal 
controls.  These results suggest that the mechanism of action of the TRPV4 mutants involves 
a “gain of function” of the ion channel likely to lead to increased intracellular Ca2+ ingress. 
The mutant TRPV4 channels were found to exhibit a change in intrinsic gating that favours 
the open state, similar to that reported by Loukin and colleagues for the brachyolmia-causing 
R616Q mutation (239).   However,  notwithstanding this increase in open probability in the 
mutants, single channel conductance remains unaffected.  The Fecto study did, however, 
concede that the “gain of function” of the mutant channels could be the result of more 
effective channel insertion of mutant TRPV4 proteins  (113).  The data obtained by Klein and 
colleagues (2011) in their study of CMT 2C also supports the proposition that “gain of 
function” of mutant TRPV4, rather than “loss of function” of these mutant channels, is 
pathologically important.  They found two mutations in the ankyrin repeat domains of 
TRPV4 either of which can produce CMT 2C.  Both mutant TRPV4 receptors have normal 
physiological localisation within the cells expressing them.  Cells transfected with these 
mutant TRPV4 receptors have elevated intracellular Ca2+ levels and cell death can be 
reversed by ruthenium red  (202).   Variations of mutations in TRPV4 occur in patients 
suffering from distal muscular atrophy (dSMA).  Thus, in a girl with dSMA and vocal cord 
paralysis, a variant mutation (p.P97R) is found localised in the cytosolic N-terminus of 
TRPV4, upstream of the ankyrin-repeat domain, where the great majority of disease-
associated mutations are found.  This mutation results in a “loss of function” TRPV4 channel 
which is responsible for the disease.  The mutation p.R232C can be found in patients with 
congenital dSMA and associated bone abnormalities  (121).  
        Another explanation which has been offered for the degeneration of peripheral motor 
and sensory nerves found  in hereditary motor and sensory neuropathies and spinal muscular 
atrophy is that overexpression or over-activation of TRPV4 in developing peripheral nerves 
may occasion neurotrophic factor-induced neuritogenesis in those nerves resulting in these or 
other pathologies (182).     
 
(iii) Other TRPV4 channelopathies 
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     Mutations encoding p.Gly270Val, p.Arg271Pro and p.Phe273Leu substitutions in the 
intracellular ankyrin-repeat domain of TRPV4 are responsible for familial digital arthropathy-
brachydactyly (FDAB).  This is primarily an inherited aggressive osteoarthropathy of the 
fingers and toes which results in the middle and distal phalanges becoming shortened.  These 
mutant TRPV4 channels are not well expressed on the surface of the cell, exhibit a 
diminished Ca2+ ingress in response to TRPV4 agonists, and fail to respond to hypotonic 
stress   (211).  Hence, the mutations found in these TRPV4 receptors, which result in the 
inherited osteoarthropathy, are of the “loss of function” variety. 
        When the human TRPV4 receptor is modified to include the TRPV4(P19S) 
polymorphism, it suffers a reduced response to hypotonic stress (compared with normal 
TRPV4) and to epoxyeicosatrienoic acid.   This mutation has also been related to serum [Na+]  
and  hyponatraemia in two non-Hispanic Caucasian male populations.   [Na+] in the blood is 
reduced in persons with TRPV4(P19S) who also are 2.4 to 6.4 times more likely to suffer 
hyponatraemia when compared to normal subjects  (403). 
 
 
12.  Conclusions    
 
      TRPV4  is a Ca2+ permeable non-selective cation channel which is activated by a 
disparate array of stimuli, ranging from hypotonicity to heat and acid.  TRPV4 has already 
been identified as subserving a great number of important physiological roles and various 
disease states are known to be attributable to the absence, or abnormal functioning, of this ion 
channel. The fact that this ion channel is constitutively expressed and capable of spontaneous 
activation in the absence of agonist stimulation is consistent with its involvement in 
mediating  important homeostatic functions, including its already known importance in the 
regulation of [Ca2+]i and control of intracellular and systemic water balance.   Other  striking 
features of TRPV4 are its widespread dissemination throughout the body and its capacity to 
interact with other proteins which, again, suggest that TRPV4 exercises a broad and diverse 
impact on physiological functioning.  As such, TRPV4 appears to be an immensely important 
target for prophylactic and therapeutic pharmacological intervention.   The antagonist RN-
1734 completely inhibits both ligand-induced, and hypotonicity-induced, activation of 
TRPV4, without affecting the activity of other TRP channels, including TRPV1, TRPV3 and 
the melastatin type 8 TRP channel, making it a useful tool for laboratory use  (417).   
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However, as with TRPV1, the difficulty in developing an antagonist of TRPV4 for 
therapeutic purposes resides in identifying a potent, selective and bioavailable small molecule 
which can target the TRPV4 channels of interest while saving harmless those TRPV4 
channels whose functioning is necessary for non-pathological physiology.  The likelihood is 
that systemic administration of an antagonist to TRPV4 will not offer a practical approach to 
targeting this receptor, and that any antagonist will have to be specifically targeted to affect 
only the delinquent receptors so as to avoid the occurrence of severe adverse effects.   Unlike, 
for example, the serotonin receptor, of which multiple variants have been identified thereby 
enabling the development of more specific antagonists, there is no evidence of similar 
success being likely in the context of TRP channels.  Since more selective blocking of 
identified delinquent variants of TRPV4 is not yet possible, another alternative may be to 
attempt to confine the antagonist to the locale of pathological interest by attaching it to 
another molecule which can be restricted to that locale.  The practical utility of a drug which 
can inhibit TRPV4 is demonstrated by the use of butamben (n-butyl-p-aminobenzoic acid)  as 
a local anaesthetic which provides analgesia.  TRPV4  and TRPA1 are blocked by 
micromolar butamben (although  butamben also activates TRPA1 at millimolar 
concentrations).  Butamben attenuates acute animal pain behaviours in a TRPA1- or TRPV4-
dependent manner  (26) and its efficacy in accessing its target receptors through the skin can 
be considerably enhanced by using liposomal gel formulations, compared to plain gel 
formulations  (62).   While a complete identification of the extent of the functional 
importance of TRPV4 remains to be elucidated, sufficient is known at this juncture to justify 
the application of resources to develop the capacity for effective pharmacological 
management of this ion channel for prophylactic and therapeutic purposes in humans.  
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